{"docstore/data": {"218954c7-0dce-4db5-ac27-8da9fc654579": {"__data__": {"id_": "218954c7-0dce-4db5-ac27-8da9fc654579", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecb250f81381bd4f81720426d36f7fb695da90e6b2b7af7695b16a81d7025e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb1862ed-92be-4312-9d52-e2efb929686b", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023. ", "original_text": "On the basis of U.S. "}, "hash": "fd36b23c607214554d6c26c51eb302f9434d9170280fe38eed30c4affd7d0a73", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion. ", "start_char_idx": 0, "end_char_idx": 648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb1862ed-92be-4312-9d52-e2efb929686b": {"__data__": {"id_": "fb1862ed-92be-4312-9d52-e2efb929686b", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecb250f81381bd4f81720426d36f7fb695da90e6b2b7af7695b16a81d7025e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "218954c7-0dce-4db5-ac27-8da9fc654579", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6846ca60fa88c40583ab8be327a62f80268efc77d92a3a0a58f8d2520f81ba92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1f21def-9e9b-4048-bd59-e229d377ca87", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter. "}, "hash": "6abb6e74a8d49ed99c51730330dc81d729ec63e5ca24a9c3c0bcf1e4713f3d36", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 648, "end_char_idx": 669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1f21def-9e9b-4048-bd59-e229d377ca87": {"__data__": {"id_": "f1f21def-9e9b-4048-bd59-e229d377ca87", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecb250f81381bd4f81720426d36f7fb695da90e6b2b7af7695b16a81d7025e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb1862ed-92be-4312-9d52-e2efb929686b", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "217179bff10a39fd7d91fb31aa2ed8a9bc210ab8bba81708a43cfafd16c3ba18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16875da3-25cc-4c16-9e42-1f6ff92231ef", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n"}, "hash": "f5454dd463593906b7e7b36955a434c35259255bef0f4bec40b98c7b23cfed8c", "class_name": "RelatedNodeInfo"}}, "text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter. ", "start_char_idx": 669, "end_char_idx": 849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16875da3-25cc-4c16-9e42-1f6ff92231ef": {"__data__": {"id_": "16875da3-25cc-4c16-9e42-1f6ff92231ef", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecb250f81381bd4f81720426d36f7fb695da90e6b2b7af7695b16a81d7025e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1f21def-9e9b-4048-bd59-e229d377ca87", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4733b967e4d936b946a83a322994423ad7aabd141b57ceaa2f0175f4678e8d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41e9a57b-7e46-420e-b7e2-b2b2e4cd74d0", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2023. "}, "hash": "71786eaf42006fe4c0ed3c709cb0a3582229ce0d33125d5ba49c8bc155f1c515", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n", "start_char_idx": 849, "end_char_idx": 1050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41e9a57b-7e46-420e-b7e2-b2b2e4cd74d0": {"__data__": {"id_": "41e9a57b-7e46-420e-b7e2-b2b2e4cd74d0", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2023. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecb250f81381bd4f81720426d36f7fb695da90e6b2b7af7695b16a81d7025e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16875da3-25cc-4c16-9e42-1f6ff92231ef", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0967e62f15fdd3c9465ef89469de942a2a386bf5a34171560e49e7f5b2089175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19dc3735-8f0f-4908-91f7-1a97fe698bc3", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr. ", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations. "}, "hash": "f90bdbbe713188e62e117efdcf77855dcaf7d1079d0d70c05c3609cfed0fb0fc", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is updating its outlook for fiscal year 2023. ", "start_char_idx": 1050, "end_char_idx": 1114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19dc3735-8f0f-4908-91f7-1a97fe698bc3": {"__data__": {"id_": "19dc3735-8f0f-4908-91f7-1a97fe698bc3", "embedding": null, "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr. ", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecb250f81381bd4f81720426d36f7fb695da90e6b2b7af7695b16a81d7025e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41e9a57b-7e46-420e-b7e2-b2b2e4cd74d0", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2023. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb06823ac7405fc8cf38857099b36e244668d7cd63a3122a752420e0887dd77a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f7bfc3f-0f94-4f0c-a83a-931da51b446b", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n"}, "hash": "b8b08cb43e68eae2f10c840a4306544bf6b5ba803f5632a7f730a802a92be4d8", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations. ", "start_char_idx": 1114, "end_char_idx": 1239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f7bfc3f-0f94-4f0c-a83a-931da51b446b": {"__data__": {"id_": "0f7bfc3f-0f94-4f0c-a83a-931da51b446b", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecb250f81381bd4f81720426d36f7fb695da90e6b2b7af7695b16a81d7025e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19dc3735-8f0f-4908-91f7-1a97fe698bc3", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr. ", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9e4f405e2b3397f76a7045b961b5eb862b81dd303e8bdcf62ac586b3d5439ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68922f8d-4872-4888-9e66-5de436a51877", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "\u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n"}, "hash": "9778dea622f7e9706a9ee0fee2f41609c8b761f0135d213b14d81a1135f3bbc3", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n", "start_char_idx": 1239, "end_char_idx": 1361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68922f8d-4872-4888-9e66-5de436a51877": {"__data__": {"id_": "68922f8d-4872-4888-9e66-5de436a51877", "embedding": null, "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "\u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecb250f81381bd4f81720426d36f7fb695da90e6b2b7af7695b16a81d7025e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f7bfc3f-0f94-4f0c-a83a-931da51b446b", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b911fe05243dd0b6c8d3779cb2f30fb4603532b6bad1f3542294923eb2c3807d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "757350f1-73cc-407f-a8eb-daf9d50b1cd5", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "\u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr. "}, "hash": "59de284a62a866f1f5f09342df78d50125d5ce4986323fa40462fa0c96c4ca86", "class_name": "RelatedNodeInfo"}}, "text": "\u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "start_char_idx": 1361, "end_char_idx": 1713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "757350f1-73cc-407f-a8eb-daf9d50b1cd5": {"__data__": {"id_": "757350f1-73cc-407f-a8eb-daf9d50b1cd5", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "\u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecb250f81381bd4f81720426d36f7fb695da90e6b2b7af7695b16a81d7025e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68922f8d-4872-4888-9e66-5de436a51877", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "\u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51b200ccd701914a4e0f2bd76a1624e95b23f86c5699ae381340ddc945afc50a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4f1a19d-574a-4d27-ae12-f00d6485f925", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "Collis continued. "}, "hash": "e6a3d60fd0dc57c64ea321ca84ff9decb2158d956ec466b09e51d9c958b00f54", "class_name": "RelatedNodeInfo"}}, "text": "\u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr. ", "start_char_idx": 1713, "end_char_idx": 1903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4f1a19d-574a-4d27-ae12-f00d6485f925": {"__data__": {"id_": "c4f1a19d-574a-4d27-ae12-f00d6485f925", "embedding": null, "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecb250f81381bd4f81720426d36f7fb695da90e6b2b7af7695b16a81d7025e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "757350f1-73cc-407f-a8eb-daf9d50b1cd5", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Y ear 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "\u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a129fba489bd871e69f98f2207cee706c4fee8ca806aebd8c58de77be9cb16d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38dd3c78-e443-44b3-b969-04fbb5635547", "node_type": "1", "metadata": {"window": "\u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "\u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1"}, "hash": "ca79d46a0a70c6834f9c62e970c1be21e5fc8d0696355135453984c8eb8607cc", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 1903, "end_char_idx": 1921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38dd3c78-e443-44b3-b969-04fbb5635547": {"__data__": {"id_": "38dd3c78-e443-44b3-b969-04fbb5635547", "embedding": null, "metadata": {"window": "\u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "\u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecb250f81381bd4f81720426d36f7fb695da90e6b2b7af7695b16a81d7025e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4f1a19d-574a-4d27-ae12-f00d6485f925", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.70 to $11.90 to a range of $11.85 to $11.95.\n \u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a946d758f21d8b62fd7d394f3040062335bd443b8c7db1ccb1872106654388a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe017de2-ae3c-4eda-8d92-304ff7759914", "node_type": "1", "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S. ", "original_text": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "74b9a7a8257843791aa130aa86fcd3b9b7ba77c764ae616d40b2e78033caa32f", "class_name": "RelatedNodeInfo"}}, "text": "\u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "start_char_idx": 1921, "end_char_idx": 2348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe017de2-ae3c-4eda-8d92-304ff7759914": {"__data__": {"id_": "fe017de2-ae3c-4eda-8d92-304ff7759914", "embedding": null, "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S. ", "original_text": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38dd3c78-e443-44b3-b969-04fbb5635547", "node_type": "1", "metadata": {"window": "\u201cIn our third quarter, AmerisourceBergen continued our strong performance as our business and balance sheet have driven our\ngrowth while enabling thoughtful, strategic investments to advance our business like our recently completed investment in\nOneOncology,\u201d said S teven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \u201cOver the last two decades AmerisourceBergen has been at the center of the healthcare ecosystem with a legacy of execution\nexcellence and commitment to delivering innovative solutions,\u201d Mr.  Collis continued.  \u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "original_text": "\u201cAs we become Cencora later this month, we\nlook forward to uniting our purpose-driven team members under our globally inclusive identity as we continue to deliver on our\npurpose and drive long-term value creation for all our stakeholders.\u201d\nThird Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $66.9B $66.9B\nGross Pr ofit $2.3B $2.2B\nOperating Expenses $1.6B $1.4B\nOperating Income $670M $822M\n1", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93d7ea96e0337c63632d42aa780ab964e0089369219e813336265ef01bb3eb08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebaf6125-b89c-4e9e-98f9-f57f3643e50f", "node_type": "1", "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "4ed01b1bb882a7c7da0dd19c47acd8ccd560c3c1d77776e6cefb63332d1539f0", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 0, "end_char_idx": 344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebaf6125-b89c-4e9e-98f9-f57f3643e50f": {"__data__": {"id_": "ebaf6125-b89c-4e9e-98f9-f57f3643e50f", "embedding": null, "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe017de2-ae3c-4eda-8d92-304ff7759914", "node_type": "1", "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S. ", "original_text": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1fd7f4e300b39b43cca966459b8781217b7928d5de59706fd51f1bfb2e74319", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32969913-ef71-4bea-8597-eae5cf4a9a27", "node_type": "1", "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n"}, "hash": "dc890f3d192bc56294bd9c376429346f11635d1cc14129887c0820b1cbed001a", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 344, "end_char_idx": 436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32969913-ef71-4bea-8597-eae5cf4a9a27": {"__data__": {"id_": "32969913-ef71-4bea-8597-eae5cf4a9a27", "embedding": null, "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebaf6125-b89c-4e9e-98f9-f57f3643e50f", "node_type": "1", "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63cf672d0eaa1d523c86002b33246dfc368c6115f62bc8e72939523c344f5969", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd0cc6b1-d421-4360-b7eb-cbc27a6b1370", "node_type": "1", "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S. "}, "hash": "e3d8fea02d75a7fcc34272005f353fb17580ee214579e0750ad00286858827b4", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n", "start_char_idx": 436, "end_char_idx": 658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd0cc6b1-d421-4360-b7eb-cbc27a6b1370": {"__data__": {"id_": "bd0cc6b1-d421-4360-b7eb-cbc27a6b1370", "embedding": null, "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32969913-ef71-4bea-8597-eae5cf4a9a27", "node_type": "1", "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c35093b641f7fcf09a8e4228c0382c9f1b6964be0df9073f8b37456da7023623", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50e0e097-f287-4db3-b94d-92e557f24cda", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D. ", "original_text": "Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n"}, "hash": "ff07ee7e370037a88fbf33876897ac1c3b58a10d12c384d686f0a4c24263eca8", "class_name": "RelatedNodeInfo"}}, "text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S. ", "start_char_idx": 658, "end_char_idx": 893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50e0e097-f287-4db3-b94d-92e557f24cda": {"__data__": {"id_": "50e0e097-f287-4db3-b94d-92e557f24cda", "embedding": null, "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D. ", "original_text": "Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd0cc6b1-d421-4360-b7eb-cbc27a6b1370", "node_type": "1", "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a850ac3aa3a75225c9fda2fa83096fe0510a56dcf81ed7f4b4c88504028261b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e776022-e7fd-4452-bd93-504aa81728ed", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements. "}, "hash": "ca725d0904f73feaf4b03f099af6a62c67d42e62211a17032c02631f7c918e2c", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n", "start_char_idx": 893, "end_char_idx": 995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e776022-e7fd-4452-bd93-504aa81728ed": {"__data__": {"id_": "9e776022-e7fd-4452-bd93-504aa81728ed", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50e0e097-f287-4db3-b94d-92e557f24cda", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D. ", "original_text": "Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91f50903f62ab13157f1e5c167c152bf95919edf01b17e7915b8ae59a892ae3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d787bb72-7bcf-49e4-b37c-55b0bf911fa6", "node_type": "1", "metadata": {"window": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "original_text": "Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n"}, "hash": "630bedad204bc415124c6cb59e50a514f5e920af66cd3e4b09cb82adef9a768e", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements. ", "start_char_idx": 995, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d787bb72-7bcf-49e4-b37c-55b0bf911fa6": {"__data__": {"id_": "d787bb72-7bcf-49e4-b37c-55b0bf911fa6", "embedding": null, "metadata": {"window": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "original_text": "Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e776022-e7fd-4452-bd93-504aa81728ed", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15eea395fcb8a153b545c5a46dfe49c06e3db841454cef54fe2f990e1b64da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28017df6-416b-4a40-a916-a46f8ecc42c6", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n", "original_text": "Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D. "}, "hash": "fb183348c094448d40c18e79defb314bc2740a2457b36ac19a4867c168538f89", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n", "start_char_idx": 1278, "end_char_idx": 1395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28017df6-416b-4a40-a916-a46f8ecc42c6": {"__data__": {"id_": "28017df6-416b-4a40-a916-a46f8ecc42c6", "embedding": null, "metadata": {"window": "Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n", "original_text": "Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d787bb72-7bcf-49e4-b37c-55b0bf911fa6", "node_type": "1", "metadata": {"window": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S.  Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "original_text": "Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e3ab21679fefde6ff2fad0039bf4a35d1ca7d8c65ae687122d511056f8b5255", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00ac0c9f-6f20-404f-b965-dd5925ed64b1", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n", "original_text": "Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n"}, "hash": "72385609a55775519fbeeb04d8f4878aa5716cb70bdbb6183f71a1a3c492cb77", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D. ", "start_char_idx": 1395, "end_char_idx": 1812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00ac0c9f-6f20-404f-b965-dd5925ed64b1": {"__data__": {"id_": "00ac0c9f-6f20-404f-b965-dd5925ed64b1", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n", "original_text": "Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28017df6-416b-4a40-a916-a46f8ecc42c6", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 5.6 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n", "original_text": "Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "459daaf76dbd843782d5f02f9d524fa0931413aee504ba25a7df1b11dd6ec5bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7efede3d-b73c-45a3-8161-8970608fbbec", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income. ", "original_text": "Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. "}, "hash": "44c975e37b81eae09c16c4e67f2d4287eb225b43e35c4fe00c01225832433b2e", "class_name": "RelatedNodeInfo"}}, "text": "Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n", "start_char_idx": 1812, "end_char_idx": 2003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7efede3d-b73c-45a3-8161-8970608fbbec": {"__data__": {"id_": "7efede3d-b73c-45a3-8161-8970608fbbec", "embedding": null, "metadata": {"window": "Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income. ", "original_text": "Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00ac0c9f-6f20-404f-b965-dd5925ed64b1", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the third quarter of fiscal 2023 was $2.3 billion, a 12.4 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements.  Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n", "original_text": "Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed49c4eac5945ef08013f1e2059410fe9aded25cef3d6f8d937b63f1ac5a71c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e791b09f-a485-43a3-a4a4-52fe9e562aeb", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n", "original_text": "Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n"}, "hash": "00723cc8dd56ff26225e8ad552a11e3918f3a7670936cc7392fa1a76f43a7bea", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "start_char_idx": 2003, "end_char_idx": 2267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e791b09f-a485-43a3-a4a4-52fe9e562aeb": {"__data__": {"id_": "e791b09f-a485-43a3-a4a4-52fe9e562aeb", "embedding": null, "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n", "original_text": "Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7efede3d-b73c-45a3-8161-8970608fbbec", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.38 percent, an increase of 2 basis points from\nthe prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income. ", "original_text": "Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a7277a878d3634fe27c8a62232e72812a00cc2e2001660316e3255b325f9381", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f08d6ea-d97f-432c-8b78-f9660ebc7d43", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n", "original_text": "Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n"}, "hash": "b52b8db046b42dc95263e42ba98059228c6ac377fda1d9ae38b1a18b86eaa006", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n", "start_char_idx": 2267, "end_char_idx": 2437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f08d6ea-d97f-432c-8b78-f9660ebc7d43": {"__data__": {"id_": "5f08d6ea-d97f-432c-8b78-f9660ebc7d43", "embedding": null, "metadata": {"window": "Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n", "original_text": "Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e791b09f-a485-43a3-a4a4-52fe9e562aeb", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2023, operating expenses were $1.6 billion, a 4.3 percent increase compared\nto the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and administrative\nexpenses, amortization expense, and restructuring and other expenses compared to the prior year quarter, offset in part by\nthe receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n", "original_text": "Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fbe39d69b5d33f5e89d274261eb981b1f3ad1ebb3ffd76584a585d1cc555c5a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65d22dec-46ba-4536-940a-3ecea7dc47a6", "node_type": "1", "metadata": {"window": "Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income. "}, "hash": "59f7b3d01ce596e56d0cc6465a6c5da1b383b4ef9b211a615e3e6f9f2de45491", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n", "start_char_idx": 2437, "end_char_idx": 2772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65d22dec-46ba-4536-940a-3ecea7dc47a6": {"__data__": {"id_": "65d22dec-46ba-4536-940a-3ecea7dc47a6", "embedding": null, "metadata": {"window": "Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f08d6ea-d97f-432c-8b78-f9660ebc7d43", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow in the current year quarter and a goodwill\nimpairment related to the Company\u2019s less-than-wholly-owned subsidiary in Brazil in the prior year quarter.\n Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n", "original_text": "Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a3e39d2d494998ab9d1bb7e342028dc4bf13c25cea28e5baaa100969ef24684", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b05b5a4d-c0be-4c49-b5e3-b36a0fc247f7", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n"}, "hash": "4457888db7dd823aab7b6a8a9ab08a35d49c99d8ebb06bf58c083b11444f24d1", "class_name": "RelatedNodeInfo"}}, "text": "Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income. ", "start_char_idx": 2772, "end_char_idx": 2943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b05b5a4d-c0be-4c49-b5e3-b36a0fc247f7": {"__data__": {"id_": "b05b5a4d-c0be-4c49-b5e3-b36a0fc247f7", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65d22dec-46ba-4536-940a-3ecea7dc47a6", "node_type": "1", "metadata": {"window": "Operating Income:  In the third quarter of fiscal 2023, operating income was $670.1 million, a 37.5 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "512766b5f0d104e716659842249645fef0b194b2ad55401b2c816222f00d82f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33e76841-d178-4f06-8ab1-27ebb97c8fee", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n"}, "hash": "45adee952c42a908cd9b657bb013243d324b7bd2ab3e89a2ddd51357d9cb3038", "class_name": "RelatedNodeInfo"}}, "text": "This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n", "start_char_idx": 2943, "end_char_idx": 3038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33e76841-d178-4f06-8ab1-27ebb97c8fee": {"__data__": {"id_": "33e76841-d178-4f06-8ab1-27ebb97c8fee", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b05b5a4d-c0be-4c49-b5e3-b36a0fc247f7", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.00 percent in the third quarter of fiscal 2023, an increase of 19\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecd1ee608d040a12d5c133f7a8ca8c870f4dae6a6cadbcb5e8771b216b7f2a35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0076b34-8b7b-4fd8-9f06-8ddfd242dfc6", "node_type": "1", "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n"}, "hash": "5957763603b0909e8cfacfbc8e00328f60264c9de37d76b26e6dd5bf86d050b8", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n", "start_char_idx": 3038, "end_char_idx": 3229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0076b34-8b7b-4fd8-9f06-8ddfd242dfc6": {"__data__": {"id_": "c0076b34-8b7b-4fd8-9f06-8ddfd242dfc6", "embedding": null, "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33e76841-d178-4f06-8ab1-27ebb97c8fee", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the third quarter of fiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the\nprior year quarter primarily due to increases in variable-rate borrowings and associated interest rates, offset in part by an\nincrease in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b9d04d66952ed010d60ea0c961e6c336f52503420bb9a747c10be49e6b9303f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48a45fa0-c01d-4e6b-a48f-84585365e67f", "node_type": "1", "metadata": {"window": "This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "3591a5c1772de40e27ab857ce13988b8d92424a13747464acc52d456a974fa5a", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n", "start_char_idx": 3229, "end_char_idx": 3496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48a45fa0-c01d-4e6b-a48f-84585365e67f": {"__data__": {"id_": "48a45fa0-c01d-4e6b-a48f-84585365e67f", "embedding": null, "metadata": {"window": "This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0076b34-8b7b-4fd8-9f06-8ddfd242dfc6", "node_type": "1", "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 21.3 percent for the third quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income.  This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9579797d26f3e8782dd72fc9b4674cb1dd8757d522fe8311a691a2b4e26c530f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51a22219-3d7b-4e2c-ae5a-02e90f0dff48", "node_type": "1", "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S. "}, "hash": "cfdb1cb96985e160947e7d5383a3f966075a23559089af184c4b6e31ff07d476", "class_name": "RelatedNodeInfo"}}, "text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 3496, "end_char_idx": 3613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51a22219-3d7b-4e2c-ae5a-02e90f0dff48": {"__data__": {"id_": "51a22219-3d7b-4e2c-ae5a-02e90f0dff48", "embedding": null, "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48a45fa0-c01d-4e6b-a48f-84585365e67f", "node_type": "1", "metadata": {"window": "This compares to 23.7 percent in the prior year quarter, which included\ndiscrete tax expenses.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f524c518f831540ac173c7f5c8ab72cd52b395c9e7b7b401283aefc0a7b9bc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c288fa8-5116-4f96-adeb-3498b1fb2540", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions. "}, "hash": "e4e9c2ef3523e3efffdddea19ec6c145156a5866cb66683e33cd18173b7605e2", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S. ", "start_char_idx": 3613, "end_char_idx": 3809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c288fa8-5116-4f96-adeb-3498b1fb2540": {"__data__": {"id_": "6c288fa8-5116-4f96-adeb-3498b1fb2540", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51a22219-3d7b-4e2c-ae5a-02e90f0dff48", "node_type": "1", "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $2.35 in the third quarter of fiscal 2023, a 22.4 percent increase\ncompared to $1.92 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a1d3fc4b21d0c2fe38cef7ab484f5ba0108ead780f9b2d07f2f6a24e7a7ea83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dba5edf-ca57-48fa-ae63-2bee61b9742a", "node_type": "1", "metadata": {"window": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n"}, "hash": "637dc6cbc2f01cde7fac44679031816912fce7f87a219590304b12eb71d56066", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions. ", "start_char_idx": 3809, "end_char_idx": 3911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dba5edf-ca57-48fa-ae63-2bee61b9742a": {"__data__": {"id_": "9dba5edf-ca57-48fa-ae63-2bee61b9742a", "embedding": null, "metadata": {"window": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c288fa8-5116-4f96-adeb-3498b1fb2540", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2023 were 204.4\nmillion, a decrease of 7.4 million shares, or 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15b4da51a9cc87ecac0f84d98eb65620b2c78ffde8c4e549a57c683edad20a17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d8d196e-91ac-4f54-8b13-d307e10f57a5", "node_type": "1", "metadata": {"window": "In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2"}, "hash": "6c127b597579aa204e366228ef72fae9e5f34c7ebbbc6b8897a4307ac975aa70", "class_name": "RelatedNodeInfo"}}, "text": "On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n", "start_char_idx": 3911, "end_char_idx": 4066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d8d196e-91ac-4f54-8b13-d307e10f57a5": {"__data__": {"id_": "2d8d196e-91ac-4f54-8b13-d307e10f57a5", "embedding": null, "metadata": {"window": "In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdfda1e0-68c5-4379-b156-215264f23181", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eb9d41c78c92578ed0ea4c8a89ded7f6b414996becc16f63e9aa3bac914a1e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dba5edf-ca57-48fa-ae63-2bee61b9742a", "node_type": "1", "metadata": {"window": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f614e4c240b70fd7d4641f78440f1cd4b09a10b3b2e657c19260a27c9dbb9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b839a19b-8689-40e4-aeb7-1efdb9eeb356", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n", "original_text": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n"}, "hash": "429778266c31bcbdb2710266bb873846bf51cc1aae3acaf0cc7dbe9a5ff24414", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "start_char_idx": 4066, "end_char_idx": 4191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b839a19b-8689-40e4-aeb7-1efdb9eeb356": {"__data__": {"id_": "b839a19b-8689-40e4-aeb7-1efdb9eeb356", "embedding": null, "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n", "original_text": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d8d196e-91ac-4f54-8b13-d307e10f57a5", "node_type": "1", "metadata": {"window": "In the third quarter of fiscal 2023, revenue was\n$66.9 billion, up 11.5 percent compared to the same quarter in the previous fiscal year, reflecting a 12.2 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.6 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, revenue was up 12.2 percent, reflecting 12.4 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2023 was $2.2 billion, an 8.0 percent increase\n2", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf5b37892161eda0c47d798471fd0111299bb07e786e4add71707efce00d91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe234d44-e5ad-49ea-b13d-941ca4a26a07", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S. "}, "hash": "9ca4c0ed6df7f5fa3181e0d5e0e7100c888ed2f9d920571601a1776a91733ca4", "class_name": "RelatedNodeInfo"}}, "text": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "start_char_idx": 0, "end_char_idx": 118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe234d44-e5ad-49ea-b13d-941ca4a26a07": {"__data__": {"id_": "fe234d44-e5ad-49ea-b13d-941ca4a26a07", "embedding": null, "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b839a19b-8689-40e4-aeb7-1efdb9eeb356", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n", "original_text": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f8892e83ebef078f7ca5d9a0684f0f2bce3ba41fd8f7a3d1b744b4a45c6f715", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b802d3e3-1e20-48e1-902b-f5341afe1297", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions. ", "original_text": "Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n"}, "hash": "8be3b9020ebb0d5b28108c9d95975d57eb5c04ec8e001cc1010e7c2142b81a5c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S. ", "start_char_idx": 118, "end_char_idx": 308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b802d3e3-1e20-48e1-902b-f5341afe1297": {"__data__": {"id_": "b802d3e3-1e20-48e1-902b-f5341afe1297", "embedding": null, "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions. ", "original_text": "Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe234d44-e5ad-49ea-b13d-941ca4a26a07", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "128e208df6c4733829fb5805e4e3c1afa7b1b5683a8a9995efe192f48f283df0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39dc12cb-f59a-4446-8de8-01c972c5aa43", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter. ", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n"}, "hash": "fca3ca559be9bac891926837c30cd938920377f8cc13589c28884e3d031d152d", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n", "start_char_idx": 308, "end_char_idx": 521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39dc12cb-f59a-4446-8de8-01c972c5aa43": {"__data__": {"id_": "39dc12cb-f59a-4446-8de8-01c972c5aa43", "embedding": null, "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter. ", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b802d3e3-1e20-48e1-902b-f5341afe1297", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions. ", "original_text": "Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a2ddec138e9434ed37ba2a3914bf8a82bbc6931db59502d81946fb5a25ad1e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7988bc19-9ebe-4cd9-a4c1-840f7e14d590", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent. ", "original_text": "Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S. "}, "hash": "abbc9e4d31062dd8ef8c96b3ac0017c9bf3d754f8438e4cb0a27dea9f884cca5", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n", "start_char_idx": 521, "end_char_idx": 789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7988bc19-9ebe-4cd9-a4c1-840f7e14d590": {"__data__": {"id_": "7988bc19-9ebe-4cd9-a4c1-840f7e14d590", "embedding": null, "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent. ", "original_text": "Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39dc12cb-f59a-4446-8de8-01c972c5aa43", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter. ", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "099670c65c8db49c4cd83373a7b06bfb2082dd2fc4c80fae0d580076f747062f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cffa49e1-33cf-4269-8514-ca6f7bfec6b5", "node_type": "1", "metadata": {"window": "Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n", "original_text": "Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions. "}, "hash": "8b8c5b161aee245fadc4445957c912909a3f53fd946d0d3164d3cfc467217ec0", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S. ", "start_char_idx": 789, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cffa49e1-33cf-4269-8514-ca6f7bfec6b5": {"__data__": {"id_": "cffa49e1-33cf-4269-8514-ca6f7bfec6b5", "embedding": null, "metadata": {"window": "Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n", "original_text": "Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7988bc19-9ebe-4cd9-a4c1-840f7e14d590", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent. ", "original_text": "Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7beee6a2051afb021a65d8f9ae17bc9b0d15d44fe2c780982a833daed2907a7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7304bee-cc7e-4eeb-b8a0-db7496516f65", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter. "}, "hash": "ebef8a5e1ea4ec7815b622364b6f7a7388fab99a0265060e41638504a0af6ac8", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions. ", "start_char_idx": 1019, "end_char_idx": 1106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7304bee-cc7e-4eeb-b8a0-db7496516f65": {"__data__": {"id_": "b7304bee-cc7e-4eeb-b8a0-db7496516f65", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cffa49e1-33cf-4269-8514-ca6f7bfec6b5", "node_type": "1", "metadata": {"window": "Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n", "original_text": "Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14056136f075dea93b2bda66ddff99edbc3fda7560ae4622106bc201a7d106d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0230bf29-9f49-43db-88a6-e90c1b9d5849", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n", "original_text": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent. "}, "hash": "ab005d70347387f153917c280671a1456783ac6c3cffd24213a2f85ded693c50", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter. ", "start_char_idx": 1106, "end_char_idx": 1234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0230bf29-9f49-43db-88a6-e90c1b9d5849": {"__data__": {"id_": "0230bf29-9f49-43db-88a6-e90c1b9d5849", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n", "original_text": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7304bee-cc7e-4eeb-b8a0-db7496516f65", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b9ee70e7842f81e6e3d070bb15ee5d60638344a7c9fabf97bf133f028a6dfa2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f19364b7-4c45-46cd-8167-9abc12972c35", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n"}, "hash": "391bca8ca25bb14f9a7b8a9a2a70d52bdf1d6e9c359743644c0e26af97726aa2", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent. ", "start_char_idx": 1234, "end_char_idx": 1347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f19364b7-4c45-46cd-8167-9abc12972c35": {"__data__": {"id_": "f19364b7-4c45-46cd-8167-9abc12972c35", "embedding": null, "metadata": {"window": "Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0230bf29-9f49-43db-88a6-e90c1b9d5849", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the third quarter of fiscal 2023, adjusted operating income was $822.3 million, an 8.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 9.5 percent increase in U.S.  Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n", "original_text": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6477188363703c226971c97cb2d0aef06e4db55fc9839dd945562e56234e06bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9c7a853-eff7-4b78-a1c3-4d7346a052a4", "node_type": "1", "metadata": {"window": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "292da674587139c8600d7b314e3d9acb7701771f7364713117006de630663e53", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n", "start_char_idx": 1347, "end_char_idx": 1521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9c7a853-eff7-4b78-a1c3-4d7346a052a4": {"__data__": {"id_": "c9c7a853-eff7-4b78-a1c3-4d7346a052a4", "embedding": null, "metadata": {"window": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f19364b7-4c45-46cd-8167-9abc12972c35", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nand a 6.2 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e33e3a74e78b802234b7638637d00d569cec51937ec6dc2e3b6158c2a78f279d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f8ac82f-d4cd-460a-afa3-7671abe92102", "node_type": "1", "metadata": {"window": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n", "original_text": "In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n"}, "hash": "3bd69e303e6d756ca8d6cc732e279744f2be8f066bb1a2162fb7bb6f46aa69b2", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 1521, "end_char_idx": 1620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f8ac82f-d4cd-460a-afa3-7671abe92102": {"__data__": {"id_": "1f8ac82f-d4cd-460a-afa3-7671abe92102", "embedding": null, "metadata": {"window": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n", "original_text": "In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9c7a853-eff7-4b78-a1c3-4d7346a052a4", "node_type": "1", "metadata": {"window": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 9.0 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0be3e59277f2d9ce1bce040d3142a84eb08e091fdc10e38adb49e3f5804568f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "775e0f0c-1f59-4828-ac90-846e1e632721", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n"}, "hash": "7d1c842344b4952749309926155f0c13db9ba1c5ba0cee14693aaab22a2e1dd1", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n", "start_char_idx": 1620, "end_char_idx": 1931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "775e0f0c-1f59-4828-ac90-846e1e632721": {"__data__": {"id_": "775e0f0c-1f59-4828-ac90-846e1e632721", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f8ac82f-d4cd-460a-afa3-7671abe92102", "node_type": "1", "metadata": {"window": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n", "original_text": "In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3112afb062a1ee53900d9a74bafc62e28720a19917b91b754be7c4d58339ee9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90ddc6f7-3628-4434-bdcb-dfd0343377a0", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter. "}, "hash": "440ca418785c9cbb782580e529ee968c6cd721e68cb7d3a5ded8f3a201f7b08a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n", "start_char_idx": 1931, "end_char_idx": 2100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90ddc6f7-3628-4434-bdcb-dfd0343377a0": {"__data__": {"id_": "90ddc6f7-3628-4434-bdcb-dfd0343377a0", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "775e0f0c-1f59-4828-ac90-846e1e632721", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.23 percent in the fiscal 2023 third quarter, a decrease of 3 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fe2fb0f1cdf08f1abb9d72772e0b6202ac111f5d1dd6f297f4c9e67ed20a315", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f66875f6-0dde-4d8c-b346-58b2cbe3ca5e", "node_type": "1", "metadata": {"window": "In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n"}, "hash": "6dc09d4baef40814b27d750e8357fd4c1544a7eb2074d3ea489f3c4742dea055", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter. ", "start_char_idx": 2100, "end_char_idx": 2310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f66875f6-0dde-4d8c-b346-58b2cbe3ca5e": {"__data__": {"id_": "f66875f6-0dde-4d8c-b346-58b2cbe3ca5e", "embedding": null, "metadata": {"window": "In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90ddc6f7-3628-4434-bdcb-dfd0343377a0", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "199f9cfe43d801f64a04e11d806675febb357f986d778b90eb89ca5f59ba7be5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72f31ac3-5a70-49d8-9414-f7c53834d68b", "node_type": "1", "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "cd0ee06e3008167730c9813a749c3d6086cd15ef169ad0cdfea523cfd53fb123", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n", "start_char_idx": 2310, "end_char_idx": 2435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72f31ac3-5a70-49d8-9414-f7c53834d68b": {"__data__": {"id_": "72f31ac3-5a70-49d8-9414-f7c53834d68b", "embedding": null, "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f66875f6-0dde-4d8c-b346-58b2cbe3ca5e", "node_type": "1", "metadata": {"window": "In the third quarter of\nfiscal 2023, net interest expense of $57.9 million increased 9.5 percent versus the prior year quarter primarily due to increases\nin variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result of higher\ninvestment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8fa65e98fc766b0e1c6777e5fa85875652f947e3dab9249fb3ae3ec7eda81266", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b531fbc8-1acd-45c2-96d9-00bfd156a431", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n"}, "hash": "f179a0fe7a5ce7a13a1bec0238d61109b8cd91d7d078b8af7c5d34442b7d6658", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 2435, "end_char_idx": 2545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b531fbc8-1acd-45c2-96d9-00bfd156a431": {"__data__": {"id_": "b531fbc8-1acd-45c2-96d9-00bfd156a431", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72f31ac3-5a70-49d8-9414-f7c53834d68b", "node_type": "1", "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.5 percent for the third quarter of fiscal 2023 compared to\n20.2 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6dd7f56254fb4c930188ea4cfcbd2aaed2813f9548ab052bde7f7d2fe567944", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e3b7e8b-1216-41aa-8b08-845a58d41f4e", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. "}, "hash": "7f42b6aefb2ee26937f85f1391372b197fe9aeac3fce0a994af612ce9b1ce78b", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n", "start_char_idx": 2545, "end_char_idx": 2783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e3b7e8b-1216-41aa-8b08-845a58d41f4e": {"__data__": {"id_": "5e3b7e8b-1216-41aa-8b08-845a58d41f4e", "embedding": null, "metadata": {"window": "On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b531fbc8-1acd-45c2-96d9-00bfd156a431", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $2.92 in the third quarter of fiscal 2023, an 11.5\npercent increase compared to $2.62 in the previous fiscal year\u2019s third quarter.  On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "082a5f371d299bc1a636bacffc2f5f200fa27c2f9e8cfe1578c76a3add8259f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15a7ea17-7fbb-4388-a932-596bb02c7b6d", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n"}, "hash": "8ee209e49edfdb94e5a5fc548af9acfe9965dd062d9ebcf618119954e130e635", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "start_char_idx": 2783, "end_char_idx": 2944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15a7ea17-7fbb-4388-a932-596bb02c7b6d": {"__data__": {"id_": "15a7ea17-7fbb-4388-a932-596bb02c7b6d", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e3b7e8b-1216-41aa-8b08-845a58d41f4e", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted diluted\nearnings per share increased 11.1 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91a37d9c295a1ab5c4e805d3a70355a66a2e1c0d3908f585af5c848aa0f29bc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f626c2d8-6ada-49a4-9f80-de222d475cca", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n", "original_text": "U.S. "}, "hash": "942bcfbbc09a75794e518b2907616162a5fff0cecb34374820deadca887d335f", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and International Healthcare Solutions.\n", "start_char_idx": 2944, "end_char_idx": 3005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f626c2d8-6ada-49a4-9f80-de222d475cca": {"__data__": {"id_": "f626c2d8-6ada-49a4-9f80-de222d475cca", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15a7ea17-7fbb-4388-a932-596bb02c7b6d", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b2614fcea548416c9f4c47d581a634392f8cf9a700f44297fbb7aa26380b61a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34dbfc48-3e12-45c0-9ec0-5cf582af42b1", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period. ", "original_text": "Healthcare Solutions\nU.S. "}, "hash": "02863254774b82f224cb7e3a1c85268e3bbfe9dc28746b3982805186fa32cc8d", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 303, "end_char_idx": 308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34dbfc48-3e12-45c0-9ec0-5cf582af42b1": {"__data__": {"id_": "34dbfc48-3e12-45c0-9ec0-5cf582af42b1", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period. ", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f626c2d8-6ada-49a4-9f80-de222d475cca", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2023 were 204.4 million, a decrease of 7.4 million shares,\nor 3.5 percent, versus the prior fiscal year third quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "daa1f2425ca187f3607b26b11e8c327d1c0a6855672cb2a6f2f4ddcc91b338b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5636d6f8-89b9-4f9a-8296-43703bd671eb", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex. ", "original_text": "Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments. "}, "hash": "5678808ec2c8daf483f84be7c2832af84b2af8e7acce0646420245ae0bea1680", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nU.S. ", "start_char_idx": 3010, "end_char_idx": 3036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5636d6f8-89b9-4f9a-8296-43703bd671eb": {"__data__": {"id_": "5636d6f8-89b9-4f9a-8296-43703bd671eb", "embedding": null, "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex. ", "original_text": "Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34dbfc48-3e12-45c0-9ec0-5cf582af42b1", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period. ", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ba81a2de213eb66bd620c2f87adcf5fde29ce498a9bea5298fe9c01bde96de8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de259583-47c7-470d-8798-6fb176cc7946", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n", "original_text": "Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n"}, "hash": "788297cfc50f589efbc47031ade4dc613327d6327cb888339119112896a61f0f", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments. ", "start_char_idx": 3036, "end_char_idx": 3550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de259583-47c7-470d-8798-6fb176cc7946": {"__data__": {"id_": "de259583-47c7-470d-8798-6fb176cc7946", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n", "original_text": "Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5636d6f8-89b9-4f9a-8296-43703bd671eb", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex. ", "original_text": "Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7abdeec370336a84d067a46da9d72ab1d1c991dbe56bd15431795fef8a990a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ba428b5-f5f5-4d0e-adb3-c2ed59ca5262", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period. "}, "hash": "ad9ce56da77a232e1f26a0cd1b298b322ad778159c3dc0026b49baa6a794176e", "class_name": "RelatedNodeInfo"}}, "text": "Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n", "start_char_idx": 3550, "end_char_idx": 3748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ba428b5-f5f5-4d0e-adb3-c2ed59ca5262": {"__data__": {"id_": "8ba428b5-f5f5-4d0e-adb3-c2ed59ca5262", "embedding": null, "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de259583-47c7-470d-8798-6fb176cc7946", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n", "original_text": "Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "701ad318631ccc298ff9e5a105aec7c9305eabb341f8c92d15b96d7263b29fff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0802277-8e58-4628-99d4-849feadc23c8", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex. "}, "hash": "adbd521cc05e812ed5481f6879eb42410a99ea51266bce5bb608168a6ee9a30d", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period. ", "start_char_idx": 3748, "end_char_idx": 4100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0802277-8e58-4628-99d4-849feadc23c8": {"__data__": {"id_": "b0802277-8e58-4628-99d4-849feadc23c8", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ba428b5-f5f5-4d0e-adb3-c2ed59ca5262", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66bd28096906e62b51a8957d413a44ee670a69952b68f307215cb5ca1221ee41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fac31b2-457d-4be7-a98b-a918378289b3", "node_type": "1", "metadata": {"window": "Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n"}, "hash": "847c466c1bafa3cc5c7593c06ce01c27e5a7304ef2794d63989d650878a0add0", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex. ", "start_char_idx": 4100, "end_char_idx": 4323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fac31b2-457d-4be7-a98b-a918378289b3": {"__data__": {"id_": "6fac31b2-457d-4be7-a98b-a918378289b3", "embedding": null, "metadata": {"window": "Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0802277-8e58-4628-99d4-849feadc23c8", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $59.9 billion in the third quarter of fiscal 2023, an increase of 12.2 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower profit margins, and increased sales of\nspecialty products to physician practices and health systems, offset in part by a decrease in sales of C OVID-19 treatments.  Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex. ", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14e7a24a7e86bdf26a1e9f975d5e6cc250b883d8943cee9746d80e7a5ecda2f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99df4e16-1a76-475b-945d-ee4c44a48900", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "Recent Comp any Highlights & Milest ones\n3"}, "hash": "9e7506a536dec8701307bc39647a2bbe06a8d8d978a421531abc618f0b321bd9", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n", "start_char_idx": 4323, "end_char_idx": 4474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99df4e16-1a76-475b-945d-ee4c44a48900": {"__data__": {"id_": "99df4e16-1a76-475b-945d-ee4c44a48900", "embedding": null, "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "Recent Comp any Highlights & Milest ones\n3", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a02a01a28a441cd7d7e10a14f321cd8c4fa66f131b738d35d3e551775aa89449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fac31b2-457d-4be7-a98b-a918378289b3", "node_type": "1", "metadata": {"window": "Segment\noperating income of $635.2 million in the third quarter of fiscal 2023 was up 9.5 percent compared to the same period in the\nprevious fiscal year as a result of an increase in gross profit.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a4c30f79e06ff8acbbc19757bb0025567239d9a92b81c681944de7146db5716", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cac3f12-2169-49e1-9f11-c4f3469de7b5", "node_type": "1", "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023. ", "original_text": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n"}, "hash": "a87414955d082f93da9a8eec8c8771f2fc80dd2124c7cc20daf30d2f48c3445a", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\n3", "start_char_idx": 4474, "end_char_idx": 4516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cac3f12-2169-49e1-9f11-c4f3469de7b5": {"__data__": {"id_": "9cac3f12-2169-49e1-9f11-c4f3469de7b5", "embedding": null, "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023. ", "original_text": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99df4e16-1a76-475b-945d-ee4c44a48900", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the third quarter of fiscal 2023, an increase of 5.6 percent from the\nprevious fiscal year\u2019s third quarter due to increased revenue across our businesses, offset in part by the divestiture of our Brazilian\nspecialty business in the prior year period.  Segment operating income in the third quarter of fiscal 2023 was $187.1 million, an\nincrease of 6.2 percent, primarily due to growth at our global specialty logistics business and the January 2023 acquisition of\nPharmaLex.  On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 12.4\npercent and 7.3 percent, respectively.\n Recent Comp any Highlights & Milest ones\n3", "original_text": "Recent Comp any Highlights & Milest ones\n3", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87f3bf26f6ebcb46afcbbd62a51b730838ea33bde2296b67278cac6463a7f1fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b398d05-1468-44dd-b7d1-9dce166835fa", "node_type": "1", "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures. ", "original_text": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n"}, "hash": "aa1ddda4ff64ad96c4de2e04806109c07b0fda6de53c780aaaaba0ebc398e081", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n", "start_char_idx": 0, "end_char_idx": 108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b398d05-1468-44dd-b7d1-9dce166835fa": {"__data__": {"id_": "8b398d05-1468-44dd-b7d1-9dce166835fa", "embedding": null, "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures. ", "original_text": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cac3f12-2169-49e1-9f11-c4f3469de7b5", "node_type": "1", "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023. ", "original_text": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38ac09511a094d9d339f1b413dcdf2ee362915b839a10337e9f4b30420ec9fc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f9ebd28-6c08-4db7-9abb-ee00fad49d15", "node_type": "1", "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n", "original_text": "AmerisourceBergen will change its name to Cencora, Inc. "}, "hash": "52d5bb286bbd8044e7451be2e3aa665a111c1c86b12cd0c667a8cfe029bb97c8", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n", "start_char_idx": 108, "end_char_idx": 266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f9ebd28-6c08-4db7-9abb-ee00fad49d15": {"__data__": {"id_": "4f9ebd28-6c08-4db7-9abb-ee00fad49d15", "embedding": null, "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n", "original_text": "AmerisourceBergen will change its name to Cencora, Inc. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b398d05-1468-44dd-b7d1-9dce166835fa", "node_type": "1", "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures. ", "original_text": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4e8c75da9ef7d424b4993df63156ee5e189cc90944538dcde5bbadfff83e13d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9c4c81e-13d8-44ba-81c9-e47e637fd61c", "node_type": "1", "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index. ", "original_text": "and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023. "}, "hash": "b91226c3a4fc3cc5e0137135616db55b5f7bb318078c1284b983f7a95586ed77", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen will change its name to Cencora, Inc. ", "start_char_idx": 266, "end_char_idx": 322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9c4c81e-13d8-44ba-81c9-e47e637fd61c": {"__data__": {"id_": "e9c4c81e-13d8-44ba-81c9-e47e637fd61c", "embedding": null, "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index. ", "original_text": "and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f9ebd28-6c08-4db7-9abb-ee00fad49d15", "node_type": "1", "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n", "original_text": "AmerisourceBergen will change its name to Cencora, Inc. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d5737fc7724931ac9fe8e4fc9f4b60a4acab4c12ca3f3cdf00015dfb04b543", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a535900-ea2a-4f9b-ab56-28008f655a46", "node_type": "1", "metadata": {"window": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n", "original_text": "The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures. "}, "hash": "1e02917c4cb25057defa8fb587fa3d0b09c6611908bb491d0f9199c55fca6b29", "class_name": "RelatedNodeInfo"}}, "text": "and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023. ", "start_char_idx": 322, "end_char_idx": 423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a535900-ea2a-4f9b-ab56-28008f655a46": {"__data__": {"id_": "3a535900-ea2a-4f9b-ab56-28008f655a46", "embedding": null, "metadata": {"window": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n", "original_text": "The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9c4c81e-13d8-44ba-81c9-e47e637fd61c", "node_type": "1", "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index. ", "original_text": "and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73b41004a1e288b7abcbd9c2577b098003238568294da050ccfea694a5c89466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dfd6b94-7133-44f1-acec-9bab3e3c8ee1", "node_type": "1", "metadata": {"window": "AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S. ", "original_text": "The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n"}, "hash": "435c43396a9cea5a56e8795c832ae45e6f81ae6b0a41c8222beae9b8463d5a4b", "class_name": "RelatedNodeInfo"}}, "text": "The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures. ", "start_char_idx": 423, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dfd6b94-7133-44f1-acec-9bab3e3c8ee1": {"__data__": {"id_": "2dfd6b94-7133-44f1-acec-9bab3e3c8ee1", "embedding": null, "metadata": {"window": "AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S. ", "original_text": "The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a535900-ea2a-4f9b-ab56-28008f655a46", "node_type": "1", "metadata": {"window": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n", "original_text": "The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a2dcffa559ff71019c567674ca1bdf83a74d90f9f6b3169cd606e5f86267795", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98ed7889-84fa-4275-aa2d-d6ae3eaf9e4a", "node_type": "1", "metadata": {"window": "and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n", "original_text": "AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index. "}, "hash": "45c2992a332a252b82887998d940a3e91c0d0faba8fd87c4ada76c342f20f750", "class_name": "RelatedNodeInfo"}}, "text": "The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n", "start_char_idx": 520, "end_char_idx": 670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98ed7889-84fa-4275-aa2d-d6ae3eaf9e4a": {"__data__": {"id_": "98ed7889-84fa-4275-aa2d-d6ae3eaf9e4a", "embedding": null, "metadata": {"window": "and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n", "original_text": "AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dfd6b94-7133-44f1-acec-9bab3e3c8ee1", "node_type": "1", "metadata": {"window": "AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S. ", "original_text": "The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9df8e14435cc80f051b93a19e5909f8c4e16e27843ea22c7b91a023124f818a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6dad90c-7024-4b57-9102-adf8eda60271", "node_type": "1", "metadata": {"window": "The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n", "original_text": "The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n"}, "hash": "9ac05e95ab64fcfdb8cf83c73c82f215e69f2a2dbf8d0057c9c16a56fae765ee", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index. ", "start_char_idx": 670, "end_char_idx": 813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6dad90c-7024-4b57-9102-adf8eda60271": {"__data__": {"id_": "d6dad90c-7024-4b57-9102-adf8eda60271", "embedding": null, "metadata": {"window": "The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n", "original_text": "The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98ed7889-84fa-4275-aa2d-d6ae3eaf9e4a", "node_type": "1", "metadata": {"window": "and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023.  The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n", "original_text": "AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e6383a5a8ef8051f48408c314990c94c557b90f2d754c4a3d0cf7d5db4f5e3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a2ef243-27c3-4f30-92ee-32642bc122bf", "node_type": "1", "metadata": {"window": "The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n", "original_text": "AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S. "}, "hash": "a036525f3330dfbb7a6afacd205ad219561c2271444d0c10deb01c9d0961670e", "class_name": "RelatedNodeInfo"}}, "text": "The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n", "start_char_idx": 813, "end_char_idx": 976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a2ef243-27c3-4f30-92ee-32642bc122bf": {"__data__": {"id_": "8a2ef243-27c3-4f30-92ee-32642bc122bf", "embedding": null, "metadata": {"window": "The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n", "original_text": "AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6dad90c-7024-4b57-9102-adf8eda60271", "node_type": "1", "metadata": {"window": "The new name reflects its bold vision and purpose-driven approach to creating healthier\nfutures.  The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n", "original_text": "The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5aaeb63a11ef32988415acc828e16f2cf5f29d3d3aaf37316e8aab3cf4971ffb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bdecd8f-3bd6-4de2-bdb2-a898d558c2f7", "node_type": "1", "metadata": {"window": "AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D. ", "original_text": "public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n"}, "hash": "5d1070de615cafd0a4922618529349f163887af799209eac2483621c2e3dda69", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S. ", "start_char_idx": 976, "end_char_idx": 1082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bdecd8f-3bd6-4de2-bdb2-a898d558c2f7": {"__data__": {"id_": "8bdecd8f-3bd6-4de2-bdb2-a898d558c2f7", "embedding": null, "metadata": {"window": "AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D. ", "original_text": "public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a2ef243-27c3-4f30-92ee-32642bc122bf", "node_type": "1", "metadata": {"window": "The new name represents a unified presence that will continue to fuel the company\u2019s ongoing growth strategy and\nadvance its impact across healthcare.\n AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n", "original_text": "AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbd1c8b708b465c59ff4165a965a6b2064667ff56ee4525dab159c9b6c6bf3c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "870c82c5-e47e-47e7-bfcf-227517d1c5b3", "node_type": "1", "metadata": {"window": "The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S. ", "original_text": "AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n"}, "hash": "0666bad6fa11497d5d74b295680aff2e83832eb2528f6446c498731a2a0894c6", "class_name": "RelatedNodeInfo"}}, "text": "public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n", "start_char_idx": 1082, "end_char_idx": 1248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "870c82c5-e47e-47e7-bfcf-227517d1c5b3": {"__data__": {"id_": "870c82c5-e47e-47e7-bfcf-227517d1c5b3", "embedding": null, "metadata": {"window": "The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S. ", "original_text": "AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bdecd8f-3bd6-4de2-bdb2-a898d558c2f7", "node_type": "1", "metadata": {"window": "AmerisourceBergen was named a \u201cBest Place to W ork for Disability Inclusion\u201d after receiving a perfect score on the Disability\nEquality Index.  The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D. ", "original_text": "public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "279945d1ed340b4e3d612199692cd0a6c58cf202436f11f532c88f11a72fb5cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab7818fd-d02f-46e4-965d-64c9e2a58fd2", "node_type": "1", "metadata": {"window": "AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy. ", "original_text": "AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n"}, "hash": "50dcea4b2e099e31756971c1fa3baaefe16fb34557aeab4830b7a2054efac19a", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n", "start_char_idx": 1248, "end_char_idx": 1425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab7818fd-d02f-46e4-965d-64c9e2a58fd2": {"__data__": {"id_": "ab7818fd-d02f-46e4-965d-64c9e2a58fd2", "embedding": null, "metadata": {"window": "AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy. ", "original_text": "AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "870c82c5-e47e-47e7-bfcf-227517d1c5b3", "node_type": "1", "metadata": {"window": "The Disability Equality Index is a joint initiative of Disability:IN and the American Association of P eople with\nDisabilities that measures disability inclusion.\n AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S. ", "original_text": "AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7dd7966829bf12a988cba20fa54a673e3fecd5f531c90d8b9506a5dac25fd00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db9eef21-8226-44f8-af34-78f5aac9e3a3", "node_type": "1", "metadata": {"window": "public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D. "}, "hash": "a02dd054caff830a259a70e397d418bd86bc2449cf8d78836f7c9fb2f2e6283e", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n", "start_char_idx": 1425, "end_char_idx": 1555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db9eef21-8226-44f8-af34-78f5aac9e3a3": {"__data__": {"id_": "db9eef21-8226-44f8-af34-78f5aac9e3a3", "embedding": null, "metadata": {"window": "public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab7818fd-d02f-46e4-965d-64c9e2a58fd2", "node_type": "1", "metadata": {"window": "AmerisourceBergen was included on Forbes\u2019 first-ever Net Zero Leaders list, which highlights the 100 U.S.  public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy. ", "original_text": "AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8cdc9aef98e292e33c1f50864b34929291c57804a62e56debbecc17115864101", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba0c139b-fb7d-426a-a92e-8b5f6fe6940f", "node_type": "1", "metadata": {"window": "AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "P ower 2022 U.S. "}, "hash": "157cfd2b5111e4b90480a3768d89efa62fc946bad62466d554eb42d5296b4339", "class_name": "RelatedNodeInfo"}}, "text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D. ", "start_char_idx": 1555, "end_char_idx": 1746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba0c139b-fb7d-426a-a92e-8b5f6fe6940f": {"__data__": {"id_": "ba0c139b-fb7d-426a-a92e-8b5f6fe6940f", "embedding": null, "metadata": {"window": "AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "P ower 2022 U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db9eef21-8226-44f8-af34-78f5aac9e3a3", "node_type": "1", "metadata": {"window": "public companies\nthat are best positioning themselves to reduce their greenhouse-gas emissions and integrating climate resilience into\nbusiness models and practices.\n AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f761db078ff56858ec05943cc4cd017d08a37c061aedd78aee40eb951e80b069", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "763b78f1-478d-4b40-b3f4-942191b26f3b", "node_type": "1", "metadata": {"window": "AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Pharmacy S tudy. "}, "hash": "113d33e858092e025b6e9d9905804852ffb59fca9c6a2b5477e1cc22b332675f", "class_name": "RelatedNodeInfo"}}, "text": "P ower 2022 U.S. ", "start_char_idx": 1746, "end_char_idx": 1763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "763b78f1-478d-4b40-b3f4-942191b26f3b": {"__data__": {"id_": "763b78f1-478d-4b40-b3f4-942191b26f3b", "embedding": null, "metadata": {"window": "AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Pharmacy S tudy. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba0c139b-fb7d-426a-a92e-8b5f6fe6940f", "node_type": "1", "metadata": {"window": "AmerisourceBergen was named to USA T oday\u2019s inaugural list of America\u2019s Climate Leaders, a data-driven recognition of\ncompanies that cut their carbon footprint in recent years.\n AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "P ower 2022 U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "696001ac57937f9bcd844d848224db132758074ffcc703a4fadb0855f210a4dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1290457-5743-4cae-a317-a0a98dd50fb5", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates. ", "original_text": "This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n"}, "hash": "f473d2409615485496906933ecb5f0289b3914f41f998e596de033603306b1ff", "class_name": "RelatedNodeInfo"}}, "text": "Pharmacy S tudy. ", "start_char_idx": 1763, "end_char_idx": 1780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1290457-5743-4cae-a317-a0a98dd50fb5": {"__data__": {"id_": "d1290457-5743-4cae-a317-a0a98dd50fb5", "embedding": null, "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates. ", "original_text": "This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "763b78f1-478d-4b40-b3f4-942191b26f3b", "node_type": "1", "metadata": {"window": "AmerisourceBergen was recognized by the Civic 50 of Greater Philadelphia for its efforts to drive social impact in its\ncommunity.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Pharmacy S tudy. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0be71ed46e6a727fa53fd79e767e26275b9f791657017de467c7ceb5666af0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5599d1a-f3a8-4bc9-853e-d984a0256967", "node_type": "1", "metadata": {"window": "P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "cd07613395d54adc9c7ab761c7448779cdb03e93905152bf9a0ea246e6e441df", "class_name": "RelatedNodeInfo"}}, "text": "This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n", "start_char_idx": 1780, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5599d1a-f3a8-4bc9-853e-d984a0256967": {"__data__": {"id_": "f5599d1a-f3a8-4bc9-853e-d984a0256967", "embedding": null, "metadata": {"window": "P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1290457-5743-4cae-a317-a0a98dd50fb5", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cFirst in Customer Satisfaction with Chain Drug S tore Pharmacies\u201d in the J.D.  P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates. ", "original_text": "This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eed4ebb767e7b44b7448df5d4c56a166d80c0fab38f8899354513f416603f0af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5a21cb1-df10-4f16-9cfa-86d862c74ba3", "node_type": "1", "metadata": {"window": "Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "5dddb7684b69dee62139e1db6c0d949a26be05e15baa6896afd0912c7e5e36c4", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 1927, "end_char_idx": 2171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5a21cb1-df10-4f16-9cfa-86d862c74ba3": {"__data__": {"id_": "a5a21cb1-df10-4f16-9cfa-86d862c74ba3", "embedding": null, "metadata": {"window": "Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5599d1a-f3a8-4bc9-853e-d984a0256967", "node_type": "1", "metadata": {"window": "P ower 2022 U.S.  Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1a4322295193887dcfe49a9cf487aaf031d1743abc01bc032d05e1e7440b7cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f26689a4-3d85-48fa-8527-86dc6cb0900b", "node_type": "1", "metadata": {"window": "This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent. ", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates. "}, "hash": "fc3dfd50ac4e7745edd7e1910d269bda0ffb4d0b470d61bbfcf4ed387b1c0d40", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 2171, "end_char_idx": 2304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f26689a4-3d85-48fa-8527-86dc6cb0900b": {"__data__": {"id_": "f26689a4-3d85-48fa-8527-86dc6cb0900b", "embedding": null, "metadata": {"window": "This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent. ", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5a21cb1-df10-4f16-9cfa-86d862c74ba3", "node_type": "1", "metadata": {"window": "Pharmacy S tudy.  This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a341972159e91a4533054777c13795df21a416c65cf21fbd8e5542f09184a4d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1ffa613-b8c9-4237-b7d4-0593162e4139", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S. ", "original_text": "The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S. "}, "hash": "5658f1e09ba783aee5c62679a38af956bb7d374c70ee171e582847f1cf427fdd", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates. ", "start_char_idx": 2304, "end_char_idx": 2542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1ffa613-b8c9-4237-b7d4-0593162e4139": {"__data__": {"id_": "d1ffa613-b8c9-4237-b7d4-0593162e4139", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S. ", "original_text": "The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f26689a4-3d85-48fa-8527-86dc6cb0900b", "node_type": "1", "metadata": {"window": "This marks the\ntwelfth time that Good Neighbor Pharmacy has earned the achievement in the last 14 years and the network's seventh\nconsecutive win.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent. ", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe5e3bbe7f25fdc55f2b6a47720653cb768c0ccbc66e4a8e811d3c621d0bb769", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36974146-18f2-482f-b545-b4511b67fe79", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n"}, "hash": "107bd97b5d34b65e655df60e0bbcdf3800146b317aa70daec7bd27d7fb53639d", "class_name": "RelatedNodeInfo"}}, "text": "The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S. ", "start_char_idx": 2542, "end_char_idx": 2659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36974146-18f2-482f-b545-b4511b67fe79": {"__data__": {"id_": "36974146-18f2-482f-b545-b4511b67fe79", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1ffa613-b8c9-4237-b7d4-0593162e4139", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S. ", "original_text": "The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273f060c1b3e33381da56ee8fe11e8291d5d927c72ce2852d9f792c09ab43d41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2f55778-1555-4b01-a3ae-ccc2a5fa73e0", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent. "}, "hash": "09efdf15d157de3702f8232bb8b6f93c873e56e8cc88215ca0be4ee2a881d16d", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n", "start_char_idx": 2659, "end_char_idx": 3619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2f55778-1555-4b01-a3ae-ccc2a5fa73e0": {"__data__": {"id_": "d2f55778-1555-4b01-a3ae-ccc2a5fa73e0", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36974146-18f2-482f-b545-b4511b67fe79", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4715363ee36d804863dd80ae597e87f60b9eed371c18170df141c3917eade54c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3664dbf6-98fd-48f9-b30a-39f618be35f0", "node_type": "1", "metadata": {"window": "The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S. "}, "hash": "3f59405441a155e12c0c1397d175ad6b1868659d31892a9c14354d8f69ee0407", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent. ", "start_char_idx": 3619, "end_char_idx": 3783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3664dbf6-98fd-48f9-b30a-39f618be35f0": {"__data__": {"id_": "3664dbf6-98fd-48f9-b30a-39f618be35f0", "embedding": null, "metadata": {"window": "The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2f55778-1555-4b01-a3ae-ccc2a5fa73e0", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and\nupdated foreign currency translation rates.  The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95f1fe712dc73851dde9d26d32c4e4a5e44890f476f4946342173fd88a58b848", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05d24ea2-cbec-4a45-95cc-7800b7285c7b", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4"}, "hash": "5fd2167f865618facaa232174b6768cfa7f9fa2aa0078420d1565051d177a63c", "class_name": "RelatedNodeInfo"}}, "text": "Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S. ", "start_char_idx": 3783, "end_char_idx": 3961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05d24ea2-cbec-4a45-95cc-7800b7285c7b": {"__data__": {"id_": "05d24ea2-cbec-4a45-95cc-7800b7285c7b", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d726a82dba338f8429f385034fc7fd7452ecc2b8e4b30f30a09416c8c178a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3664dbf6-98fd-48f9-b30a-39f618be35f0", "node_type": "1", "metadata": {"window": "The Company now expects:\nRevenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2431e94d71cc43c767f6a4bda041bd06c193a3460bfd99754d44b9035a12667c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42c78839-07a1-4a18-ba29-c5351faf793c", "node_type": "1", "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n", "original_text": "range of 3 to 5 percent. "}, "hash": "b30b013bb9eda9fa783240f2d9e0b9d64e92e5170d199dd15a7ed64a8912acfc", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "start_char_idx": 3961, "end_char_idx": 4071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42c78839-07a1-4a18-ba29-c5351faf793c": {"__data__": {"id_": "42c78839-07a1-4a18-ba29-c5351faf793c", "embedding": null, "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n", "original_text": "range of 3 to 5 percent. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05d24ea2-cbec-4a45-95cc-7800b7285c7b", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a\n3 percent decline to flat;\nAdjusted Diluted Earnings P er Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from\nthe previous range of $11.70 to $11.90;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 9 to 10 percent, from\nthe previous range of 8 to 10 percent;\nExcluding contributions related to C OVID-19, adjusted diluted earnings per share growth to be in the range of 12 to 13\npercent, from the previous range of 11 to 13 percent; and\nOn a constant currency basis excluding contributions related to C OVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 14 percent, from the previous range of 13 to 15 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 3 to 4 percent, from the previous range of 2 to 4\npercent.  Excluding contributions related to C OVID-19, adjusted consolidated operating income growth to be in the range of 6\nto 7 percent, from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 4 to 5 percent, from the previous\n4", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "645619888b7846371824ca041b26efe4d4022ab6f420d32d77e6e75f2f30bb2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "861191f4-8e2b-4be0-aad7-dc0c9041201e", "node_type": "1", "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures. ", "original_text": "Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n"}, "hash": "3a160a16586e92c30346028062ee82a9b3ae340648874a85e3dfe8d182e7edd9", "class_name": "RelatedNodeInfo"}}, "text": "range of 3 to 5 percent. ", "start_char_idx": 0, "end_char_idx": 25, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "861191f4-8e2b-4be0-aad7-dc0c9041201e": {"__data__": {"id_": "861191f4-8e2b-4be0-aad7-dc0c9041201e", "embedding": null, "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures. ", "original_text": "Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42c78839-07a1-4a18-ba29-c5351faf793c", "node_type": "1", "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n", "original_text": "range of 3 to 5 percent. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "296773d37bda0f1bb6aa9e7d1ad3ceadb7ee18d9ffe6eb457b325b5a242bb6e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a786d4e3-2c8c-486b-97a8-714a9f783f98", "node_type": "1", "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d. ", "original_text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n"}, "hash": "acb596b4f1bcab00da1c0568171388685ab3a1ff5dca29f79feee3aeff2fe085", "class_name": "RelatedNodeInfo"}}, "text": "Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n", "start_char_idx": 25, "end_char_idx": 678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a786d4e3-2c8c-486b-97a8-714a9f783f98": {"__data__": {"id_": "a786d4e3-2c8c-486b-97a8-714a9f783f98", "embedding": null, "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d. ", "original_text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "861191f4-8e2b-4be0-aad7-dc0c9041201e", "node_type": "1", "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures. ", "original_text": "Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf3eeee22295caf590279443032644562fafcc6a2f9a35df9d6a4477aba8d57d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4baa3b76-3509-4e1a-951b-0cf7d64b5ef2", "node_type": "1", "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n"}, "hash": "4a27e62038596a6d0269485aa3e0953d2de05af358a02803d2841dc90b6de028", "class_name": "RelatedNodeInfo"}}, "text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n", "start_char_idx": 678, "end_char_idx": 819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4baa3b76-3509-4e1a-951b-0cf7d64b5ef2": {"__data__": {"id_": "4baa3b76-3509-4e1a-951b-0cf7d64b5ef2", "embedding": null, "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a786d4e3-2c8c-486b-97a8-714a9f783f98", "node_type": "1", "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d. ", "original_text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df0b332d9ff1c050bf2a1b1a251a5d6324d74085639416aa85cc68e815f19f77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cf9a015-110c-419c-a7fa-6787551430ff", "node_type": "1", "metadata": {"window": "Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n", "original_text": "Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures. "}, "hash": "1879b8969af2dcf65977793fce0ec778bfd1c01e2274ebc40c73c7fda415d6a5", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n", "start_char_idx": 819, "end_char_idx": 1032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cf9a015-110c-419c-a7fa-6787551430ff": {"__data__": {"id_": "2cf9a015-110c-419c-a7fa-6787551430ff", "embedding": null, "metadata": {"window": "Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n", "original_text": "Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4baa3b76-3509-4e1a-951b-0cf7d64b5ef2", "node_type": "1", "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea99bc3f197984fb7c3e4329fa13fe520ecc64c04952813651b86cc7bf24da65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0c9f898-b4c6-4b06-998f-3bf91be0a098", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d. "}, "hash": "1156782a54fc3063379b7cbf5bff3b70ea19edbbf606f096d855b27b1057ed5a", "class_name": "RelatedNodeInfo"}}, "text": "Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures. ", "start_char_idx": 1032, "end_char_idx": 1210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0c9f898-b4c6-4b06-998f-3bf91be0a098": {"__data__": {"id_": "d0c9f898-b4c6-4b06-998f-3bf91be0a098", "embedding": null, "metadata": {"window": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cf9a015-110c-419c-a7fa-6787551430ff", "node_type": "1", "metadata": {"window": "Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n", "original_text": "Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22d944a651979fb8055f3bf101f0db5e2d091b6ddd750889a8a12920ee36a0e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5273373a-add9-4c38-812f-843d6da3eecf", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023. ", "original_text": "The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n"}, "hash": "ccb70124c4deb62795d359b4673ab95f70b4dfade3e8ac54884cd8ca5e0b9a29", "class_name": "RelatedNodeInfo"}}, "text": "Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d. ", "start_char_idx": 1210, "end_char_idx": 1369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5273373a-add9-4c38-812f-843d6da3eecf": {"__data__": {"id_": "5273373a-add9-4c38-812f-843d6da3eecf", "embedding": null, "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023. ", "original_text": "The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0c9f898-b4c6-4b06-998f-3bf91be0a098", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "010a6681f619cba98e11125a7c73c5fa17757a831ecf3378e91f9d16cca0071f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "983f1bc7-107f-4b9d-ba86-17a79dfc8195", "node_type": "1", "metadata": {"window": "Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "original_text": "Confer ence Call & Slide Pr esentation.\n"}, "hash": "c5bdf140c94ae2f011c5432ac938b93f572ded28e879d32462d3e1fe9830af9b", "class_name": "RelatedNodeInfo"}}, "text": "The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n", "start_char_idx": 1369, "end_char_idx": 1532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "983f1bc7-107f-4b9d-ba86-17a79dfc8195": {"__data__": {"id_": "983f1bc7-107f-4b9d-ba86-17a79dfc8195", "embedding": null, "metadata": {"window": "Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "original_text": "Confer ence Call & Slide Pr esentation.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5273373a-add9-4c38-812f-843d6da3eecf", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023. ", "original_text": "The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "010b4512877d7ad34d53def24fb48bcc496532c0e4904b5c7c195b70f05404d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfa7d28a-5162-4b04-9e31-77085cd22c9c", "node_type": "1", "metadata": {"window": "Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "The Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "abe0b05f2136ca25cbb000e447b0008ced79abba3258e6162ab1edcfbd50493d", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation.\n", "start_char_idx": 1532, "end_char_idx": 1572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfa7d28a-5162-4b04-9e31-77085cd22c9c": {"__data__": {"id_": "cfa7d28a-5162-4b04-9e31-77085cd22c9c", "embedding": null, "metadata": {"window": "Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "The Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "983f1bc7-107f-4b9d-ba86-17a79dfc8195", "node_type": "1", "metadata": {"window": "Name Change\nOn January 24, 2023, the Company announced its intent to change its name to better reflect its bold vision and purpose-driven\napproach to creating healthier futures.  Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "original_text": "Confer ence Call & Slide Pr esentation.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d952235106c30842375c8eca2536720c95ac72f42455134aa103cde137c7530", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15fc4415-2561-468c-972b-db601454e046", "node_type": "1", "metadata": {"window": "The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on August 2, 2023. "}, "hash": "4169fec7ea3abd52a88fbc5bd971d8587ea9229f8db5f97cc1601363e8cac816", "class_name": "RelatedNodeInfo"}}, "text": "The Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 1572, "end_char_idx": 1648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15fc4415-2561-468c-972b-db601454e046": {"__data__": {"id_": "15fc4415-2561-468c-972b-db601454e046", "embedding": null, "metadata": {"window": "The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on August 2, 2023. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfa7d28a-5162-4b04-9e31-77085cd22c9c", "node_type": "1", "metadata": {"window": "Effective August 30, 2023, the Company will begin operating as Cencora and will begin\ntrading on the New Y ork S tock Exchange under the ticker symbol \u201cC OR\u201d.  The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "The Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5382b88e1d1ee0c0fcbe19f8fadaf8c321fb561a10019a2a7c7c43bd43b4a3e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8c49f3b-fcc0-4e81-82a9-8c1688c79b82", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. "}, "hash": "97910086032ea88402cc4fdc42d37a22634aacee53bfdcf7899d9eba8697c283", "class_name": "RelatedNodeInfo"}}, "text": "ET on August 2, 2023. ", "start_char_idx": 1648, "end_char_idx": 1670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8c49f3b-fcc0-4e81-82a9-8c1688c79b82": {"__data__": {"id_": "a8c49f3b-fcc0-4e81-82a9-8c1688c79b82", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15fc4415-2561-468c-972b-db601454e046", "node_type": "1", "metadata": {"window": "The new name represents a unified presence that will\ncontinue to fuel the Company\u2019s ongoing growth strategy and advance its impact across the healthcare industry.\n Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on August 2, 2023. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "afd1c395b34b7267cd4d68ad4e533855cc2dff0eb70dc83eae0cfa3d82eb1736", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ee92c0a-ced4-481a-948d-f81f4596bf12", "node_type": "1", "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "original_text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. "}, "hash": "02eff111d5b49e957276c674675473c05994502aab38944e89e07527a6fbdcaa", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "start_char_idx": 1670, "end_char_idx": 1786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ee92c0a-ced4-481a-948d-f81f4596bf12": {"__data__": {"id_": "1ee92c0a-ced4-481a-948d-f81f4596bf12", "embedding": null, "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "original_text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8c49f3b-fcc0-4e81-82a9-8c1688c79b82", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation.\n The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfe4698f64359cb248b08e0f838a26a2bf5235b6bab4c8bd553a912d454d1ce6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "870bfd00-a7fa-438f-b90f-2dfd19a8db9c", "node_type": "1", "metadata": {"window": "ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. "}, "hash": "7c9edeb8aab48cbc73c54c5ed3e8a838fb829cd386cac1abc60943a4c4d9e5b2", "class_name": "RelatedNodeInfo"}}, "text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "start_char_idx": 1786, "end_char_idx": 2026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "870bfd00-a7fa-438f-b90f-2dfd19a8db9c": {"__data__": {"id_": "870bfd00-a7fa-438f-b90f-2dfd19a8db9c", "embedding": null, "metadata": {"window": "ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ee92c0a-ced4-481a-948d-f81f4596bf12", "node_type": "1", "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "original_text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da24555cd06a37c59e2fc4fbdc56f9297b344bea01f66d3ddf4b9280d3a83381", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70b8e530-6251-4226-a548-296abdbf6c7d", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 742015. "}, "hash": "0fe9235ffa0661742ab0591c41e9b30dcbd5318f8b6dbc86f41dcad59a08053e", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "start_char_idx": 2026, "end_char_idx": 2094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70b8e530-6251-4226-a548-296abdbf6c7d": {"__data__": {"id_": "70b8e530-6251-4226-a548-296abdbf6c7d", "embedding": null, "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 742015. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "870bfd00-a7fa-438f-b90f-2dfd19a8db9c", "node_type": "1", "metadata": {"window": "ET on August 2, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68dbb5da58f88b5d5258dae03adb51b4e803f5bb12e2df6b183ef7593dbcb18e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "573759bf-1adf-4214-a4c2-e0d515864f13", "node_type": "1", "metadata": {"window": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . "}, "hash": "7e6c4e906599fe9ea7bc70d8a209b21eb5c352200b81f366655a73d8deb8d12f", "class_name": "RelatedNodeInfo"}}, "text": "The\naccess code for the call will be 742015. ", "start_char_idx": 2094, "end_char_idx": 2139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "573759bf-1adf-4214-a4c2-e0d515864f13": {"__data__": {"id_": "573759bf-1adf-4214-a4c2-e0d515864f13", "embedding": null, "metadata": {"window": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70b8e530-6251-4226-a548-296abdbf6c7d", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 742015. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ac7cc47ebe03b1e23b89da22d386d6e83d41c2c747bfd4711f7a580049b2da0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b989948f-bf78-41f9-b215-6d87ccb0cb9c", "node_type": "1", "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n"}, "hash": "cb4c35f92069c9c581db76adef325be61f2cd3d9e83d00193e877ad8f563a60c", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "start_char_idx": 2139, "end_char_idx": 2236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b989948f-bf78-41f9-b215-6d87ccb0cb9c": {"__data__": {"id_": "b989948f-bf78-41f9-b215-6d87ccb0cb9c", "embedding": null, "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "573759bf-1adf-4214-a4c2-e0d515864f13", "node_type": "1", "metadata": {"window": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "061a4cfb855ac6d09efd51ce477872e004cc6387dc9960ec1962c29522849557", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92fa3eca-130c-4f49-8478-c33c91330f99", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "6d53829a460e233a342c0b0fc11b7e0ecdaa6a8912fa8ff3943f74905f2c2f1e", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "start_char_idx": 2236, "end_char_idx": 2359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92fa3eca-130c-4f49-8478-c33c91330f99": {"__data__": {"id_": "92fa3eca-130c-4f49-8478-c33c91330f99", "embedding": null, "metadata": {"window": "The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b989948f-bf78-41f9-b215-6d87ccb0cb9c", "node_type": "1", "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8913c1cc77ac52ba46ebb3724de648f920d4e6a2910b553b603405113662c567", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2874f08-6c3b-4cfd-830a-10cb75d17c55", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. "}, "hash": "29e314d6414d65b2bd1a33c5e1f11b65a75b1264b7363a5f348696ba789fc258", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 2359, "end_char_idx": 2429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2874f08-6c3b-4cfd-830a-10cb75d17c55": {"__data__": {"id_": "b2874f08-6c3b-4cfd-830a-10cb75d17c55", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92fa3eca-130c-4f49-8478-c33c91330f99", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 742015.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "230e386c0731de33db70062becdd68004e98f68de066b85ec07cc68c63757eb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75232879-0654-4bf4-a216-c04e248d7785", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. "}, "hash": "d788f73ab0b1d6fee2af8b5ef118776c7a154426d3406cffad578eae2a28edc4", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 2429, "end_char_idx": 2598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75232879-0654-4bf4-a216-c04e248d7785": {"__data__": {"id_": "75232879-0654-4bf4-a216-c04e248d7785", "embedding": null, "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2874f08-6c3b-4cfd-830a-10cb75d17c55", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f717fa7936377d3a33135023b50df85b52ad807e758611c6f2569d1492e4aec1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "538c378f-5e0a-4e9d-a63e-5e15b017f5bf", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n", "original_text": "T o access the telephone replay from within the U.S. "}, "hash": "35d3e90b000a346697f92b124fe2adbe93caa48af30800d4f82cf46f020d792a", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 2598, "end_char_idx": 2740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "538c378f-5e0a-4e9d-a63e-5e15b017f5bf": {"__data__": {"id_": "538c378f-5e0a-4e9d-a63e-5e15b017f5bf", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n", "original_text": "T o access the telephone replay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75232879-0654-4bf4-a216-c04e248d7785", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cbd4cb1412bf5be016ff0f8012e94486d3e625ba0ad3af91f07d7ce86de88ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd3722bf-08e4-459b-a40b-73baa74e9051", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "and Canada, dial (866) 813-9403. "}, "hash": "4ba264718a015e9faa19f444b1bde481070a08d706bb0d64be9181cd96091367", "class_name": "RelatedNodeInfo"}}, "text": "T o access the telephone replay from within the U.S. ", "start_char_idx": 2740, "end_char_idx": 2793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd3722bf-08e4-459b-a40b-73baa74e9051": {"__data__": {"id_": "dd3722bf-08e4-459b-a40b-73baa74e9051", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "538c378f-5e0a-4e9d-a63e-5e15b017f5bf", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n", "original_text": "T o access the telephone replay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f41078e9d0d971497825b5c9e881b67a839324a91601ddc2a71c3a730d7e52a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd9c7210-a30d-4923-bbe9-c84c3a848e59", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "From outside the United S tates and\nCanada, dial +44 (204) 525-0658. "}, "hash": "108523cac1b890050353f092e3fed803e5d7d4cdf9f1a91b34e2e34bf264fa05", "class_name": "RelatedNodeInfo"}}, "text": "and Canada, dial (866) 813-9403. ", "start_char_idx": 2793, "end_char_idx": 2826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd9c7210-a30d-4923-bbe9-c84c3a848e59": {"__data__": {"id_": "dd9c7210-a30d-4923-bbe9-c84c3a848e59", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "From outside the United S tates and\nCanada, dial +44 (204) 525-0658. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd3722bf-08e4-459b-a40b-73baa74e9051", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7134b0a5177866d82d27894d07e60a6f07ba38db72a76f2e2df8e16bbd4ec14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5024e4c6-9387-458e-86c0-06677adb9353", "node_type": "1", "metadata": {"window": "T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "The access code for the replay is 498053.\n"}, "hash": "01e99aa7616f4aa802b86cadae6e36f6abc9ca8df9305628ce2ff6762621a17b", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United S tates and\nCanada, dial +44 (204) 525-0658. ", "start_char_idx": 2826, "end_char_idx": 2895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5024e4c6-9387-458e-86c0-06677adb9353": {"__data__": {"id_": "5024e4c6-9387-458e-86c0-06677adb9353", "embedding": null, "metadata": {"window": "T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "The access code for the replay is 498053.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd9c7210-a30d-4923-bbe9-c84c3a848e59", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "From outside the United S tates and\nCanada, dial +44 (204) 525-0658. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8710be50f2dc00d879c4840103c29e751cd73bbc1c03d535ff882322ee40491", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "191dca9b-02d4-413b-aa5f-c29142c88116", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "1933cee699a9bd33a0634a36d8b691770d9c107d222417e2a5cbc70fdd828096", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 498053.\n", "start_char_idx": 2895, "end_char_idx": 2937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "191dca9b-02d4-413b-aa5f-c29142c88116": {"__data__": {"id_": "191dca9b-02d4-413b-aa5f-c29142c88116", "embedding": null, "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5024e4c6-9387-458e-86c0-06677adb9353", "node_type": "1", "metadata": {"window": "T o access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "The access code for the replay is 498053.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2a7c1a81db46eb5e7f70cf9401370b01c409f2d46a0e3abf8d7239b9261adf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d3622f7-f749-4c1d-b616-f1aa865382db", "node_type": "1", "metadata": {"window": "From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "5"}, "hash": "3dbfeab97c1a6b59eedc59cd44dfabf1ad8a8e5ecd292c8ccb03ff44ac7b69d1", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 2937, "end_char_idx": 3310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d3622f7-f749-4c1d-b616-f1aa865382db": {"__data__": {"id_": "5d3622f7-f749-4c1d-b616-f1aa865382db", "embedding": null, "metadata": {"window": "From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "5", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1566f4d6-9561-4343-b260-d4f89df55e7c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d976f5b1fec1e228104d5c8edb52b7f7a0a3f193fb5324d32ce1d46cdd78ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "191dca9b-02d4-413b-aa5f-c29142c88116", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a79eee64122cebcb3a2f9158f9a64226ece07751e996367cdcd89a2319ed37b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee2298b0-2aaa-4521-bef6-48c570eed225", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. "}, "hash": "68a18ba7b272f06e244f3d374b2255fa66d692d3b000a76ba21ef9190780f67e", "class_name": "RelatedNodeInfo"}}, "text": "5", "start_char_idx": 14, "end_char_idx": 15, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee2298b0-2aaa-4521-bef6-48c570eed225": {"__data__": {"id_": "ee2298b0-2aaa-4521-bef6-48c570eed225", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61039336-e01b-441b-852e-b8eb51b938aa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc6e7d28fa11ef3131d9f3c68a5ad1d1d84ddde9f363f550372b87ac5bbc799", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d3622f7-f749-4c1d-b616-f1aa865382db", "node_type": "1", "metadata": {"window": "From outside the United S tates and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 498053.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nMorgan S tanley Global Healthcare Conference, September 11, 2023; and\nBaird Healthcare Conference, September 12, 2023\nPlease check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n 5", "original_text": "5", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81f702a97c4baad6764382fcdc8ebffe10c308c3d18b262e91835ca4f4c35e64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf08eda2-7279-463b-8849-1b71cff9e8ba", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. "}, "hash": "b98565ab5920980aa5f95fd7ed65df45be4d8cc9aa460d8e13fe84c6275e419b", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. ", "start_char_idx": 0, "end_char_idx": 174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf08eda2-7279-463b-8849-1b71cff9e8ba": {"__data__": {"id_": "cf08eda2-7279-463b-8849-1b71cff9e8ba", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61039336-e01b-441b-852e-b8eb51b938aa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc6e7d28fa11ef3131d9f3c68a5ad1d1d84ddde9f363f550372b87ac5bbc799", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee2298b0-2aaa-4521-bef6-48c570eed225", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f734d53172ab9037cf1c5f82a580c227d6f92b6e4fc9abafda15db7a5c9777b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05be8aae-ad7b-444c-adea-24dcd4b34841", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. "}, "hash": "1147a63b5befa0e4347fd085f3238863133ece25de52ebf0fe1e9713376cae4c", "class_name": "RelatedNodeInfo"}}, "text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "start_char_idx": 174, "end_char_idx": 295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05be8aae-ad7b-444c-adea-24dcd4b34841": {"__data__": {"id_": "05be8aae-ad7b-444c-adea-24dcd4b34841", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61039336-e01b-441b-852e-b8eb51b938aa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc6e7d28fa11ef3131d9f3c68a5ad1d1d84ddde9f363f550372b87ac5bbc799", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf08eda2-7279-463b-8849-1b71cff9e8ba", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353336c0da7bd2306cd9796e6cec1c66f3dee3b6871f399fe826f44e2bdfbb67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdb0924a-8bdc-4ffb-a15f-39f3c689c3ca", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. "}, "hash": "9d2963d029583108da44cfdcd394036ec97aa29f2f197dd532408149e9e654c6", "class_name": "RelatedNodeInfo"}}, "text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "start_char_idx": 295, "end_char_idx": 413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdb0924a-8bdc-4ffb-a15f-39f3c689c3ca": {"__data__": {"id_": "bdb0924a-8bdc-4ffb-a15f-39f3c689c3ca", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61039336-e01b-441b-852e-b8eb51b938aa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc6e7d28fa11ef3131d9f3c68a5ad1d1d84ddde9f363f550372b87ac5bbc799", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05be8aae-ad7b-444c-adea-24dcd4b34841", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d95c1c0ef7ef9cf1a0f3d2da07a94d3f9d0024766ba1aa3106b49fa3f79c257c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08e13b09-58ab-48c9-bf05-56b8e2a594d4", "node_type": "1", "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. "}, "hash": "d7e4f50b553b7536ca1fba1c699fabe0941445335c9ab80ce1d929ada47f20ec", "class_name": "RelatedNodeInfo"}}, "text": "Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 413, "end_char_idx": 587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08e13b09-58ab-48c9-bf05-56b8e2a594d4": {"__data__": {"id_": "08e13b09-58ab-48c9-bf05-56b8e2a594d4", "embedding": null, "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61039336-e01b-441b-852e-b8eb51b938aa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc6e7d28fa11ef3131d9f3c68a5ad1d1d84ddde9f363f550372b87ac5bbc799", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdb0924a-8bdc-4ffb-a15f-39f3c689c3ca", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36b69ab1818bb8a95a0346bb8d0b8cee7ea3100ee2c0ab45c89d618225cba80f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15976b30-2677-4a89-8dfa-3079d63a755e", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n"}, "hash": "0171d50022fda8522a78a8e56688d4dab9db36ee6604b891e232ff380e5d3276", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "start_char_idx": 587, "end_char_idx": 719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15976b30-2677-4a89-8dfa-3079d63a755e": {"__data__": {"id_": "15976b30-2677-4a89-8dfa-3079d63a755e", "embedding": null, "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61039336-e01b-441b-852e-b8eb51b938aa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc6e7d28fa11ef3131d9f3c68a5ad1d1d84ddde9f363f550372b87ac5bbc799", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08e13b09-58ab-48c9-bf05-56b8e2a594d4", "node_type": "1", "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45563c4187299c5e9557cd5a076c866e50b4047d7d3b29cd582bd9a1ff0473f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d37018e-8d50-4bea-98e1-e18f94b010ef", "node_type": "1", "metadata": {"window": "Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). "}, "hash": "7e00684c236502e775779da5d6d13ddd7cf96ea853769a78a6a0b78ef7cdbee0", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com .\n", "start_char_idx": 719, "end_char_idx": 766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d37018e-8d50-4bea-98e1-e18f94b010ef": {"__data__": {"id_": "7d37018e-8d50-4bea-98e1-e18f94b010ef", "embedding": null, "metadata": {"window": "Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61039336-e01b-441b-852e-b8eb51b938aa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc6e7d28fa11ef3131d9f3c68a5ad1d1d84ddde9f363f550372b87ac5bbc799", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15976b30-2677-4a89-8dfa-3079d63a755e", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "606e8b88351180dc5483d8e8811abba8328e35437e46d35f834adbc79f412158", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "386f6d8c-7761-4976-b69e-e130fffe3fbd", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. "}, "hash": "bf3b1727e7baebcf901d53434e3d5f3a27838c52f38a093745d65ab13df9d63d", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "start_char_idx": 766, "end_char_idx": 1113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "386f6d8c-7761-4976-b69e-e130fffe3fbd": {"__data__": {"id_": "386f6d8c-7761-4976-b69e-e130fffe3fbd", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61039336-e01b-441b-852e-b8eb51b938aa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc6e7d28fa11ef3131d9f3c68a5ad1d1d84ddde9f363f550372b87ac5bbc799", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d37018e-8d50-4bea-98e1-e18f94b010ef", "node_type": "1", "metadata": {"window": "Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8182d9b2f44444f76a0859ca9f397f759f7e9daa3c5cdff817af185805b8e872", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e7cf294-7f70-4679-96c9-ac420d7ead8c", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. "}, "hash": "29562951d8e98e774c3a5e2cade4ff4e99bf7013d21437fe53413468d9f1c916", "class_name": "RelatedNodeInfo"}}, "text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "start_char_idx": 1113, "end_char_idx": 1557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e7cf294-7f70-4679-96c9-ac420d7ead8c": {"__data__": {"id_": "6e7cf294-7f70-4679-96c9-ac420d7ead8c", "embedding": null, "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61039336-e01b-441b-852e-b8eb51b938aa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc6e7d28fa11ef3131d9f3c68a5ad1d1d84ddde9f363f550372b87ac5bbc799", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "386f6d8c-7761-4976-b69e-e130fffe3fbd", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f01e896bdfd06ce341b5ce3b8d35f80d85eb25fa5e35a7ea92a584b2494246e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1958f19-4af6-4e0a-8269-1565cf73fb81", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. "}, "hash": "70eb71caf4e0d07e04a059ab53afd70c6dd329e1de234b32b1b427e4e28c5466", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "start_char_idx": 1557, "end_char_idx": 1719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1958f19-4af6-4e0a-8269-1565cf73fb81": {"__data__": {"id_": "c1958f19-4af6-4e0a-8269-1565cf73fb81", "embedding": null, "metadata": {"window": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61039336-e01b-441b-852e-b8eb51b938aa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc6e7d28fa11ef3131d9f3c68a5ad1d1d84ddde9f363f550372b87ac5bbc799", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e7cf294-7f70-4679-96c9-ac420d7ead8c", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "351dfe5e124f5e8dcd041507ba4fa71b963605557702b60970a924c5ab979b56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31ee3eac-5d0a-4a82-a301-19fd12ac43c5", "node_type": "1", "metadata": {"window": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6"}, "hash": "c22f9e730664a5b216ad906b81e59df60e7815190afd9c8fad4a75ae6c86768a", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "start_char_idx": 1719, "end_char_idx": 1918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31ee3eac-5d0a-4a82-a301-19fd12ac43c5": {"__data__": {"id_": "31ee3eac-5d0a-4a82-a301-19fd12ac43c5", "embedding": null, "metadata": {"window": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61039336-e01b-441b-852e-b8eb51b938aa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc6e7d28fa11ef3131d9f3c68a5ad1d1d84ddde9f363f550372b87ac5bbc799", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1958f19-4af6-4e0a-8269-1565cf73fb81", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c24d09f6b9933a93700c035fa0e34366dfaf2b1ef8abf02f91ee6d4a9dbfef0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ace612a-cae5-4d4d-a191-497cc4c1b34d", "node_type": "1", "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc. "}, "hash": "2aaa4d2346ee6739f7844cfcd78931c4e8ef03fb926fb49f06464755bf8a5a2e", "class_name": "RelatedNodeInfo"}}, "text": "Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "start_char_idx": 1918, "end_char_idx": 4977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ace612a-cae5-4d4d-a191-497cc4c1b34d": {"__data__": {"id_": "2ace612a-cae5-4d4d-a191-497cc4c1b34d", "embedding": null, "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc. ", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e563a3a8-f110-411d-abfe-c4214270a573", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a22e515e8fd8e83329de2afdcd18d5a3867075d75e06ac34ee03bc0492496a6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31ee3eac-5d0a-4a82-a301-19fd12ac43c5", "node_type": "1", "metadata": {"window": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d\n\u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "original_text": "Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing C OVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the C OVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United S tates healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the C OVID-19 impact on such payment terms;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\n6", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0b6ac8cdcd8687a27cb116d80d03e8ea76e2ef8bd79650c06002869a17804a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "941c0354-68d8-4850-a789-2342a161a352", "node_type": "1", "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n", "original_text": "and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S. "}, "hash": "3c556d647d30821b4dbe7fcbb1f01185abc1a48b3929f02444c41c8ec3f576d5", "class_name": "RelatedNodeInfo"}}, "text": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc. ", "start_char_idx": 0, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "941c0354-68d8-4850-a789-2342a161a352": {"__data__": {"id_": "941c0354-68d8-4850-a789-2342a161a352", "embedding": null, "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n", "original_text": "and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S. ", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e563a3a8-f110-411d-abfe-c4214270a573", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a22e515e8fd8e83329de2afdcd18d5a3867075d75e06ac34ee03bc0492496a6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ace612a-cae5-4d4d-a191-497cc4c1b34d", "node_type": "1", "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc. ", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d96233c0ece357e974087019d98a920910fdf15bf3d1f4976f27b9aedc1dd3f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1180eec6-7def-435c-8423-da2417e42805", "node_type": "1", "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n"}, "hash": "c14997aefeeb3c35826bed6a8cf37c7f3b49a92a62cb6788aad923959e66fd85", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S. ", "start_char_idx": 724, "end_char_idx": 935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1180eec6-7def-435c-8423-da2417e42805": {"__data__": {"id_": "1180eec6-7def-435c-8423-da2417e42805", "embedding": null, "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e563a3a8-f110-411d-abfe-c4214270a573", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a22e515e8fd8e83329de2afdcd18d5a3867075d75e06ac34ee03bc0492496a6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "941c0354-68d8-4850-a789-2342a161a352", "node_type": "1", "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n", "original_text": "and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S. ", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91d9350c2c7c79cd547dd0d40fefab39059dbf3c8c3a29cf420614fad29ff619", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfeff777-71b1-44b9-aa1d-4566903b97ff", "node_type": "1", "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act. "}, "hash": "456b74390e2365869de8817bba489860c54e5b8f8116c4da7b50fdc56293b457", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n", "start_char_idx": 935, "end_char_idx": 3005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfeff777-71b1-44b9-aa1d-4566903b97ff": {"__data__": {"id_": "bfeff777-71b1-44b9-aa1d-4566903b97ff", "embedding": null, "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e563a3a8-f110-411d-abfe-c4214270a573", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a22e515e8fd8e83329de2afdcd18d5a3867075d75e06ac34ee03bc0492496a6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1180eec6-7def-435c-8423-da2417e42805", "node_type": "1", "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "572f93f341ea814763ae6d38c4a8fecbd18b0122b4d1c30ecd9141f9291bf0cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cfcc48d-ab68-4c93-8c96-f02d3a3357b6", "node_type": "1", "metadata": {"window": "and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n"}, "hash": "d67e5c0e842e54869bb251ca79470a10e2c473c5a5b0923ccb6dc57f3c25a4de", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act. ", "start_char_idx": 3005, "end_char_idx": 3592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cfcc48d-ab68-4c93-8c96-f02d3a3357b6": {"__data__": {"id_": "0cfcc48d-ab68-4c93-8c96-f02d3a3357b6", "embedding": null, "metadata": {"window": "and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e563a3a8-f110-411d-abfe-c4214270a573", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a22e515e8fd8e83329de2afdcd18d5a3867075d75e06ac34ee03bc0492496a6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfeff777-71b1-44b9-aa1d-4566903b97ff", "node_type": "1", "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "562f115419b002112dc1ae4fb87802be8d295f58bae9343ae780ec6cf503cdea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0f60f4f-c0ae-4437-b177-42312f8c8101", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7"}, "hash": "92be13f769b07d30b770434503517298d97da424f5ec4fb0b28b1a09510242fa", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n", "start_char_idx": 3592, "end_char_idx": 3741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0f60f4f-c0ae-4437-b177-42312f8c8101": {"__data__": {"id_": "d0f60f4f-c0ae-4437-b177-42312f8c8101", "embedding": null, "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e563a3a8-f110-411d-abfe-c4214270a573", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a22e515e8fd8e83329de2afdcd18d5a3867075d75e06ac34ee03bc0492496a6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cfcc48d-ab68-4c93-8c96-f02d3a3357b6", "node_type": "1", "metadata": {"window": "and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8ccae415b9dcd6555cadb517035b764b46760c198d157ad505a2b9114917a0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4245eda2-2418-466a-8f1f-e93fe705b3f1", "node_type": "1", "metadata": {"window": "Revenue \u00a0$66,947,043 \u00a0\u00a0 \u00a0$60,064,601 \u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a064,682,397 \u00a0\u00a0\u00a0 \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a011.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,264,646 \u00a0\u00a03.38 %\u00a0\u00a02,015,369 \u00a0\u00a03.36 %\u00a012.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,304,141 \u00a0\u00a01.95 %\u00a0\u00a01,212,152 \u00a0\u00a02.02 %\u00a07.6 %\nDepreciation and amortization \u00a0\u00a0274,272 \u00a0\u00a00.41 %\u00a0\u00a0172,114 \u00a0\u00a00.29 %\u00a059.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(67,102 )\u00a0\u00a0 \u00a0\u00a023,442 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a019,283 \u00a0\u00a0\u00a0 \u00a0\u00a036,570 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a063,924 \u00a0\u00a0\u00a0 \u00a0\u00a07,858 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,594,518 \u00a0\u00a02.38 %\u00a0\u00a01,528,072 \u00a0\u00a02.54 %\u00a04.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0670,128 \u00a0\u00a01.00 %\u00a0\u00a0487,297 \u00a0\u00a00.81 %\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a0\u00a03,436 \u00a0\u00a0\u00a0 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a057,864 \u00a0\u00a0\u00a0 \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0608,828 \u00a0\u00a00.91 %\u00a0\u00a0476,323 \u00a0\u00a00.79 %\u00a027.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0129,615 \u00a0\u00a0\u00a0 \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0479,213 \u00a0\u00a00.72 %\u00a0\u00a0363,203 \u00a0\u00a00.60 %\u00a031.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a0368 \u00a0\u00a0\u00a0 \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "Revenue \u00a0$66,947,043 \u00a0\u00a0 \u00a0$60,064,601 \u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a064,682,397 \u00a0\u00a0\u00a0 \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a011.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,264,646 \u00a0\u00a03.38 %\u00a0\u00a02,015,369 \u00a0\u00a03.36 %\u00a012.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,304,141 \u00a0\u00a01.95 %\u00a0\u00a01,212,152 \u00a0\u00a02.02 %\u00a07.6 %\nDepreciation and amortization \u00a0\u00a0274,272 \u00a0\u00a00.41 %\u00a0\u00a0172,114 \u00a0\u00a00.29 %\u00a059.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(67,102 )\u00a0\u00a0 \u00a0\u00a023,442 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a019,283 \u00a0\u00a0\u00a0 \u00a0\u00a036,570 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a063,924 \u00a0\u00a0\u00a0 \u00a0\u00a07,858 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,594,518 \u00a0\u00a02.38 %\u00a0\u00a01,528,072 \u00a0\u00a02.54 %\u00a04.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0670,128 \u00a0\u00a01.00 %\u00a0\u00a0487,297 \u00a0\u00a00.81 %\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a0\u00a03,436 \u00a0\u00a0\u00a0 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a057,864 \u00a0\u00a0\u00a0 \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0608,828 \u00a0\u00a00.91 %\u00a0\u00a0476,323 \u00a0\u00a00.79 %\u00a027.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0129,615 \u00a0\u00a0\u00a0 \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0479,213 \u00a0\u00a00.72 %\u00a0\u00a0363,203 \u00a0\u00a00.60 %\u00a031.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a0368 \u00a0\u00a0\u00a0 \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0\n8"}, "hash": "190a195a79ff2328410ea9997c6a675602deba84b0e2278228be1dae046979d0", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "start_char_idx": 3741, "end_char_idx": 3959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4245eda2-2418-466a-8f1f-e93fe705b3f1": {"__data__": {"id_": "4245eda2-2418-466a-8f1f-e93fe705b3f1", "embedding": null, "metadata": {"window": "Revenue \u00a0$66,947,043 \u00a0\u00a0 \u00a0$60,064,601 \u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a064,682,397 \u00a0\u00a0\u00a0 \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a011.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,264,646 \u00a0\u00a03.38 %\u00a0\u00a02,015,369 \u00a0\u00a03.36 %\u00a012.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,304,141 \u00a0\u00a01.95 %\u00a0\u00a01,212,152 \u00a0\u00a02.02 %\u00a07.6 %\nDepreciation and amortization \u00a0\u00a0274,272 \u00a0\u00a00.41 %\u00a0\u00a0172,114 \u00a0\u00a00.29 %\u00a059.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(67,102 )\u00a0\u00a0 \u00a0\u00a023,442 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a019,283 \u00a0\u00a0\u00a0 \u00a0\u00a036,570 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a063,924 \u00a0\u00a0\u00a0 \u00a0\u00a07,858 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,594,518 \u00a0\u00a02.38 %\u00a0\u00a01,528,072 \u00a0\u00a02.54 %\u00a04.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0670,128 \u00a0\u00a01.00 %\u00a0\u00a0487,297 \u00a0\u00a00.81 %\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a0\u00a03,436 \u00a0\u00a0\u00a0 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a057,864 \u00a0\u00a0\u00a0 \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0608,828 \u00a0\u00a00.91 %\u00a0\u00a0476,323 \u00a0\u00a00.79 %\u00a027.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0129,615 \u00a0\u00a0\u00a0 \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0479,213 \u00a0\u00a00.72 %\u00a0\u00a0363,203 \u00a0\u00a00.60 %\u00a031.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a0368 \u00a0\u00a0\u00a0 \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "Revenue \u00a0$66,947,043 \u00a0\u00a0 \u00a0$60,064,601 \u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a064,682,397 \u00a0\u00a0\u00a0 \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a011.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,264,646 \u00a0\u00a03.38 %\u00a0\u00a02,015,369 \u00a0\u00a03.36 %\u00a012.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,304,141 \u00a0\u00a01.95 %\u00a0\u00a01,212,152 \u00a0\u00a02.02 %\u00a07.6 %\nDepreciation and amortization \u00a0\u00a0274,272 \u00a0\u00a00.41 %\u00a0\u00a0172,114 \u00a0\u00a00.29 %\u00a059.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(67,102 )\u00a0\u00a0 \u00a0\u00a023,442 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a019,283 \u00a0\u00a0\u00a0 \u00a0\u00a036,570 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a063,924 \u00a0\u00a0\u00a0 \u00a0\u00a07,858 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,594,518 \u00a0\u00a02.38 %\u00a0\u00a01,528,072 \u00a0\u00a02.54 %\u00a04.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0670,128 \u00a0\u00a01.00 %\u00a0\u00a0487,297 \u00a0\u00a00.81 %\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a0\u00a03,436 \u00a0\u00a0\u00a0 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a057,864 \u00a0\u00a0\u00a0 \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0608,828 \u00a0\u00a00.91 %\u00a0\u00a0476,323 \u00a0\u00a00.79 %\u00a027.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0129,615 \u00a0\u00a0\u00a0 \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0479,213 \u00a0\u00a00.72 %\u00a0\u00a0363,203 \u00a0\u00a00.60 %\u00a031.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a0368 \u00a0\u00a0\u00a0 \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "403889d1-3893-486c-84c5-06b58967796a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "870fee7b97d256a5db2bfc5e0b3c5a93e912594e3c0c99e18e933d3545024837", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0f60f4f-c0ae-4437-b177-42312f8c8101", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly\nupdate or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded\nJune 30,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded\nJune 30,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\n7", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0143b154595c73f8fe20cd816d08ad1738b0d39ebf2a2ab586799006b3795eb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c4e1cea-9ad6-420d-805c-344e344929fc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023. "}, "hash": "4bbfdc6bf03ba9ab49f6c6a65b62bc7b48bf41bcc936c97386ef3cf8856ae4f4", "class_name": "RelatedNodeInfo"}}, "text": "Revenue \u00a0$66,947,043 \u00a0\u00a0 \u00a0$60,064,601 \u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a064,682,397 \u00a0\u00a0\u00a0 \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a011.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,264,646 \u00a0\u00a03.38 %\u00a0\u00a02,015,369 \u00a0\u00a03.36 %\u00a012.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,304,141 \u00a0\u00a01.95 %\u00a0\u00a01,212,152 \u00a0\u00a02.02 %\u00a07.6 %\nDepreciation and amortization \u00a0\u00a0274,272 \u00a0\u00a00.41 %\u00a0\u00a0172,114 \u00a0\u00a00.29 %\u00a059.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(67,102 )\u00a0\u00a0 \u00a0\u00a023,442 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a019,283 \u00a0\u00a0\u00a0 \u00a0\u00a036,570 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a063,924 \u00a0\u00a0\u00a0 \u00a0\u00a07,858 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,594,518 \u00a0\u00a02.38 %\u00a0\u00a01,528,072 \u00a0\u00a02.54 %\u00a04.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0670,128 \u00a0\u00a01.00 %\u00a0\u00a0487,297 \u00a0\u00a00.81 %\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a0\u00a03,436 \u00a0\u00a0\u00a0 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a057,864 \u00a0\u00a0\u00a0 \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0608,828 \u00a0\u00a00.91 %\u00a0\u00a0476,323 \u00a0\u00a00.79 %\u00a027.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0129,615 \u00a0\u00a0\u00a0 \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0479,213 \u00a0\u00a00.72 %\u00a0\u00a0363,203 \u00a0\u00a00.60 %\u00a031.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a0368 \u00a0\u00a0\u00a0 \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0\n8", "start_char_idx": 0, "end_char_idx": 1286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c4e1cea-9ad6-420d-805c-344e344929fc": {"__data__": {"id_": "2c4e1cea-9ad6-420d-805c-344e344929fc", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023. ", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12210a45-b151-4a5a-87fd-8b2953a99b23", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed141d23528c41293fa8b99a4557f23ead1c01b58a636162228a55306e0ca00d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4245eda2-2418-466a-8f1f-e93fe705b3f1", "node_type": "1", "metadata": {"window": "Revenue \u00a0$66,947,043 \u00a0\u00a0 \u00a0$60,064,601 \u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a064,682,397 \u00a0\u00a0\u00a0 \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a011.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,264,646 \u00a0\u00a03.38 %\u00a0\u00a02,015,369 \u00a0\u00a03.36 %\u00a012.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,304,141 \u00a0\u00a01.95 %\u00a0\u00a01,212,152 \u00a0\u00a02.02 %\u00a07.6 %\nDepreciation and amortization \u00a0\u00a0274,272 \u00a0\u00a00.41 %\u00a0\u00a0172,114 \u00a0\u00a00.29 %\u00a059.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(67,102 )\u00a0\u00a0 \u00a0\u00a023,442 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a019,283 \u00a0\u00a0\u00a0 \u00a0\u00a036,570 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a063,924 \u00a0\u00a0\u00a0 \u00a0\u00a07,858 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,594,518 \u00a0\u00a02.38 %\u00a0\u00a01,528,072 \u00a0\u00a02.54 %\u00a04.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0670,128 \u00a0\u00a01.00 %\u00a0\u00a0487,297 \u00a0\u00a00.81 %\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a0\u00a03,436 \u00a0\u00a0\u00a0 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a057,864 \u00a0\u00a0\u00a0 \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0608,828 \u00a0\u00a00.91 %\u00a0\u00a0476,323 \u00a0\u00a00.79 %\u00a027.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0129,615 \u00a0\u00a0\u00a0 \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0479,213 \u00a0\u00a00.72 %\u00a0\u00a0363,203 \u00a0\u00a00.60 %\u00a031.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a0368 \u00a0\u00a0\u00a0 \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "Revenue \u00a0$66,947,043 \u00a0\u00a0 \u00a0$60,064,601 \u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a064,682,397 \u00a0\u00a0\u00a0 \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a011.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,264,646 \u00a0\u00a03.38 %\u00a0\u00a02,015,369 \u00a0\u00a03.36 %\u00a012.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,304,141 \u00a0\u00a01.95 %\u00a0\u00a01,212,152 \u00a0\u00a02.02 %\u00a07.6 %\nDepreciation and amortization \u00a0\u00a0274,272 \u00a0\u00a00.41 %\u00a0\u00a0172,114 \u00a0\u00a00.29 %\u00a059.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(67,102 )\u00a0\u00a0 \u00a0\u00a023,442 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a019,283 \u00a0\u00a0\u00a0 \u00a0\u00a036,570 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a063,924 \u00a0\u00a0\u00a0 \u00a0\u00a07,858 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,594,518 \u00a0\u00a02.38 %\u00a0\u00a01,528,072 \u00a0\u00a02.54 %\u00a04.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0670,128 \u00a0\u00a01.00 %\u00a0\u00a0487,297 \u00a0\u00a00.81 %\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a0\u00a03,436 \u00a0\u00a0\u00a0 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a057,864 \u00a0\u00a0\u00a0 \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0608,828 \u00a0\u00a00.91 %\u00a0\u00a0476,323 \u00a0\u00a00.79 %\u00a027.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0129,615 \u00a0\u00a0\u00a0 \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0479,213 \u00a0\u00a00.72 %\u00a0\u00a0363,203 \u00a0\u00a00.60 %\u00a031.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a0368 \u00a0\u00a0\u00a0 \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7c197bc81325321b1ebf8c5ef7f56d6abb1184f4d84f0f123705da219eff05b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f27e92a-b775-413b-b3af-632e69622206", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n", "original_text": "Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n"}, "hash": "38dceab47bf187da2e7078a55212a5f7d2190d17b38d01c985ef0748f8d825e4", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023. ", "start_char_idx": 0, "end_char_idx": 658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f27e92a-b775-413b-b3af-632e69622206": {"__data__": {"id_": "9f27e92a-b775-413b-b3af-632e69622206", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n", "original_text": "Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12210a45-b151-4a5a-87fd-8b2953a99b23", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed141d23528c41293fa8b99a4557f23ead1c01b58a636162228a55306e0ca00d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c4e1cea-9ad6-420d-805c-344e344929fc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023. ", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0df05c3245d70941caedd14144c5acc545ae361dc81b1466ee1e162cc9b0121d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b56e9a60-0ef3-4751-9a6a-0fa025608dce", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n", "original_text": "2Includes the receipt of $83.4 million from the H.D. "}, "hash": "5073c3c98a96e4520e8cd1f6e2151bd4089848a7f5b5fa460062cff28023df01", "class_name": "RelatedNodeInfo"}}, "text": "Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n", "start_char_idx": 658, "end_char_idx": 804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b56e9a60-0ef3-4751-9a6a-0fa025608dce": {"__data__": {"id_": "b56e9a60-0ef3-4751-9a6a-0fa025608dce", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n", "original_text": "2Includes the receipt of $83.4 million from the H.D. ", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12210a45-b151-4a5a-87fd-8b2953a99b23", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed141d23528c41293fa8b99a4557f23ead1c01b58a636162228a55306e0ca00d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f27e92a-b775-413b-b3af-632e69622206", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n", "original_text": "Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dee18fff0026d68c7c63691b9c317964c24276cccc1f297734331c4e796b7823", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c68613e9-66fa-4305-bcc5-c0bcd84efe1a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n"}, "hash": "842d05dc562f532cbe0601d28026c5e0f88e02a00ac72f3a9dbcecb92d7ae6f6", "class_name": "RelatedNodeInfo"}}, "text": "2Includes the receipt of $83.4 million from the H.D. ", "start_char_idx": 804, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c68613e9-66fa-4305-bcc5-c0bcd84efe1a": {"__data__": {"id_": "c68613e9-66fa-4305-bcc5-c0bcd84efe1a", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12210a45-b151-4a5a-87fd-8b2953a99b23", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed141d23528c41293fa8b99a4557f23ead1c01b58a636162228a55306e0ca00d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b56e9a60-0ef3-4751-9a6a-0fa025608dce", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n", "original_text": "2Includes the receipt of $83.4 million from the H.D. ", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a90963986a0f2219fa2eca22d3fda5d5301416b3bc529e0b382675e01c03a687", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca003966-1fb8-46ed-bb43-7372bdd42fcb", "node_type": "1", "metadata": {"window": "Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n"}, "hash": "faed2e360e7538ee0ab22f159fc5adaed5b746885956a3dd82dc76c69b12858b", "class_name": "RelatedNodeInfo"}}, "text": "Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n", "start_char_idx": 857, "end_char_idx": 939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca003966-1fb8-46ed-bb43-7372bdd42fcb": {"__data__": {"id_": "ca003966-1fb8-46ed-bb43-7372bdd42fcb", "embedding": null, "metadata": {"window": "Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12210a45-b151-4a5a-87fd-8b2953a99b23", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed141d23528c41293fa8b99a4557f23ead1c01b58a636162228a55306e0ca00d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c68613e9-66fa-4305-bcc5-c0bcd84efe1a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3aca577b3506894c7b38670d6c717795d71440cfee8fc9d231b88adacf07a1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9472cfe2-f123-45a1-a749-8685fece04d3", "node_type": "1", "metadata": {"window": "2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n"}, "hash": "88d2e044fcccf478d96a136de447194d5345a5795a7c77a29c675e10175c85ea", "class_name": "RelatedNodeInfo"}}, "text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n", "start_char_idx": 939, "end_char_idx": 1077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9472cfe2-f123-45a1-a749-8685fece04d3": {"__data__": {"id_": "9472cfe2-f123-45a1-a749-8685fece04d3", "embedding": null, "metadata": {"window": "2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12210a45-b151-4a5a-87fd-8b2953a99b23", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed141d23528c41293fa8b99a4557f23ead1c01b58a636162228a55306e0ca00d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca003966-1fb8-46ed-bb43-7372bdd42fcb", "node_type": "1", "metadata": {"window": "Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d7e555e14e247e72386297466c2e749a0e48556d08ebb6cfe9b927b50fc5132", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "276088be-7225-40e8-bfbb-366a0951ce3a", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9"}, "hash": "f7f403adbde1046b9a3dd5f33bf03e623b089354371da2aa236c2ee9642b3ebe", "class_name": "RelatedNodeInfo"}}, "text": "4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n", "start_char_idx": 1077, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "276088be-7225-40e8-bfbb-366a0951ce3a": {"__data__": {"id_": "276088be-7225-40e8-bfbb-366a0951ce3a", "embedding": null, "metadata": {"window": "Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12210a45-b151-4a5a-87fd-8b2953a99b23", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed141d23528c41293fa8b99a4557f23ead1c01b58a636162228a55306e0ca00d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9472cfe2-f123-45a1-a749-8685fece04d3", "node_type": "1", "metadata": {"window": "2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e3a1e223649dc120e2ed5602e8c8ef902c30d47306663120a463acf5a648708", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "008e31ea-1071-43bd-8bee-78533f283e17", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,706,041 \u00a0\u00a03.47 %\u00a0\u00a06,310,808 \u00a0\u00a03.56 %\u00a06.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,916,156 \u00a0\u00a02.03 %\u00a0\u00a03,585,500 \u00a0\u00a02.02 %\u00a09.2 %\nDepreciation and amortization \u00a0\u00a0687,678 \u00a0\u00a00.36 %\u00a0\u00a0523,333 \u00a0\u00a00.29 %\u00a031.4 %\nLitigation and opioid-related (credit)\nexpenses 2 \u00a0\u00a0(38,583 )\u00a0\u00a0 \u00a0\u00a0108,167 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a099,392 \u00a0\u00a0\u00a0 \u00a0\u00a069,710 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0177,608 \u00a0\u00a0\u00a0 \u00a0\u00a031,357 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,842,251 \u00a0\u00a02.51 %\u00a0\u00a04,398,949 \u00a0\u00a02.48 %\u00a010.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,863,790 \u00a0\u00a00.96 %\u00a0\u00a01,911,859 \u00a0\u00a01.08 %\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0\u00a0(18,612 )\u00a0\u00a0 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0167,989 \u00a0\u00a0\u00a0 \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a05.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,714,413 \u00a0\u00a00.89 %\u00a0\u00a01,800,717 \u00a0\u00a01.01 %\u00a0(4.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0330,817 \u00a0\u00a0\u00a0 \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,383,596 \u00a0\u00a00.72 %\u00a0\u00a01,367,864 \u00a0\u00a00.77 %\u00a01.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a011,132 \u00a0\u00a0\u00a0 \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,706,041 \u00a0\u00a03.47 %\u00a0\u00a06,310,808 \u00a0\u00a03.56 %\u00a06.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,916,156 \u00a0\u00a02.03 %\u00a0\u00a03,585,500 \u00a0\u00a02.02 %\u00a09.2 %\nDepreciation and amortization \u00a0\u00a0687,678 \u00a0\u00a00.36 %\u00a0\u00a0523,333 \u00a0\u00a00.29 %\u00a031.4 %\nLitigation and opioid-related (credit)\nexpenses 2 \u00a0\u00a0(38,583 )\u00a0\u00a0 \u00a0\u00a0108,167 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a099,392 \u00a0\u00a0\u00a0 \u00a0\u00a069,710 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0177,608 \u00a0\u00a0\u00a0 \u00a0\u00a031,357 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,842,251 \u00a0\u00a02.51 %\u00a0\u00a04,398,949 \u00a0\u00a02.48 %\u00a010.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,863,790 \u00a0\u00a00.96 %\u00a0\u00a01,911,859 \u00a0\u00a01.08 %\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0\u00a0(18,612 )\u00a0\u00a0 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0167,989 \u00a0\u00a0\u00a0 \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a05.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,714,413 \u00a0\u00a00.89 %\u00a0\u00a01,800,717 \u00a0\u00a01.01 %\u00a0(4.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0330,817 \u00a0\u00a0\u00a0 \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,383,596 \u00a0\u00a00.72 %\u00a0\u00a01,367,864 \u00a0\u00a00.77 %\u00a01.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a011,132 \u00a0\u00a0\u00a0 \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10"}, "hash": "3e4706758a8d4c8c90f0ee7c40626456d5f1ff6a85ea71a91686e2f069e02770", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "start_char_idx": 1184, "end_char_idx": 1530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "008e31ea-1071-43bd-8bee-78533f283e17": {"__data__": {"id_": "008e31ea-1071-43bd-8bee-78533f283e17", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,706,041 \u00a0\u00a03.47 %\u00a0\u00a06,310,808 \u00a0\u00a03.56 %\u00a06.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,916,156 \u00a0\u00a02.03 %\u00a0\u00a03,585,500 \u00a0\u00a02.02 %\u00a09.2 %\nDepreciation and amortization \u00a0\u00a0687,678 \u00a0\u00a00.36 %\u00a0\u00a0523,333 \u00a0\u00a00.29 %\u00a031.4 %\nLitigation and opioid-related (credit)\nexpenses 2 \u00a0\u00a0(38,583 )\u00a0\u00a0 \u00a0\u00a0108,167 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a099,392 \u00a0\u00a0\u00a0 \u00a0\u00a069,710 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0177,608 \u00a0\u00a0\u00a0 \u00a0\u00a031,357 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,842,251 \u00a0\u00a02.51 %\u00a0\u00a04,398,949 \u00a0\u00a02.48 %\u00a010.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,863,790 \u00a0\u00a00.96 %\u00a0\u00a01,911,859 \u00a0\u00a01.08 %\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0\u00a0(18,612 )\u00a0\u00a0 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0167,989 \u00a0\u00a0\u00a0 \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a05.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,714,413 \u00a0\u00a00.89 %\u00a0\u00a01,800,717 \u00a0\u00a01.01 %\u00a0(4.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0330,817 \u00a0\u00a0\u00a0 \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,383,596 \u00a0\u00a00.72 %\u00a0\u00a01,367,864 \u00a0\u00a00.77 %\u00a01.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a011,132 \u00a0\u00a0\u00a0 \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,706,041 \u00a0\u00a03.47 %\u00a0\u00a06,310,808 \u00a0\u00a03.56 %\u00a06.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,916,156 \u00a0\u00a02.03 %\u00a0\u00a03,585,500 \u00a0\u00a02.02 %\u00a09.2 %\nDepreciation and amortization \u00a0\u00a0687,678 \u00a0\u00a00.36 %\u00a0\u00a0523,333 \u00a0\u00a00.29 %\u00a031.4 %\nLitigation and opioid-related (credit)\nexpenses 2 \u00a0\u00a0(38,583 )\u00a0\u00a0 \u00a0\u00a0108,167 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a099,392 \u00a0\u00a0\u00a0 \u00a0\u00a069,710 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0177,608 \u00a0\u00a0\u00a0 \u00a0\u00a031,357 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,842,251 \u00a0\u00a02.51 %\u00a0\u00a04,398,949 \u00a0\u00a02.48 %\u00a010.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,863,790 \u00a0\u00a00.96 %\u00a0\u00a01,911,859 \u00a0\u00a01.08 %\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0\u00a0(18,612 )\u00a0\u00a0 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0167,989 \u00a0\u00a0\u00a0 \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a05.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,714,413 \u00a0\u00a00.89 %\u00a0\u00a01,800,717 \u00a0\u00a01.01 %\u00a0(4.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0330,817 \u00a0\u00a0\u00a0 \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,383,596 \u00a0\u00a00.72 %\u00a0\u00a01,367,864 \u00a0\u00a00.77 %\u00a01.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a011,132 \u00a0\u00a0\u00a0 \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87f9a5b7-61fa-4b1c-8884-fa660fbf7a35", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3c34252e42c6a87f29278e09288b86f40ff51a9fa578dd028d2d17a6c225e0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "276088be-7225-40e8-bfbb-366a0951ce3a", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the three months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the three months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n FINANCIAL SUMMAR Y \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months\nEnded\nJune 30, 2023 \u00a0% of\nRevenue \u00a0Nine Months\nEnded\nJune 30, 2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$193,251,080 \u00a0\u00a0\u00a0 \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a08.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0186,545,039 \u00a0\u00a0\u00a0 \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a09.0 %\n9", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c844b29344e9840b550ada177d7a59b86bfe8a9c6010b2b7379defef234545b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "863ef71d-6a51-4e7f-8dfc-36b9c473c51c", "node_type": "1", "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n", "original_text": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023. "}, "hash": "9373183d4d9f669b176d8640f64e8ddc5d15735372a4200ba50509d5c6b1726a", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,706,041 \u00a0\u00a03.47 %\u00a0\u00a06,310,808 \u00a0\u00a03.56 %\u00a06.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,916,156 \u00a0\u00a02.03 %\u00a0\u00a03,585,500 \u00a0\u00a02.02 %\u00a09.2 %\nDepreciation and amortization \u00a0\u00a0687,678 \u00a0\u00a00.36 %\u00a0\u00a0523,333 \u00a0\u00a00.29 %\u00a031.4 %\nLitigation and opioid-related (credit)\nexpenses 2 \u00a0\u00a0(38,583 )\u00a0\u00a0 \u00a0\u00a0108,167 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a099,392 \u00a0\u00a0\u00a0 \u00a0\u00a069,710 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0177,608 \u00a0\u00a0\u00a0 \u00a0\u00a031,357 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,842,251 \u00a0\u00a02.51 %\u00a0\u00a04,398,949 \u00a0\u00a02.48 %\u00a010.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,863,790 \u00a0\u00a00.96 %\u00a0\u00a01,911,859 \u00a0\u00a01.08 %\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0\u00a0(18,612 )\u00a0\u00a0 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0167,989 \u00a0\u00a0\u00a0 \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a05.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,714,413 \u00a0\u00a00.89 %\u00a0\u00a01,800,717 \u00a0\u00a01.01 %\u00a0(4.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0330,817 \u00a0\u00a0\u00a0 \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,383,596 \u00a0\u00a00.72 %\u00a0\u00a01,367,864 \u00a0\u00a00.77 %\u00a01.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a011,132 \u00a0\u00a0\u00a0 \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "start_char_idx": 0, "end_char_idx": 1238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "863ef71d-6a51-4e7f-8dfc-36b9c473c51c": {"__data__": {"id_": "863ef71d-6a51-4e7f-8dfc-36b9c473c51c", "embedding": null, "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n", "original_text": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023. ", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c920c468-d834-4ab3-b790-75fe74ceb760", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c481e94c323aa7915fa900edd9f15ef41a5c7d7ada893c7f96c9d225467ff35d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "008e31ea-1071-43bd-8bee-78533f283e17", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,706,041 \u00a0\u00a03.47 %\u00a0\u00a06,310,808 \u00a0\u00a03.56 %\u00a06.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,916,156 \u00a0\u00a02.03 %\u00a0\u00a03,585,500 \u00a0\u00a02.02 %\u00a09.2 %\nDepreciation and amortization \u00a0\u00a0687,678 \u00a0\u00a00.36 %\u00a0\u00a0523,333 \u00a0\u00a00.29 %\u00a031.4 %\nLitigation and opioid-related (credit)\nexpenses 2 \u00a0\u00a0(38,583 )\u00a0\u00a0 \u00a0\u00a0108,167 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a099,392 \u00a0\u00a0\u00a0 \u00a0\u00a069,710 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0177,608 \u00a0\u00a0\u00a0 \u00a0\u00a031,357 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,842,251 \u00a0\u00a02.51 %\u00a0\u00a04,398,949 \u00a0\u00a02.48 %\u00a010.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,863,790 \u00a0\u00a00.96 %\u00a0\u00a01,911,859 \u00a0\u00a01.08 %\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0\u00a0(18,612 )\u00a0\u00a0 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0167,989 \u00a0\u00a0\u00a0 \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a05.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,714,413 \u00a0\u00a00.89 %\u00a0\u00a01,800,717 \u00a0\u00a01.01 %\u00a0(4.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0330,817 \u00a0\u00a0\u00a0 \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,383,596 \u00a0\u00a00.72 %\u00a0\u00a01,367,864 \u00a0\u00a00.77 %\u00a01.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a011,132 \u00a0\u00a0\u00a0 \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,706,041 \u00a0\u00a03.47 %\u00a0\u00a06,310,808 \u00a0\u00a03.56 %\u00a06.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,916,156 \u00a0\u00a02.03 %\u00a0\u00a03,585,500 \u00a0\u00a02.02 %\u00a09.2 %\nDepreciation and amortization \u00a0\u00a0687,678 \u00a0\u00a00.36 %\u00a0\u00a0523,333 \u00a0\u00a00.29 %\u00a031.4 %\nLitigation and opioid-related (credit)\nexpenses 2 \u00a0\u00a0(38,583 )\u00a0\u00a0 \u00a0\u00a0108,167 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a099,392 \u00a0\u00a0\u00a0 \u00a0\u00a069,710 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0177,608 \u00a0\u00a0\u00a0 \u00a0\u00a031,357 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,842,251 \u00a0\u00a02.51 %\u00a0\u00a04,398,949 \u00a0\u00a02.48 %\u00a010.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,863,790 \u00a0\u00a00.96 %\u00a0\u00a01,911,859 \u00a0\u00a01.08 %\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0\u00a0(18,612 )\u00a0\u00a0 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0167,989 \u00a0\u00a0\u00a0 \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a05.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,714,413 \u00a0\u00a00.89 %\u00a0\u00a01,800,717 \u00a0\u00a01.01 %\u00a0(4.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0330,817 \u00a0\u00a0\u00a0 \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,383,596 \u00a0\u00a00.72 %\u00a0\u00a01,367,864 \u00a0\u00a00.77 %\u00a01.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a011,132 \u00a0\u00a0\u00a0 \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01f0579ae9d3a235b5a30f331b91dd978d3404fe6fb1c5d5b455d50c099b778f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f447299d-e824-4301-9f12-fa8d809f3626", "node_type": "1", "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n", "original_text": "Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n"}, "hash": "c0a6c6f50efc819c4306071b0678bb627c77008812871bac92fe24b92f675c81", "class_name": "RelatedNodeInfo"}}, "text": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023. ", "start_char_idx": 0, "end_char_idx": 644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f447299d-e824-4301-9f12-fa8d809f3626": {"__data__": {"id_": "f447299d-e824-4301-9f12-fa8d809f3626", "embedding": null, "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n", "original_text": "Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c920c468-d834-4ab3-b790-75fe74ceb760", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c481e94c323aa7915fa900edd9f15ef41a5c7d7ada893c7f96c9d225467ff35d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "863ef71d-6a51-4e7f-8dfc-36b9c473c51c", "node_type": "1", "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n", "original_text": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023. ", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bea35aba84fa4d93ecbd6e13cdb289f07fe35531503208ef8363c8ff709188f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36900705-60cd-43b5-9329-602427ba09e4", "node_type": "1", "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n", "original_text": "2Includes the receipt of $83.4 million from the H.D. "}, "hash": "e134a979177da6e3450ddd961f84e44550bd905ed8caf1b0b60e1d5f52369155", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n", "start_char_idx": 644, "end_char_idx": 788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36900705-60cd-43b5-9329-602427ba09e4": {"__data__": {"id_": "36900705-60cd-43b5-9329-602427ba09e4", "embedding": null, "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n", "original_text": "2Includes the receipt of $83.4 million from the H.D. ", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c920c468-d834-4ab3-b790-75fe74ceb760", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c481e94c323aa7915fa900edd9f15ef41a5c7d7ada893c7f96c9d225467ff35d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f447299d-e824-4301-9f12-fa8d809f3626", "node_type": "1", "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n", "original_text": "Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3f6b98744d1799a3c857138e71dc4fecd337c80979cb068322e30d039cc8d21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "667ff934-d571-4291-a0b7-22fbe279a436", "node_type": "1", "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n"}, "hash": "8efe8468dfca9d1ea9ff7badc6df0cf0f222fafeb3349907fdc0c350ed873377", "class_name": "RelatedNodeInfo"}}, "text": "2Includes the receipt of $83.4 million from the H.D. ", "start_char_idx": 788, "end_char_idx": 841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "667ff934-d571-4291-a0b7-22fbe279a436": {"__data__": {"id_": "667ff934-d571-4291-a0b7-22fbe279a436", "embedding": null, "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c920c468-d834-4ab3-b790-75fe74ceb760", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c481e94c323aa7915fa900edd9f15ef41a5c7d7ada893c7f96c9d225467ff35d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36900705-60cd-43b5-9329-602427ba09e4", "node_type": "1", "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n", "original_text": "2Includes the receipt of $83.4 million from the H.D. ", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e09a8e4e7d03f68dfb0c4f99d02be8e4b885ed8e3c0f74bf0a71adf3884d39ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f739847-cdcd-4c17-817a-f70841f5c4f2", "node_type": "1", "metadata": {"window": "Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n"}, "hash": "6b5f1c1c100e7a7d77f0e5d0cfdeed7144cbb8dce8e72fb09b687c490c13582c", "class_name": "RelatedNodeInfo"}}, "text": "Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n", "start_char_idx": 841, "end_char_idx": 922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f739847-cdcd-4c17-817a-f70841f5c4f2": {"__data__": {"id_": "7f739847-cdcd-4c17-817a-f70841f5c4f2", "embedding": null, "metadata": {"window": "Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c920c468-d834-4ab3-b790-75fe74ceb760", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c481e94c323aa7915fa900edd9f15ef41a5c7d7ada893c7f96c9d225467ff35d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "667ff934-d571-4291-a0b7-22fbe279a436", "node_type": "1", "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67599310e09800c92471cba9d7004793da263c338a1c2cfbc3ef6b9fc71c3688", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1f977a1-97c8-4c68-89a9-3e07f8e626a0", "node_type": "1", "metadata": {"window": "2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n"}, "hash": "9ddc7a26f79137ed10b3ea09871a45015e8b926fc0bbf9d965cc6838eaa8b215", "class_name": "RelatedNodeInfo"}}, "text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n", "start_char_idx": 922, "end_char_idx": 1059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1f977a1-97c8-4c68-89a9-3e07f8e626a0": {"__data__": {"id_": "a1f977a1-97c8-4c68-89a9-3e07f8e626a0", "embedding": null, "metadata": {"window": "2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c920c468-d834-4ab3-b790-75fe74ceb760", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c481e94c323aa7915fa900edd9f15ef41a5c7d7ada893c7f96c9d225467ff35d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f739847-cdcd-4c17-817a-f70841f5c4f2", "node_type": "1", "metadata": {"window": "Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f3597518974acfa2455e98631a1def6706c485de3e71097fed6a0d1f3c5aa7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4908475e-a3a3-4d27-a534-ee43500bd6a8", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11"}, "hash": "b32a1f2365d8820419735ad5538a8444f0aad15864a9ad685e0d15cb24234a0c", "class_name": "RelatedNodeInfo"}}, "text": "4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n", "start_char_idx": 1059, "end_char_idx": 1165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4908475e-a3a3-4d27-a534-ee43500bd6a8": {"__data__": {"id_": "4908475e-a3a3-4d27-a534-ee43500bd6a8", "embedding": null, "metadata": {"window": "Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c920c468-d834-4ab3-b790-75fe74ceb760", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c481e94c323aa7915fa900edd9f15ef41a5c7d7ada893c7f96c9d225467ff35d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1f977a1-97c8-4c68-89a9-3e07f8e626a0", "node_type": "1", "metadata": {"window": "2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "151607d4124e5db3fbbc085c3e520c11f1b3d46c3fcbb73ace31d2f549621400", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f5b0d1e-9971-477b-bccb-112f3d2f69ad", "node_type": "1", "metadata": {"window": "Gains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(118,611 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(118,611 )\u00a0\u00a0(118,611 )\u00a0\u00a0(27,518 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(91,093 )\u00a0\u00a0(0.45 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a034,952 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a08,037 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,915 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a050,580 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a050,580 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,154 )\u00a0\u00a0169,154 \u00a0\u00a0\u00a0169,154 \u00a0\u00a0\u00a039,087 \u00a0\u00a0\u00a0(969 )\u00a0\u00a0129,098 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,102 \u00a0\u00a0\u00a0(67,102 )\u00a0\u00a0(67,102 )\u00a0\u00a03,750 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,852 )\u00a0\u00a0(0.35 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(19,283 )\u00a0\u00a019,283 \u00a0\u00a0\u00a019,283 \u00a0\u00a0\u00a04,393 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,890 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,924 )\u00a0\u00a063,924 \u00a0\u00a0\u00a063,924 \u00a0\u00a0\u00a014,733 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a049,191 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,823 )\u00a0\u00a0(8,748 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,925 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,231,567 \u00a0\u00a0$1,409,259 \u00a0\u00a0$822,308 \u00a0\u00a0$760,186 \u00a0\u00a0$163,349 \u00a0\u00a0$(601 )\u00a0$596,236 \u00a0\u00a0$2.92 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "Gains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(118,611 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(118,611 )\u00a0\u00a0(118,611 )\u00a0\u00a0(27,518 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(91,093 )\u00a0\u00a0(0.45 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a034,952 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a08,037 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,915 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a050,580 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a050,580 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,154 )\u00a0\u00a0169,154 \u00a0\u00a0\u00a0169,154 \u00a0\u00a0\u00a039,087 \u00a0\u00a0\u00a0(969 )\u00a0\u00a0129,098 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,102 \u00a0\u00a0\u00a0(67,102 )\u00a0\u00a0(67,102 )\u00a0\u00a03,750 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,852 )\u00a0\u00a0(0.35 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(19,283 )\u00a0\u00a019,283 \u00a0\u00a0\u00a019,283 \u00a0\u00a0\u00a04,393 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,890 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,924 )\u00a0\u00a063,924 \u00a0\u00a0\u00a063,924 \u00a0\u00a0\u00a014,733 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a049,191 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,823 )\u00a0\u00a0(8,748 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,925 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,231,567 \u00a0\u00a0$1,409,259 \u00a0\u00a0$822,308 \u00a0\u00a0$760,186 \u00a0\u00a0$163,349 \u00a0\u00a0$(601 )\u00a0$596,236 \u00a0\u00a0$2.92 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12"}, "hash": "6a9ea548ea87c8da6392afa97faa140668cb6c8c30a87d3d0119f89e99a6270d", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "start_char_idx": 1165, "end_char_idx": 1679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f5b0d1e-9971-477b-bccb-112f3d2f69ad": {"__data__": {"id_": "9f5b0d1e-9971-477b-bccb-112f3d2f69ad", "embedding": null, "metadata": {"window": "Gains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(118,611 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(118,611 )\u00a0\u00a0(118,611 )\u00a0\u00a0(27,518 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(91,093 )\u00a0\u00a0(0.45 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a034,952 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a08,037 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,915 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a050,580 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a050,580 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,154 )\u00a0\u00a0169,154 \u00a0\u00a0\u00a0169,154 \u00a0\u00a0\u00a039,087 \u00a0\u00a0\u00a0(969 )\u00a0\u00a0129,098 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,102 \u00a0\u00a0\u00a0(67,102 )\u00a0\u00a0(67,102 )\u00a0\u00a03,750 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,852 )\u00a0\u00a0(0.35 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(19,283 )\u00a0\u00a019,283 \u00a0\u00a0\u00a019,283 \u00a0\u00a0\u00a04,393 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,890 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,924 )\u00a0\u00a063,924 \u00a0\u00a0\u00a063,924 \u00a0\u00a0\u00a014,733 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a049,191 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,823 )\u00a0\u00a0(8,748 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,925 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,231,567 \u00a0\u00a0$1,409,259 \u00a0\u00a0$822,308 \u00a0\u00a0$760,186 \u00a0\u00a0$163,349 \u00a0\u00a0$(601 )\u00a0$596,236 \u00a0\u00a0$2.92 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "Gains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(118,611 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(118,611 )\u00a0\u00a0(118,611 )\u00a0\u00a0(27,518 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(91,093 )\u00a0\u00a0(0.45 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a034,952 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a08,037 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,915 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a050,580 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a050,580 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,154 )\u00a0\u00a0169,154 \u00a0\u00a0\u00a0169,154 \u00a0\u00a0\u00a039,087 \u00a0\u00a0\u00a0(969 )\u00a0\u00a0129,098 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,102 \u00a0\u00a0\u00a0(67,102 )\u00a0\u00a0(67,102 )\u00a0\u00a03,750 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,852 )\u00a0\u00a0(0.35 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(19,283 )\u00a0\u00a019,283 \u00a0\u00a0\u00a019,283 \u00a0\u00a0\u00a04,393 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,890 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,924 )\u00a0\u00a063,924 \u00a0\u00a0\u00a063,924 \u00a0\u00a0\u00a014,733 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a049,191 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,823 )\u00a0\u00a0(8,748 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,925 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,231,567 \u00a0\u00a0$1,409,259 \u00a0\u00a0$822,308 \u00a0\u00a0$760,186 \u00a0\u00a0$163,349 \u00a0\u00a0$(601 )\u00a0$596,236 \u00a0\u00a0$2.92 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "page_label": "12", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec519faf-8c72-4d79-b13f-c0eaa494d3f3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee04d6c0e1aa0142390ea77137c529d42454221e25a8e706aaf40108bfdd79d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4908475e-a3a3-4d27-a534-ee43500bd6a8", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the nine months ended\nJune 30, 2022.\n 4Includes a $60.0 million gain on the sale of non-core businesses in the nine months ended June 30, 2022.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,264,646 \u00a0\u00a0$1,594,518 \u00a0\u00a0$670,128 \u00a0\u00a0$608,828 \u00a0\u00a0$129,615 \u00a0\u00a0$368 \u00a0\u00a0$479,581 \u00a0\u00a0$2.35 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92466814bbc720be6b2c40cb92b203fd2d532d9d7c49338fe68e2f1622b9bf30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41d1c070-d7d9-439e-b173-420bb0e0009e", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n", "original_text": "Adjusted Non-\nGAAP %\nchange vs.\n"}, "hash": "f576d6ca662ff23792d3663110f308bbed170f2ad4ad5e42d96b7b082fa96ede", "class_name": "RelatedNodeInfo"}}, "text": "Gains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(118,611 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(118,611 )\u00a0\u00a0(118,611 )\u00a0\u00a0(27,518 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(91,093 )\u00a0\u00a0(0.45 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a034,952 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a08,037 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,915 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a050,580 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a050,580 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,154 )\u00a0\u00a0169,154 \u00a0\u00a0\u00a0169,154 \u00a0\u00a0\u00a039,087 \u00a0\u00a0\u00a0(969 )\u00a0\u00a0129,098 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,102 \u00a0\u00a0\u00a0(67,102 )\u00a0\u00a0(67,102 )\u00a0\u00a03,750 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,852 )\u00a0\u00a0(0.35 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(19,283 )\u00a0\u00a019,283 \u00a0\u00a0\u00a019,283 \u00a0\u00a0\u00a04,393 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,890 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,924 )\u00a0\u00a063,924 \u00a0\u00a0\u00a063,924 \u00a0\u00a0\u00a014,733 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a049,191 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,823 )\u00a0\u00a0(8,748 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,925 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,231,567 \u00a0\u00a0$1,409,259 \u00a0\u00a0$822,308 \u00a0\u00a0$760,186 \u00a0\u00a0$163,349 \u00a0\u00a0$(601 )\u00a0$596,236 \u00a0\u00a0$2.92 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "start_char_idx": 0, "end_char_idx": 1328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41d1c070-d7d9-439e-b173-420bb0e0009e": {"__data__": {"id_": "41d1c070-d7d9-439e-b173-420bb0e0009e", "embedding": null, "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n", "original_text": "Adjusted Non-\nGAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "187cfde363379ed7c224598720957d03ba9637bfbd03f99e6358deeb622d7741", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f5b0d1e-9971-477b-bccb-112f3d2f69ad", "node_type": "1", "metadata": {"window": "Gains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(118,611 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(118,611 )\u00a0\u00a0(118,611 )\u00a0\u00a0(27,518 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(91,093 )\u00a0\u00a0(0.45 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a034,952 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a08,037 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,915 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a050,580 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a050,580 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,154 )\u00a0\u00a0169,154 \u00a0\u00a0\u00a0169,154 \u00a0\u00a0\u00a039,087 \u00a0\u00a0\u00a0(969 )\u00a0\u00a0129,098 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,102 \u00a0\u00a0\u00a0(67,102 )\u00a0\u00a0(67,102 )\u00a0\u00a03,750 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,852 )\u00a0\u00a0(0.35 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(19,283 )\u00a0\u00a019,283 \u00a0\u00a0\u00a019,283 \u00a0\u00a0\u00a04,393 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,890 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,924 )\u00a0\u00a063,924 \u00a0\u00a0\u00a063,924 \u00a0\u00a0\u00a014,733 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a049,191 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,823 )\u00a0\u00a0(8,748 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,925 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,231,567 \u00a0\u00a0$1,409,259 \u00a0\u00a0$822,308 \u00a0\u00a0$760,186 \u00a0\u00a0$163,349 \u00a0\u00a0$(601 )\u00a0$596,236 \u00a0\u00a0$2.92 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "Gains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(118,611 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(118,611 )\u00a0\u00a0(118,611 )\u00a0\u00a0(27,518 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(91,093 )\u00a0\u00a0(0.45 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a034,952 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a08,037 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,915 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a050,580 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a050,580 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,154 )\u00a0\u00a0169,154 \u00a0\u00a0\u00a0169,154 \u00a0\u00a0\u00a039,087 \u00a0\u00a0\u00a0(969 )\u00a0\u00a0129,098 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,102 \u00a0\u00a0\u00a0(67,102 )\u00a0\u00a0(67,102 )\u00a0\u00a03,750 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,852 )\u00a0\u00a0(0.35 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(19,283 )\u00a0\u00a019,283 \u00a0\u00a0\u00a019,283 \u00a0\u00a0\u00a04,393 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,890 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,924 )\u00a0\u00a063,924 \u00a0\u00a0\u00a063,924 \u00a0\u00a0\u00a014,733 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a049,191 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,823 )\u00a0\u00a0(8,748 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,925 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,231,567 \u00a0\u00a0$1,409,259 \u00a0\u00a0$822,308 \u00a0\u00a0$760,186 \u00a0\u00a0$163,349 \u00a0\u00a0$(601 )\u00a0$596,236 \u00a0\u00a0$2.92 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "page_label": "12", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64c0c5937e69c9f933330df97dcfc7f308ac3bc4eced8682aac4bd1eb6a6e1a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbb1eb20-1656-4a47-b1fc-0becd813ecfe", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0", "original_text": "prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. "}, "hash": "b78d2d352dcec4d40fb247c6764274e8dd44e59af556030a8036e0c30874251f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Non-\nGAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 32, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbb1eb20-1656-4a47-b1fc-0becd813ecfe": {"__data__": {"id_": "dbb1eb20-1656-4a47-b1fc-0becd813ecfe", "embedding": null, "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0", "original_text": "prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. ", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "187cfde363379ed7c224598720957d03ba9637bfbd03f99e6358deeb622d7741", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41d1c070-d7d9-439e-b173-420bb0e0009e", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n", "original_text": "Adjusted Non-\nGAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebc910db094bfbd7d27e8754c7eefbffab407723e3afd3c3e04366d853876a3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2866fe5-35b3-42f7-935c-86a634492dc8", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Smith opioid litigation indemnity escrow.\n"}, "hash": "e35ec264ac9728c89f6fe22f5852afe7f392cadcb21d35091ba2510ec9930c9e", "class_name": "RelatedNodeInfo"}}, "text": "prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. ", "start_char_idx": 32, "end_char_idx": 336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2866fe5-35b3-42f7-935c-86a634492dc8": {"__data__": {"id_": "f2866fe5-35b3-42f7-935c-86a634492dc8", "embedding": null, "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Smith opioid litigation indemnity escrow.\n", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "187cfde363379ed7c224598720957d03ba9637bfbd03f99e6358deeb622d7741", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbb1eb20-1656-4a47-b1fc-0becd813ecfe", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0", "original_text": "prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. ", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74e5de775aab879a2d22735e2772c353b5b722f978171e85c0cde036ca956b40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3ab3498-b782-4985-8075-bc5a4a4b383f", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n"}, "hash": "6872c9df68b6669ac39f9ba0e6eb915668ee54e4e02b0ccc6a97f0cab36d49c2", "class_name": "RelatedNodeInfo"}}, "text": "Smith opioid litigation indemnity escrow.\n", "start_char_idx": 336, "end_char_idx": 378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3ab3498-b782-4985-8075-bc5a4a4b383f": {"__data__": {"id_": "f3ab3498-b782-4985-8075-bc5a4a4b383f", "embedding": null, "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "187cfde363379ed7c224598720957d03ba9637bfbd03f99e6358deeb622d7741", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2866fe5-35b3-42f7-935c-86a634492dc8", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Smith opioid litigation indemnity escrow.\n", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "044bd7d171de30ab210649c3958de3f662bd11e79f1391c462837a5cc056c6b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19e618b5-bca3-47ba-aa2d-fb63f1249bca", "node_type": "1", "metadata": {"window": "prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0"}, "hash": "dfa6624683f17b2449ba8b00ca337dab0965d5e05c1d9cef511bc03cac11a276", "class_name": "RelatedNodeInfo"}}, "text": "2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n", "start_char_idx": 378, "end_char_idx": 577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19e618b5-bca3-47ba-aa2d-fb63f1249bca": {"__data__": {"id_": "19e618b5-bca3-47ba-aa2d-fb63f1249bca", "embedding": null, "metadata": {"window": "prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "187cfde363379ed7c224598720957d03ba9637bfbd03f99e6358deeb622d7741", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3ab3498-b782-4985-8075-bc5a4a4b383f", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "801620ec567bcbacb98bc45ba04709470d808f5d73628cef29ef066e24cdc9a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83b6918a-594a-415c-b0b7-1a913603c26d", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "510560c6e26ce4051d5f931722740d119227656fd598261b1550836b82a4f024", "class_name": "RelatedNodeInfo"}}, "text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "start_char_idx": 577, "end_char_idx": 647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83b6918a-594a-415c-b0b7-1a913603c26d": {"__data__": {"id_": "83b6918a-594a-415c-b0b7-1a913603c26d", "embedding": null, "metadata": {"window": "Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "187cfde363379ed7c224598720957d03ba9637bfbd03f99e6358deeb622d7741", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19e618b5-bca3-47ba-aa2d-fb63f1249bca", "node_type": "1", "metadata": {"window": "prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4be90b01bfd88a33e20883cddf103ba310b59c9f73c26299d06660e98b949c2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f62e4aa3-5764-4ed0-ac38-61a4bb16f6e7", "node_type": "1", "metadata": {"window": "2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13"}, "hash": "a42fba87658a2210fe2e81be5f7d2fecba12c38fa9de9d57c9d489571f2105e2", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 647, "end_char_idx": 824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f62e4aa3-5764-4ed0-ac38-61a4bb16f6e7": {"__data__": {"id_": "f62e4aa3-5764-4ed0-ac38-61a4bb16f6e7", "embedding": null, "metadata": {"window": "2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "187cfde363379ed7c224598720957d03ba9637bfbd03f99e6358deeb622d7741", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83b6918a-594a-415c-b0b7-1a913603c26d", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf1b220586cd5061275775a6b39ba0278e9ce65cae2ae8ea1af016301ac0c927", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7df7fe71-963a-4170-866f-d8c7d424700c", "node_type": "1", "metadata": {"window": "LIFO expense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a023,442 \u00a0\u00a0\u00a023,442 \u00a0\u00a0\u00a07,795 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a015,647 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(36,570 )\u00a0\u00a036,570 \u00a0\u00a0\u00a036,570 \u00a0\u00a0\u00a010,791 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,779 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(7,858 )\u00a0\u00a07,858 \u00a0\u00a0\u00a07,858 \u00a0\u00a0\u00a02,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a05,005 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.36% \u00a03.44%\n14", "original_text": "LIFO expense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a023,442 \u00a0\u00a0\u00a023,442 \u00a0\u00a0\u00a07,795 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a015,647 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(36,570 )\u00a0\u00a036,570 \u00a0\u00a0\u00a036,570 \u00a0\u00a0\u00a010,791 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,779 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(7,858 )\u00a0\u00a07,858 \u00a0\u00a0\u00a07,858 \u00a0\u00a0\u00a02,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a05,005 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.36% \u00a03.44%\n14"}, "hash": "8904b823126b1182333ce966103cfefde99313ec01587ebb1b577b55b5d93535", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "start_char_idx": 824, "end_char_idx": 1456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7df7fe71-963a-4170-866f-d8c7d424700c": {"__data__": {"id_": "7df7fe71-963a-4170-866f-d8c7d424700c", "embedding": null, "metadata": {"window": "LIFO expense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a023,442 \u00a0\u00a0\u00a023,442 \u00a0\u00a0\u00a07,795 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a015,647 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(36,570 )\u00a0\u00a036,570 \u00a0\u00a0\u00a036,570 \u00a0\u00a0\u00a010,791 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,779 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(7,858 )\u00a0\u00a07,858 \u00a0\u00a0\u00a07,858 \u00a0\u00a0\u00a02,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a05,005 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.36% \u00a03.44%\n14", "original_text": "LIFO expense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a023,442 \u00a0\u00a0\u00a023,442 \u00a0\u00a0\u00a07,795 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a015,647 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(36,570 )\u00a0\u00a036,570 \u00a0\u00a0\u00a036,570 \u00a0\u00a0\u00a010,791 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,779 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(7,858 )\u00a0\u00a07,858 \u00a0\u00a0\u00a07,858 \u00a0\u00a0\u00a02,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a05,005 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.36% \u00a03.44%\n14", "page_label": "14", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0dc22fe7-c04e-4cdd-bbee-1e2ccf44bc91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f86956806c44cd6847b0fa9b59ff57913a7454a847b16e9ad47b80c6bd55b58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f62e4aa3-5764-4ed0-ac38-61a4bb16f6e7", "node_type": "1", "metadata": {"window": "2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,015,369 \u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "200b800d7443eaa190c53f5c5b996012b7afdee661452515a262782e29526ae1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61b0e9d4-1e2d-4adf-a26c-1a01406bfe38", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n"}, "hash": "06af56bed32981800bfe243418be8b18d64b3b1c97e509dcdac7a58ad6ff0a3f", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a023,442 \u00a0\u00a0\u00a023,442 \u00a0\u00a0\u00a07,795 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a015,647 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(36,570 )\u00a0\u00a036,570 \u00a0\u00a0\u00a036,570 \u00a0\u00a0\u00a010,791 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,779 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(7,858 )\u00a0\u00a07,858 \u00a0\u00a0\u00a07,858 \u00a0\u00a0\u00a02,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a05,005 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.36% \u00a03.44%\n14", "start_char_idx": 0, "end_char_idx": 1326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61b0e9d4-1e2d-4adf-a26c-1a01406bfe38": {"__data__": {"id_": "61b0e9d4-1e2d-4adf-a26c-1a01406bfe38", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n", "page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "80410240-586e-4299-b19b-f4fe6745802a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "662c0b9eae2f47a58cd39869ccaceea66adcc71e28cc81f8bea2b81a737a6e67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7df7fe71-963a-4170-866f-d8c7d424700c", "node_type": "1", "metadata": {"window": "LIFO expense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a023,442 \u00a0\u00a0\u00a023,442 \u00a0\u00a0\u00a07,795 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a015,647 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(36,570 )\u00a0\u00a036,570 \u00a0\u00a0\u00a036,570 \u00a0\u00a0\u00a010,791 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,779 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(7,858 )\u00a0\u00a07,858 \u00a0\u00a0\u00a07,858 \u00a0\u00a0\u00a02,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a05,005 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.36% \u00a03.44%\n14", "original_text": "LIFO expense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a023,442 \u00a0\u00a0\u00a023,442 \u00a0\u00a0\u00a07,795 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a015,647 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(36,570 )\u00a0\u00a036,570 \u00a0\u00a0\u00a036,570 \u00a0\u00a0\u00a010,791 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,779 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(7,858 )\u00a0\u00a07,858 \u00a0\u00a0\u00a07,858 \u00a0\u00a0\u00a02,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a05,005 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.36% \u00a03.44%\n14", "page_label": "14", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0629a2f69c24a1f40cf62436c00571052c44e3d7eb445dc7eafb953fba0878f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5eb7efc-c326-484b-8717-e1c0fc054b16", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0"}, "hash": "be94827f790dfa9ab24d97d7d78fd08b6ca6f93c9f03b7f3d701c3690aff3ace", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n", "start_char_idx": 0, "end_char_idx": 290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5eb7efc-c326-484b-8717-e1c0fc054b16": {"__data__": {"id_": "c5eb7efc-c326-484b-8717-e1c0fc054b16", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "80410240-586e-4299-b19b-f4fe6745802a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "662c0b9eae2f47a58cd39869ccaceea66adcc71e28cc81f8bea2b81a737a6e67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61b0e9d4-1e2d-4adf-a26c-1a01406bfe38", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n", "page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6806a5fbe81e10687bb0afffd70cbed196784d34a7faaaced783bab126b32f04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb756de1-b21b-4b97-a7dd-f51220b982a4", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "632cb803aa5bb498ba02dc03421acdcdc5f4ac5f109e710e64cf69e139a38577", "class_name": "RelatedNodeInfo"}}, "text": "2The sum of the components does not equal the total due to rounding.\n\u00a0", "start_char_idx": 290, "end_char_idx": 360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb756de1-b21b-4b97-a7dd-f51220b982a4": {"__data__": {"id_": "cb756de1-b21b-4b97-a7dd-f51220b982a4", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "80410240-586e-4299-b19b-f4fe6745802a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "662c0b9eae2f47a58cd39869ccaceea66adcc71e28cc81f8bea2b81a737a6e67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5eb7efc-c326-484b-8717-e1c0fc054b16", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23c7bdf8fded697fa06a4cafe8b669b3b84409989932f6e38091e488944cba5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13eee86b-affe-4c50-b47a-ff89d12e9038", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15"}, "hash": "8b2d2acd0c4aece796310759b8aff5e0282c1391d5d967075672590ed1d654f8", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 360, "end_char_idx": 537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13eee86b-affe-4c50-b47a-ff89d12e9038": {"__data__": {"id_": "13eee86b-affe-4c50-b47a-ff89d12e9038", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "80410240-586e-4299-b19b-f4fe6745802a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "662c0b9eae2f47a58cd39869ccaceea66adcc71e28cc81f8bea2b81a737a6e67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb756de1-b21b-4b97-a7dd-f51220b982a4", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71c3a31e3ebfd2e18a21a4593b1e151b9fa50b927d2dbb1d082627f6901c2b61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f1da757-962c-42e8-ae64-6391b5a2b8ad", "node_type": "1", "metadata": {"window": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n prior year \u00a0\u00a06.5 %\u00a0\u00a08.9 %\u00a0\u00a02.7 %\u00a0\u00a02.7 %\u00a0\u00a0(2.2 )%\u00a0\u00a0 \u00a0\u00a04.9 %\u00a0\u00a08.3 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n16", "original_text": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n"}, "hash": "6440c36dc6520f76373b40eabf794c3fe30a7a2b89a1fcc71b1f042ecb91dccf", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "start_char_idx": 537, "end_char_idx": 1476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f1da757-962c-42e8-ae64-6391b5a2b8ad": {"__data__": {"id_": "2f1da757-962c-42e8-ae64-6391b5a2b8ad", "embedding": null, "metadata": {"window": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n prior year \u00a0\u00a06.5 %\u00a0\u00a08.9 %\u00a0\u00a02.7 %\u00a0\u00a02.7 %\u00a0\u00a0(2.2 )%\u00a0\u00a0 \u00a0\u00a04.9 %\u00a0\u00a08.3 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n16", "original_text": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n", "page_label": "16", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "155679d0-1d96-433e-b071-6e1b37c5a889", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4febf48b500a394de2218bb51b233dc4eed4acafda3d6fa78d05c36d5a000c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13eee86b-affe-4c50-b47a-ff89d12e9038", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304fba902fb2f4f7839f12d7963b752b4eb5570a412a46a8800966da08166710", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be295d28-8448-4238-a077-722f46e925a3", "node_type": "1", "metadata": {"window": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n prior year \u00a0\u00a06.5 %\u00a0\u00a08.9 %\u00a0\u00a02.7 %\u00a0\u00a02.7 %\u00a0\u00a0(2.2 )%\u00a0\u00a0 \u00a0\u00a04.9 %\u00a0\u00a08.3 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n16", "original_text": "prior year \u00a0\u00a06.5 %\u00a0\u00a08.9 %\u00a0\u00a02.7 %\u00a0\u00a02.7 %\u00a0\u00a0(2.2 )%\u00a0\u00a0 \u00a0\u00a04.9 %\u00a0\u00a08.3 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n16"}, "hash": "da4601f12a2a92a95cfc76e41aa7accc5945b38acfbc2bee7a46af73fbe62f35", "class_name": "RelatedNodeInfo"}}, "text": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n", "start_char_idx": 0, "end_char_idx": 1058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be295d28-8448-4238-a077-722f46e925a3": {"__data__": {"id_": "be295d28-8448-4238-a077-722f46e925a3", "embedding": null, "metadata": {"window": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n prior year \u00a0\u00a06.5 %\u00a0\u00a08.9 %\u00a0\u00a02.7 %\u00a0\u00a02.7 %\u00a0\u00a0(2.2 )%\u00a0\u00a0 \u00a0\u00a04.9 %\u00a0\u00a08.3 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n16", "original_text": "prior year \u00a0\u00a06.5 %\u00a0\u00a08.9 %\u00a0\u00a02.7 %\u00a0\u00a02.7 %\u00a0\u00a0(2.2 )%\u00a0\u00a0 \u00a0\u00a04.9 %\u00a0\u00a08.3 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n16", "page_label": "16", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "155679d0-1d96-433e-b071-6e1b37c5a889", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4febf48b500a394de2218bb51b233dc4eed4acafda3d6fa78d05c36d5a000c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f1da757-962c-42e8-ae64-6391b5a2b8ad", "node_type": "1", "metadata": {"window": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n prior year \u00a0\u00a06.5 %\u00a0\u00a08.9 %\u00a0\u00a02.7 %\u00a0\u00a02.7 %\u00a0\u00a0(2.2 )%\u00a0\u00a0 \u00a0\u00a04.9 %\u00a0\u00a08.3 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n16", "original_text": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n", "page_label": "16", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9997c6a0eb432183bb77b9bbe5ae168a8401ec47ee4a815b042074938f7749d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7f3381b-f42b-4799-ae6c-9a02fdb84a7f", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0", "original_text": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. "}, "hash": "e8361241ee033a2b26844744bd441ed31bf81c6a905442a4ce9d65621f1c719c", "class_name": "RelatedNodeInfo"}}, "text": "prior year \u00a0\u00a06.5 %\u00a0\u00a08.9 %\u00a0\u00a02.7 %\u00a0\u00a02.7 %\u00a0\u00a0(2.2 )%\u00a0\u00a0 \u00a0\u00a04.9 %\u00a0\u00a08.3 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n16", "start_char_idx": 1058, "end_char_idx": 1179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7f3381b-f42b-4799-ae6c-9a02fdb84a7f": {"__data__": {"id_": "e7f3381b-f42b-4799-ae6c-9a02fdb84a7f", "embedding": null, "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0", "original_text": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. ", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63207d80-146d-4b31-9d2d-6493950bdc19", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c5b4321382f438c18912fc1f39521a82f462a008b82fe8b504629368ab2d37d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be295d28-8448-4238-a077-722f46e925a3", "node_type": "1", "metadata": {"window": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n prior year \u00a0\u00a06.5 %\u00a0\u00a08.9 %\u00a0\u00a02.7 %\u00a0\u00a02.7 %\u00a0\u00a0(2.2 )%\u00a0\u00a0 \u00a0\u00a04.9 %\u00a0\u00a08.3 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n16", "original_text": "prior year \u00a0\u00a06.5 %\u00a0\u00a08.9 %\u00a0\u00a02.7 %\u00a0\u00a02.7 %\u00a0\u00a0(2.2 )%\u00a0\u00a0 \u00a0\u00a04.9 %\u00a0\u00a08.3 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n16", "page_label": "16", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9bfe17841b9437854526e922e5f3012fceed8f0ba20ab0422acf11d2589063", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9884b84a-2dd4-4910-8bb5-f8562286679c", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Smith opioid litigation indemnity escrow.\n"}, "hash": "26caacc2342a88019b81e11fc63f24d3c31e65371d8885692c34fa2d96b5061a", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. ", "start_char_idx": 0, "end_char_idx": 185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9884b84a-2dd4-4910-8bb5-f8562286679c": {"__data__": {"id_": "9884b84a-2dd4-4910-8bb5-f8562286679c", "embedding": null, "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Smith opioid litigation indemnity escrow.\n", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63207d80-146d-4b31-9d2d-6493950bdc19", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c5b4321382f438c18912fc1f39521a82f462a008b82fe8b504629368ab2d37d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7f3381b-f42b-4799-ae6c-9a02fdb84a7f", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0", "original_text": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. ", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f6014a417db3281a0e39e7580c9f58169f8ea730ea7a01214f0430474168660", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04cb0bd1-badc-4668-9e9b-b357539b102c", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n"}, "hash": "ee3a04a1bb7c4c6615257018a611d62edf6bc0792a45b10b037c91640622a064", "class_name": "RelatedNodeInfo"}}, "text": "Smith opioid litigation indemnity escrow.\n", "start_char_idx": 185, "end_char_idx": 227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04cb0bd1-badc-4668-9e9b-b357539b102c": {"__data__": {"id_": "04cb0bd1-badc-4668-9e9b-b357539b102c", "embedding": null, "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63207d80-146d-4b31-9d2d-6493950bdc19", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c5b4321382f438c18912fc1f39521a82f462a008b82fe8b504629368ab2d37d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9884b84a-2dd4-4910-8bb5-f8562286679c", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Smith opioid litigation indemnity escrow.\n", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b490df4d32e1ebb7861198716390db79c1676f823aee5d4c0aeda2047732a957", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b585166-d964-460e-a969-0c00ce2c0eae", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0"}, "hash": "f651af357e86bc8907adf7b7496c3dced5450464299b270f46485edc1a6d8ebf", "class_name": "RelatedNodeInfo"}}, "text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n", "start_char_idx": 227, "end_char_idx": 410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b585166-d964-460e-a969-0c00ce2c0eae": {"__data__": {"id_": "7b585166-d964-460e-a969-0c00ce2c0eae", "embedding": null, "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63207d80-146d-4b31-9d2d-6493950bdc19", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c5b4321382f438c18912fc1f39521a82f462a008b82fe8b504629368ab2d37d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04cb0bd1-badc-4668-9e9b-b357539b102c", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9885fddffdf38da9461de7817446ca3d088a63444dac08288487a650b2f4ad21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98b37981-f4d9-41d8-8417-58c0780e19cc", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "dc7d310f9a6485fb514e0ae4ce2bb73038b0bd0b3d2acede97af4e11f92f7b2b", "class_name": "RelatedNodeInfo"}}, "text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "start_char_idx": 410, "end_char_idx": 480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98b37981-f4d9-41d8-8417-58c0780e19cc": {"__data__": {"id_": "98b37981-f4d9-41d8-8417-58c0780e19cc", "embedding": null, "metadata": {"window": "Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63207d80-146d-4b31-9d2d-6493950bdc19", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c5b4321382f438c18912fc1f39521a82f462a008b82fe8b504629368ab2d37d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b585166-d964-460e-a969-0c00ce2c0eae", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f8efed16498bbeaf379df88a31ce718d666f5cd81a321e7b431609ecae346a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90c55f0e-58c1-423d-8a38-ad094edae6f1", "node_type": "1", "metadata": {"window": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17"}, "hash": "d39101587239c252148f85013e5213838ba535359052b2522d03d7fb40f741e2", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 480, "end_char_idx": 657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90c55f0e-58c1-423d-8a38-ad094edae6f1": {"__data__": {"id_": "90c55f0e-58c1-423d-8a38-ad094edae6f1", "embedding": null, "metadata": {"window": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63207d80-146d-4b31-9d2d-6493950bdc19", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c5b4321382f438c18912fc1f39521a82f462a008b82fe8b504629368ab2d37d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98b37981-f4d9-41d8-8417-58c0780e19cc", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49fe12dbb1e6eca9966614b155e8f05eeb3a6603c178a222491ff34c8cdbaaca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d34738d-0a16-435b-98e4-7c88a4cf79fe", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0108,167 \u00a0\u00a0\u00a0108,167 \u00a0\u00a0\u00a019,005 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a089,162 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(69,710 )\u00a0\u00a069,710 \u00a0\u00a0\u00a069,710 \u00a0\u00a0\u00a018,507 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,203 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(31,357 )\u00a0\u00a031,357 \u00a0\u00a0\u00a031,357 \u00a0\u00a0\u00a08,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,033 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n18", "original_text": "Acquisition-\nrelated intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0108,167 \u00a0\u00a0\u00a0108,167 \u00a0\u00a0\u00a019,005 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a089,162 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(69,710 )\u00a0\u00a069,710 \u00a0\u00a0\u00a069,710 \u00a0\u00a0\u00a018,507 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,203 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(31,357 )\u00a0\u00a031,357 \u00a0\u00a0\u00a031,357 \u00a0\u00a0\u00a08,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,033 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n18"}, "hash": "6330b74ddc33e24773ad28e447ff81f51bd5340e107df305219e3ec3165240e6", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "start_char_idx": 657, "end_char_idx": 1563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d34738d-0a16-435b-98e4-7c88a4cf79fe": {"__data__": {"id_": "6d34738d-0a16-435b-98e4-7c88a4cf79fe", "embedding": null, "metadata": {"window": "Acquisition-\nrelated intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0108,167 \u00a0\u00a0\u00a0108,167 \u00a0\u00a0\u00a019,005 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a089,162 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(69,710 )\u00a0\u00a069,710 \u00a0\u00a0\u00a069,710 \u00a0\u00a0\u00a018,507 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,203 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(31,357 )\u00a0\u00a031,357 \u00a0\u00a0\u00a031,357 \u00a0\u00a0\u00a08,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,033 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n18", "original_text": "Acquisition-\nrelated intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0108,167 \u00a0\u00a0\u00a0108,167 \u00a0\u00a0\u00a019,005 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a089,162 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(69,710 )\u00a0\u00a069,710 \u00a0\u00a0\u00a069,710 \u00a0\u00a0\u00a018,507 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,203 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(31,357 )\u00a0\u00a031,357 \u00a0\u00a0\u00a031,357 \u00a0\u00a0\u00a08,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,033 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n18", "page_label": "18", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5f3bf78-ae07-48d9-8e79-6d5cb2146ad0", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b6927860b5f59b725b1f82bcdab2b095d9a6ac768a6e810d1b0f504cbe8f8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90c55f0e-58c1-423d-8a38-ad094edae6f1", "node_type": "1", "metadata": {"window": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n17", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85b0d55c612475fa3e943c7b0375f3cea4fbce4d912254c07e9f00caa6725009", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14a0d4f0-9820-4a46-9b78-a52317210776", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "original_text": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n"}, "hash": "1c441f8c465fc40f43718099ee18a1befc7e3f502070342c3ba993ea8698de90", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-\nrelated intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0108,167 \u00a0\u00a0\u00a0108,167 \u00a0\u00a0\u00a019,005 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a089,162 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(69,710 )\u00a0\u00a069,710 \u00a0\u00a0\u00a069,710 \u00a0\u00a0\u00a018,507 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,203 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(31,357 )\u00a0\u00a031,357 \u00a0\u00a0\u00a031,357 \u00a0\u00a0\u00a08,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,033 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n18", "start_char_idx": 0, "end_char_idx": 1314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14a0d4f0-9820-4a46-9b78-a52317210776": {"__data__": {"id_": "14a0d4f0-9820-4a46-9b78-a52317210776", "embedding": null, "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "original_text": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c0f4bc-1904-4832-874f-f5afe7384803", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a20b4bac5e241d081a59e28881627cd26a89a4c1b9464a76c3391d9d013ec1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d34738d-0a16-435b-98e4-7c88a4cf79fe", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0108,167 \u00a0\u00a0\u00a0108,167 \u00a0\u00a0\u00a019,005 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a089,162 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(69,710 )\u00a0\u00a069,710 \u00a0\u00a0\u00a069,710 \u00a0\u00a0\u00a018,507 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,203 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(31,357 )\u00a0\u00a031,357 \u00a0\u00a0\u00a031,357 \u00a0\u00a0\u00a08,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,033 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n18", "original_text": "Acquisition-\nrelated intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0108,167 \u00a0\u00a0\u00a0108,167 \u00a0\u00a0\u00a019,005 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a089,162 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(69,710 )\u00a0\u00a069,710 \u00a0\u00a0\u00a069,710 \u00a0\u00a0\u00a018,507 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,203 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(31,357 )\u00a0\u00a031,357 \u00a0\u00a0\u00a031,357 \u00a0\u00a0\u00a08,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,033 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n18", "page_label": "18", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d07fcf63a25ae680372ed2d3b9cef6e6717c86a932e4c1a83d663dff0e1bcc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11eeb226-e95e-4bce-82a1-017f3e5a7b68", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0"}, "hash": "500d9c4d0a2aeb07939aa0377ceddb2ebffc7056e0f059c3e888d566b5a2b455", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n", "start_char_idx": 0, "end_char_idx": 310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11eeb226-e95e-4bce-82a1-017f3e5a7b68": {"__data__": {"id_": "11eeb226-e95e-4bce-82a1-017f3e5a7b68", "embedding": null, "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c0f4bc-1904-4832-874f-f5afe7384803", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a20b4bac5e241d081a59e28881627cd26a89a4c1b9464a76c3391d9d013ec1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14a0d4f0-9820-4a46-9b78-a52317210776", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "original_text": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af809cf1c10eecb76bfbbab55792a6db703ef8318b0a659308d3315fcd75494b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "617a56b6-0403-4f01-a95b-fcd54c92872c", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "b2280de5a1a9854408e5f40b865f5c37805a0ed9a603309e20de3d7db364efb7", "class_name": "RelatedNodeInfo"}}, "text": "2The sum of the components does not equal the total due to rounding.\n\u00a0", "start_char_idx": 310, "end_char_idx": 380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "617a56b6-0403-4f01-a95b-fcd54c92872c": {"__data__": {"id_": "617a56b6-0403-4f01-a95b-fcd54c92872c", "embedding": null, "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c0f4bc-1904-4832-874f-f5afe7384803", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a20b4bac5e241d081a59e28881627cd26a89a4c1b9464a76c3391d9d013ec1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11eeb226-e95e-4bce-82a1-017f3e5a7b68", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "958d70d26e87b2e61c28955edaccba0c9e01f8f5752d1b68bbc7a3edf0b2bc22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57e8bd2f-7514-4c89-b407-bf0eeffac7fe", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. "}, "hash": "689d6e7bbbc256a7e5fc284c96116536e7ebd00e361523bbc7784511880e1ca8", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 380, "end_char_idx": 557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57e8bd2f-7514-4c89-b407-bf0eeffac7fe": {"__data__": {"id_": "57e8bd2f-7514-4c89-b407-bf0eeffac7fe", "embedding": null, "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c0f4bc-1904-4832-874f-f5afe7384803", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a20b4bac5e241d081a59e28881627cd26a89a4c1b9464a76c3391d9d013ec1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "617a56b6-0403-4f01-a95b-fcd54c92872c", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e25e7f68a0dce3d7d3bd6372a9be5d86290287d096cfd3beeae4e2f34d5b8344", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bb09df0-e152-4f59-8a54-374ed01c78cc", "node_type": "1", "metadata": {"window": "2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S. "}, "hash": "e45c1e153e17305307d13802b2da2445fddf16b12560d63e9dfb5306d513f524", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "start_char_idx": 557, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bb09df0-e152-4f59-8a54-374ed01c78cc": {"__data__": {"id_": "2bb09df0-e152-4f59-8a54-374ed01c78cc", "embedding": null, "metadata": {"window": "2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c0f4bc-1904-4832-874f-f5afe7384803", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a20b4bac5e241d081a59e28881627cd26a89a4c1b9464a76c3391d9d013ec1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57e8bd2f-7514-4c89-b407-bf0eeffac7fe", "node_type": "1", "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc31c92661007ac410fbb7ad3c1a71b87cb2c4c37f895af687d0d58ba33221c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e8b87d8-9a4a-4a50-9669-9d38af526af2", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19"}, "hash": "de42672c66a7583e4c2f0e7f8ab13837de8175582546428b6ac3e1829805140d", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "start_char_idx": 720, "end_char_idx": 1022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e8b87d8-9a4a-4a50-9669-9d38af526af2": {"__data__": {"id_": "4e8b87d8-9a4a-4a50-9669-9d38af526af2", "embedding": null, "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c0f4bc-1904-4832-874f-f5afe7384803", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a20b4bac5e241d081a59e28881627cd26a89a4c1b9464a76c3391d9d013ec1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bb09df0-e152-4f59-8a54-374ed01c78cc", "node_type": "1", "metadata": {"window": "2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f7f26f0560c458a42fdc104f191d7b0f30ab96a224b964829e9d3033b67b246", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71cee173-dc46-4d1b-bad9-ee405d93e205", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.36 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.29 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a01.09 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.65 %\u00a0\u00a011.05 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.99 %\u00a0\u00a08.41 %\u00a0\u00a0\nOperating income \u00a0\u00a02.66 %\u00a0\u00a02.64 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.38 %\u00a0\u00a03.36 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.38 %\u00a0\u00a02.54 %\u00a0\u00a0\nOperating income \u00a0\u00a01.00 %\u00a0\u00a00.81 %\u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "e2fe7e34ae9b24eeb8e6db3cee617d805883a774fd8af46e430328b4ab86df5a", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "start_char_idx": 1022, "end_char_idx": 1198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71cee173-dc46-4d1b-bad9-ee405d93e205": {"__data__": {"id_": "71cee173-dc46-4d1b-bad9-ee405d93e205", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.36 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.29 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a01.09 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.65 %\u00a0\u00a011.05 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.99 %\u00a0\u00a08.41 %\u00a0\u00a0\nOperating income \u00a0\u00a02.66 %\u00a0\u00a02.64 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.38 %\u00a0\u00a03.36 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.38 %\u00a0\u00a02.54 %\u00a0\u00a0\nOperating income \u00a0\u00a01.00 %\u00a0\u00a00.81 %\u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "20", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec0ed34a-d2bd-4a70-b995-4894391fab16", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2f3c1b9927cb88c08bc158a5dc8e50dbdd91490a3bc93b4d78e9f69fb70fed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e8b87d8-9a4a-4a50-9669-9d38af526af2", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$59,900,199 \u00a0\u00a0$53,389,345 \u00a0\u00a012.2 %\nInternational Healthcare Solutions \u00a0\u00a07,047,777 \u00a0\u00a0\u00a06,676,726 \u00a0\u00a05.6 %\nIntersegment eliminations \u00a0\u00a0(933 )\u00a0\u00a0(1,470 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$66,947,043 \u00a0\u00a0$60,064,601 \u00a0\u00a011.5 %\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "original_text": "Healthcare Solutions \u00a0$635,176 \u00a0\u00a0$579,927 \u00a0\u00a09.5 %\nInternational Healthcare Solutions \u00a0\u00a0187,132 \u00a0\u00a0\u00a0176,272 \u00a0\u00a06.2 %\nTotal segment operating income \u00a0\u00a0822,308 \u00a0\u00a0\u00a0756,199 \u00a0\u00a08.7 %\n19", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b2357b143fab2f4dc0b3ba2ed627148ba5e02ee8168a0b1a29be84b95231265", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b3d13ec-30f9-4ee2-903b-527519bf006b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.36 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.29 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a01.09 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.65 %\u00a0\u00a011.05 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.99 %\u00a0\u00a08.41 %\u00a0\u00a0\nOperating income \u00a0\u00a02.66 %\u00a0\u00a02.64 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.38 %\u00a0\u00a03.36 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.38 %\u00a0\u00a02.54 %\u00a0\u00a0\nOperating income \u00a0\u00a01.00 %\u00a0\u00a00.81 %\u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.36 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.29 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a01.09 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.65 %\u00a0\u00a011.05 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.99 %\u00a0\u00a08.41 %\u00a0\u00a0\nOperating income \u00a0\u00a02.66 %\u00a0\u00a02.64 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.38 %\u00a0\u00a03.36 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.38 %\u00a0\u00a02.54 %\u00a0\u00a0\nOperating income \u00a0\u00a01.00 %\u00a0\u00a00.81 %\u00a0\u00a0\n20"}, "hash": "75038f800d71eaddf3551b50ec587e9c502f1336e802be127038bdec158256cf", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b3d13ec-30f9-4ee2-903b-527519bf006b": {"__data__": {"id_": "9b3d13ec-30f9-4ee2-903b-527519bf006b", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.36 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.29 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a01.09 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.65 %\u00a0\u00a011.05 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.99 %\u00a0\u00a08.41 %\u00a0\u00a0\nOperating income \u00a0\u00a02.66 %\u00a0\u00a02.64 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.38 %\u00a0\u00a03.36 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.38 %\u00a0\u00a02.54 %\u00a0\u00a0\nOperating income \u00a0\u00a01.00 %\u00a0\u00a00.81 %\u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.36 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.29 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a01.09 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.65 %\u00a0\u00a011.05 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.99 %\u00a0\u00a08.41 %\u00a0\u00a0\nOperating income \u00a0\u00a02.66 %\u00a0\u00a02.64 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.38 %\u00a0\u00a03.36 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.38 %\u00a0\u00a02.54 %\u00a0\u00a0\nOperating income \u00a0\u00a01.00 %\u00a0\u00a00.81 %\u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec0ed34a-d2bd-4a70-b995-4894391fab16", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2f3c1b9927cb88c08bc158a5dc8e50dbdd91490a3bc93b4d78e9f69fb70fed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71cee173-dc46-4d1b-bad9-ee405d93e205", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.36 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.29 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a01.09 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.65 %\u00a0\u00a011.05 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.99 %\u00a0\u00a08.41 %\u00a0\u00a0\nOperating income \u00a0\u00a02.66 %\u00a0\u00a02.64 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.38 %\u00a0\u00a03.36 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.38 %\u00a0\u00a02.54 %\u00a0\u00a0\nOperating income \u00a0\u00a01.00 %\u00a0\u00a00.81 %\u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "20", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e09029c494b20d5965ac2f1d2d665d60f9cb88922d20ddabf27bcafa5d8fc8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66eae9ec-7c9d-452d-a1e1-7fea129e59f8", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "09e11590eec74281fa10a4063a8023b702dc52d863012ef32d4a1bbb11bd4943", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.36 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.29 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a01.09 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.65 %\u00a0\u00a011.05 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.99 %\u00a0\u00a08.41 %\u00a0\u00a0\nOperating income \u00a0\u00a02.66 %\u00a0\u00a02.64 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.38 %\u00a0\u00a03.36 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.38 %\u00a0\u00a02.54 %\u00a0\u00a0\nOperating income \u00a0\u00a01.00 %\u00a0\u00a00.81 %\u00a0\u00a0\n20", "start_char_idx": 593, "end_char_idx": 1057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66eae9ec-7c9d-452d-a1e1-7fea129e59f8": {"__data__": {"id_": "66eae9ec-7c9d-452d-a1e1-7fea129e59f8", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf94e8-aea2-49f0-b52d-1a5443cd3e34", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14fe98d36fb72b4b78bd403426eb7194b5b66eb52a450cfff06c44959ef58277", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b3d13ec-30f9-4ee2-903b-527519bf006b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.36 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.29 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a01.09 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.65 %\u00a0\u00a011.05 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.99 %\u00a0\u00a08.41 %\u00a0\u00a0\nOperating income \u00a0\u00a02.66 %\u00a0\u00a02.64 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.38 %\u00a0\u00a03.36 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.38 %\u00a0\u00a02.54 %\u00a0\u00a0\nOperating income \u00a0\u00a01.00 %\u00a0\u00a00.81 %\u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.36 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.29 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a01.09 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.65 %\u00a0\u00a011.05 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.99 %\u00a0\u00a08.41 %\u00a0\u00a0\nOperating income \u00a0\u00a02.66 %\u00a0\u00a02.64 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.38 %\u00a0\u00a03.36 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.38 %\u00a0\u00a02.54 %\u00a0\u00a0\nOperating income \u00a0\u00a01.00 %\u00a0\u00a00.81 %\u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe1af6bca301779f0c56f99ea18d181a8bde1745d9dbe42b314fe1b671cfaabd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a31a7ca-8e7c-4bbc-aab4-2e3065e3441f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. "}, "hash": "cb2b3f1ffc8a0ffeeb9b490167647e996cbe9a1e260c50992cacf87945122ed8", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 0, "end_char_idx": 371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a31a7ca-8e7c-4bbc-aab4-2e3065e3441f": {"__data__": {"id_": "9a31a7ca-8e7c-4bbc-aab4-2e3065e3441f", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf94e8-aea2-49f0-b52d-1a5443cd3e34", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14fe98d36fb72b4b78bd403426eb7194b5b66eb52a450cfff06c44959ef58277", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66eae9ec-7c9d-452d-a1e1-7fea129e59f8", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "583a8781f741d4ad029e5f860b231282f86b67fae8c3f0e54f53d6ec64aa7e89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "256878f0-fe0d-4628-ba9f-d3158285a91e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S. "}, "hash": "685a0e42308b6d1a96da567312113f759466827b87a3f85db09a6ae264c406e8", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "start_char_idx": 371, "end_char_idx": 533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "256878f0-fe0d-4628-ba9f-d3158285a91e": {"__data__": {"id_": "256878f0-fe0d-4628-ba9f-d3158285a91e", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf94e8-aea2-49f0-b52d-1a5443cd3e34", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14fe98d36fb72b4b78bd403426eb7194b5b66eb52a450cfff06c44959ef58277", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a31a7ca-8e7c-4bbc-aab4-2e3065e3441f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8b8adadab4a38b97c3935eb6b0ba675b98aad158decb1e0791f38d221600cda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bbbf0a4-5916-4b8e-937c-cdeefd29ee98", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21"}, "hash": "c539e43aa36996da6cd9aeab7a809766b3528e604ceb02d00284472d25aebfcf", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "start_char_idx": 533, "end_char_idx": 840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bbbf0a4-5916-4b8e-937c-cdeefd29ee98": {"__data__": {"id_": "8bbbf0a4-5916-4b8e-937c-cdeefd29ee98", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8bf94e8-aea2-49f0-b52d-1a5443cd3e34", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14fe98d36fb72b4b78bd403426eb7194b5b66eb52a450cfff06c44959ef58277", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "256878f0-fe0d-4628-ba9f-d3158285a91e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57568ffac6d6f8cee4445786b35a9d5b6a6744200d90093f965251631b1c2f6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63e839c1-039b-4ffe-bcde-a9540e7e437d", "node_type": "1", "metadata": {"window": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.52 %\u00a0\u00a02.59 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.38 %\u00a0\u00a01.39 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.19 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.57 %\u00a0\u00a011.09 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.00 %\u00a0\u00a08.39 %\u00a0\u00a0\nOperating income \u00a0\u00a02.57 %\u00a0\u00a02.70 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.47 %\u00a0\u00a03.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.51 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating income \u00a0\u00a00.96 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "e1d352006c2d0ab200c7f94285f4288d02a637a19917ea2531a9cd9e09637ed0", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "start_char_idx": 840, "end_char_idx": 1104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63e839c1-039b-4ffe-bcde-a9540e7e437d": {"__data__": {"id_": "63e839c1-039b-4ffe-bcde-a9540e7e437d", "embedding": null, "metadata": {"window": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.52 %\u00a0\u00a02.59 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.38 %\u00a0\u00a01.39 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.19 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.57 %\u00a0\u00a011.09 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.00 %\u00a0\u00a08.39 %\u00a0\u00a0\nOperating income \u00a0\u00a02.57 %\u00a0\u00a02.70 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.47 %\u00a0\u00a03.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.51 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating income \u00a0\u00a00.96 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "22", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16315473-540d-424a-9e4f-772f79cceea8", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba5bfd8df5c865ff515ccd7c24cf8318a852fa527a5395397f3591bc4b21adf9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bbbf0a4-5916-4b8e-937c-cdeefd29ee98", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68cb86f1b742b47651f16b8d434e117485550ec638b45d03dc6739d5650e62f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6da1a4c3-15d7-4444-aa0d-930b2b4a05fb", "node_type": "1", "metadata": {"window": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.52 %\u00a0\u00a02.59 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.38 %\u00a0\u00a01.39 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.19 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.57 %\u00a0\u00a011.09 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.00 %\u00a0\u00a08.39 %\u00a0\u00a0\nOperating income \u00a0\u00a02.57 %\u00a0\u00a02.70 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.47 %\u00a0\u00a03.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.51 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating income \u00a0\u00a00.96 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.52 %\u00a0\u00a02.59 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.38 %\u00a0\u00a01.39 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.19 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.57 %\u00a0\u00a011.09 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.00 %\u00a0\u00a08.39 %\u00a0\u00a0\nOperating income \u00a0\u00a02.57 %\u00a0\u00a02.70 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.47 %\u00a0\u00a03.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.51 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating income \u00a0\u00a00.96 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22"}, "hash": "7906c52f73ebf4a796008b3050e1f23bdc1bebd4dfd1b786accf0ef4e70dbed9", "class_name": "RelatedNodeInfo"}}, "text": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6da1a4c3-15d7-4444-aa0d-930b2b4a05fb": {"__data__": {"id_": "6da1a4c3-15d7-4444-aa0d-930b2b4a05fb", "embedding": null, "metadata": {"window": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.52 %\u00a0\u00a02.59 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.38 %\u00a0\u00a01.39 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.19 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.57 %\u00a0\u00a011.09 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.00 %\u00a0\u00a08.39 %\u00a0\u00a0\nOperating income \u00a0\u00a02.57 %\u00a0\u00a02.70 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.47 %\u00a0\u00a03.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.51 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating income \u00a0\u00a00.96 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.52 %\u00a0\u00a02.59 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.38 %\u00a0\u00a01.39 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.19 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.57 %\u00a0\u00a011.09 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.00 %\u00a0\u00a08.39 %\u00a0\u00a0\nOperating income \u00a0\u00a02.57 %\u00a0\u00a02.70 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.47 %\u00a0\u00a03.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.51 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating income \u00a0\u00a00.96 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "page_label": "22", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16315473-540d-424a-9e4f-772f79cceea8", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba5bfd8df5c865ff515ccd7c24cf8318a852fa527a5395397f3591bc4b21adf9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63e839c1-039b-4ffe-bcde-a9540e7e437d", "node_type": "1", "metadata": {"window": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.52 %\u00a0\u00a02.59 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.38 %\u00a0\u00a01.39 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.19 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.57 %\u00a0\u00a011.09 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.00 %\u00a0\u00a08.39 %\u00a0\u00a0\nOperating income \u00a0\u00a02.57 %\u00a0\u00a02.70 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.47 %\u00a0\u00a03.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.51 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating income \u00a0\u00a00.96 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "22", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcf7843e0d1e54e4e118eaa4d45cc2ab630a3861b8271680363580d56f980069", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff16f042-2195-47a8-ace6-2d704b64cefd", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED BAL ANCE SHEET S \n (in thousands) \n (unaudited)\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2023 \u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,389,345 \u00a0$3,388,189\nAccounts receivable, net \u00a020,796,648 \u00a0\u00a0\u00a018,452,675 \u00a0\nInventories \u00a016,852,340 \u00a0\u00a0\u00a015,556,394 \u00a0\nRight to recover assets \u00a01,417,551 \u00a0\u00a0\u00a01,532,061 \u00a0\nPrepaid expenses and other \u00a0530,700 \u00a0\u00a0\u00a0660,439 \u00a0\nTotal current assets \u00a040,986,584 \u00a0\u00a0\u00a039,589,758 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,147,881 \u00a0\u00a0\u00a02,135,003 \u00a0\nGoodwill and other intangible assets \u00a014,425,265 \u00a0\u00a0\u00a012,836,623 \u00a0\nDeferred income taxes \u00a0221,235 \u00a0\u00a0\u00a0237,571 \u00a0\nOther long-term assets \u00a03,396,231 \u00a0\u00a0\u00a01,761,661 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "de09de4609d5e264353e0499717cdd75111dec5cda3a0e795a406cfba54de545", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.52 %\u00a0\u00a02.59 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.38 %\u00a0\u00a01.39 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.19 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.57 %\u00a0\u00a011.09 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.00 %\u00a0\u00a08.39 %\u00a0\u00a0\nOperating income \u00a0\u00a02.57 %\u00a0\u00a02.70 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.47 %\u00a0\u00a03.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.51 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating income \u00a0\u00a00.96 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "start_char_idx": 576, "end_char_idx": 1051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff16f042-2195-47a8-ace6-2d704b64cefd": {"__data__": {"id_": "ff16f042-2195-47a8-ace6-2d704b64cefd", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED BAL ANCE SHEET S \n (in thousands) \n (unaudited)\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2023 \u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,389,345 \u00a0$3,388,189\nAccounts receivable, net \u00a020,796,648 \u00a0\u00a0\u00a018,452,675 \u00a0\nInventories \u00a016,852,340 \u00a0\u00a0\u00a015,556,394 \u00a0\nRight to recover assets \u00a01,417,551 \u00a0\u00a0\u00a01,532,061 \u00a0\nPrepaid expenses and other \u00a0530,700 \u00a0\u00a0\u00a0660,439 \u00a0\nTotal current assets \u00a040,986,584 \u00a0\u00a0\u00a039,589,758 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,147,881 \u00a0\u00a0\u00a02,135,003 \u00a0\nGoodwill and other intangible assets \u00a014,425,265 \u00a0\u00a0\u00a012,836,623 \u00a0\nDeferred income taxes \u00a0221,235 \u00a0\u00a0\u00a0237,571 \u00a0\nOther long-term assets \u00a03,396,231 \u00a0\u00a0\u00a01,761,661 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "23", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4fbb8b3-21bb-4377-9587-a63e396b892e", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa304dfd06d10c894b534ecc144de48484c5f8b60ab15ffe36a908a70b522fe7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6da1a4c3-15d7-4444-aa0d-930b2b4a05fb", "node_type": "1", "metadata": {"window": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.52 %\u00a0\u00a02.59 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.38 %\u00a0\u00a01.39 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.19 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.57 %\u00a0\u00a011.09 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.00 %\u00a0\u00a08.39 %\u00a0\u00a0\nOperating income \u00a0\u00a02.57 %\u00a0\u00a02.70 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.47 %\u00a0\u00a03.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.51 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating income \u00a0\u00a00.96 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.52 %\u00a0\u00a02.59 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.38 %\u00a0\u00a01.39 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.19 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.57 %\u00a0\u00a011.09 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.00 %\u00a0\u00a08.39 %\u00a0\u00a0\nOperating income \u00a0\u00a02.57 %\u00a0\u00a02.70 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.47 %\u00a0\u00a03.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.51 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating income \u00a0\u00a00.96 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "page_label": "22", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecaa8268770e259ed202fb041d0c518860f1ba1fe27076ade1150fd63b7f28ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bacaebc4-e64b-49b7-a5cf-e88274c91789", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED BAL ANCE SHEET S \n (in thousands) \n (unaudited)\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2023 \u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,389,345 \u00a0$3,388,189\nAccounts receivable, net \u00a020,796,648 \u00a0\u00a0\u00a018,452,675 \u00a0\nInventories \u00a016,852,340 \u00a0\u00a0\u00a015,556,394 \u00a0\nRight to recover assets \u00a01,417,551 \u00a0\u00a0\u00a01,532,061 \u00a0\nPrepaid expenses and other \u00a0530,700 \u00a0\u00a0\u00a0660,439 \u00a0\nTotal current assets \u00a040,986,584 \u00a0\u00a0\u00a039,589,758 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,147,881 \u00a0\u00a0\u00a02,135,003 \u00a0\nGoodwill and other intangible assets \u00a014,425,265 \u00a0\u00a0\u00a012,836,623 \u00a0\nDeferred income taxes \u00a0221,235 \u00a0\u00a0\u00a0237,571 \u00a0\nOther long-term assets \u00a03,396,231 \u00a0\u00a0\u00a01,761,661 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED BAL ANCE SHEET S \n (in thousands) \n (unaudited)\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2023 \u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,389,345 \u00a0$3,388,189\nAccounts receivable, net \u00a020,796,648 \u00a0\u00a0\u00a018,452,675 \u00a0\nInventories \u00a016,852,340 \u00a0\u00a0\u00a015,556,394 \u00a0\nRight to recover assets \u00a01,417,551 \u00a0\u00a0\u00a01,532,061 \u00a0\nPrepaid expenses and other \u00a0530,700 \u00a0\u00a0\u00a0660,439 \u00a0\nTotal current assets \u00a040,986,584 \u00a0\u00a0\u00a039,589,758 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,147,881 \u00a0\u00a0\u00a02,135,003 \u00a0\nGoodwill and other intangible assets \u00a014,425,265 \u00a0\u00a0\u00a012,836,623 \u00a0\nDeferred income taxes \u00a0221,235 \u00a0\u00a0\u00a0237,571 \u00a0\nOther long-term assets \u00a03,396,231 \u00a0\u00a0\u00a01,761,661 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23"}, "hash": "8ffa75143067817d130806041e85f3bddd5da8b6f710f821909c6ba8a7e21c65", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 0, "end_char_idx": 360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bacaebc4-e64b-49b7-a5cf-e88274c91789": {"__data__": {"id_": "bacaebc4-e64b-49b7-a5cf-e88274c91789", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED BAL ANCE SHEET S \n (in thousands) \n (unaudited)\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2023 \u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,389,345 \u00a0$3,388,189\nAccounts receivable, net \u00a020,796,648 \u00a0\u00a0\u00a018,452,675 \u00a0\nInventories \u00a016,852,340 \u00a0\u00a0\u00a015,556,394 \u00a0\nRight to recover assets \u00a01,417,551 \u00a0\u00a0\u00a01,532,061 \u00a0\nPrepaid expenses and other \u00a0530,700 \u00a0\u00a0\u00a0660,439 \u00a0\nTotal current assets \u00a040,986,584 \u00a0\u00a0\u00a039,589,758 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,147,881 \u00a0\u00a0\u00a02,135,003 \u00a0\nGoodwill and other intangible assets \u00a014,425,265 \u00a0\u00a0\u00a012,836,623 \u00a0\nDeferred income taxes \u00a0221,235 \u00a0\u00a0\u00a0237,571 \u00a0\nOther long-term assets \u00a03,396,231 \u00a0\u00a0\u00a01,761,661 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED BAL ANCE SHEET S \n (in thousands) \n (unaudited)\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2023 \u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,389,345 \u00a0$3,388,189\nAccounts receivable, net \u00a020,796,648 \u00a0\u00a0\u00a018,452,675 \u00a0\nInventories \u00a016,852,340 \u00a0\u00a0\u00a015,556,394 \u00a0\nRight to recover assets \u00a01,417,551 \u00a0\u00a0\u00a01,532,061 \u00a0\nPrepaid expenses and other \u00a0530,700 \u00a0\u00a0\u00a0660,439 \u00a0\nTotal current assets \u00a040,986,584 \u00a0\u00a0\u00a039,589,758 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,147,881 \u00a0\u00a0\u00a02,135,003 \u00a0\nGoodwill and other intangible assets \u00a014,425,265 \u00a0\u00a0\u00a012,836,623 \u00a0\nDeferred income taxes \u00a0221,235 \u00a0\u00a0\u00a0237,571 \u00a0\nOther long-term assets \u00a03,396,231 \u00a0\u00a0\u00a01,761,661 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "page_label": "23", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4fbb8b3-21bb-4377-9587-a63e396b892e", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa304dfd06d10c894b534ecc144de48484c5f8b60ab15ffe36a908a70b522fe7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff16f042-2195-47a8-ace6-2d704b64cefd", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED BAL ANCE SHEET S \n (in thousands) \n (unaudited)\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2023 \u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,389,345 \u00a0$3,388,189\nAccounts receivable, net \u00a020,796,648 \u00a0\u00a0\u00a018,452,675 \u00a0\nInventories \u00a016,852,340 \u00a0\u00a0\u00a015,556,394 \u00a0\nRight to recover assets \u00a01,417,551 \u00a0\u00a0\u00a01,532,061 \u00a0\nPrepaid expenses and other \u00a0530,700 \u00a0\u00a0\u00a0660,439 \u00a0\nTotal current assets \u00a040,986,584 \u00a0\u00a0\u00a039,589,758 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,147,881 \u00a0\u00a0\u00a02,135,003 \u00a0\nGoodwill and other intangible assets \u00a014,425,265 \u00a0\u00a0\u00a012,836,623 \u00a0\nDeferred income taxes \u00a0221,235 \u00a0\u00a0\u00a0237,571 \u00a0\nOther long-term assets \u00a03,396,231 \u00a0\u00a0\u00a01,761,661 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "23", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b448a1c51b935d67dfecf4bef7e83717217979947e6100448114eb0a04e2c03c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ec6254b-9e65-46d7-ba61-834801256547", "node_type": "1", "metadata": {"window": "Total assets $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $43,752,080 \u00a0\u00a0$40,192,890 \u00a0\nAccrued expenses and other \u00a02,170,270 \u00a0\u00a0\u00a02,214,592 \u00a0\nShort-term debt \u00a0860,861 \u00a0\u00a0\u00a01,070,473 \u00a0\nTotal current liabilities \u00a046,783,211 \u00a0\u00a0\u00a043,477,955 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,159,853 \u00a0\u00a0\u00a04,632,360 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0284,020 \u00a0\u00a0\u00a0320,274 \u00a0\nDeferred income taxes \u00a01,716,360 \u00a0\u00a0\u00a01,620,413 \u00a0\nAccrued litigation liability \u00a05,455,000 \u00a0\u00a0\u00a05,461,758 \u00a0\nOther long-term liabilities \u00a01,856,708 \u00a0\u00a0\u00a0976,583 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0922,044 \u00a0\u00a0\u00a071,273 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\nAMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2023 \u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\n24", "original_text": "Total assets $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $43,752,080 \u00a0\u00a0$40,192,890 \u00a0\nAccrued expenses and other \u00a02,170,270 \u00a0\u00a0\u00a02,214,592 \u00a0\nShort-term debt \u00a0860,861 \u00a0\u00a0\u00a01,070,473 \u00a0\nTotal current liabilities \u00a046,783,211 \u00a0\u00a0\u00a043,477,955 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,159,853 \u00a0\u00a0\u00a04,632,360 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0284,020 \u00a0\u00a0\u00a0320,274 \u00a0\nDeferred income taxes \u00a01,716,360 \u00a0\u00a0\u00a01,620,413 \u00a0\nAccrued litigation liability \u00a05,455,000 \u00a0\u00a0\u00a05,461,758 \u00a0\nOther long-term liabilities \u00a01,856,708 \u00a0\u00a0\u00a0976,583 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0922,044 \u00a0\u00a0\u00a071,273 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\nAMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2023 \u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\n24"}, "hash": "48bae2f271ad86913985bf0664bc346fc54219fef3fb67934dc071a2e24153f7", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED BAL ANCE SHEET S \n (in thousands) \n (unaudited)\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2023 \u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,389,345 \u00a0$3,388,189\nAccounts receivable, net \u00a020,796,648 \u00a0\u00a0\u00a018,452,675 \u00a0\nInventories \u00a016,852,340 \u00a0\u00a0\u00a015,556,394 \u00a0\nRight to recover assets \u00a01,417,551 \u00a0\u00a0\u00a01,532,061 \u00a0\nPrepaid expenses and other \u00a0530,700 \u00a0\u00a0\u00a0660,439 \u00a0\nTotal current assets \u00a040,986,584 \u00a0\u00a0\u00a039,589,758 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,147,881 \u00a0\u00a0\u00a02,135,003 \u00a0\nGoodwill and other intangible assets \u00a014,425,265 \u00a0\u00a0\u00a012,836,623 \u00a0\nDeferred income taxes \u00a0221,235 \u00a0\u00a0\u00a0237,571 \u00a0\nOther long-term assets \u00a03,396,231 \u00a0\u00a0\u00a01,761,661 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "start_char_idx": 360, "end_char_idx": 1067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ec6254b-9e65-46d7-ba61-834801256547": {"__data__": {"id_": "5ec6254b-9e65-46d7-ba61-834801256547", "embedding": null, "metadata": {"window": "Total assets $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $43,752,080 \u00a0\u00a0$40,192,890 \u00a0\nAccrued expenses and other \u00a02,170,270 \u00a0\u00a0\u00a02,214,592 \u00a0\nShort-term debt \u00a0860,861 \u00a0\u00a0\u00a01,070,473 \u00a0\nTotal current liabilities \u00a046,783,211 \u00a0\u00a0\u00a043,477,955 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,159,853 \u00a0\u00a0\u00a04,632,360 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0284,020 \u00a0\u00a0\u00a0320,274 \u00a0\nDeferred income taxes \u00a01,716,360 \u00a0\u00a0\u00a01,620,413 \u00a0\nAccrued litigation liability \u00a05,455,000 \u00a0\u00a0\u00a05,461,758 \u00a0\nOther long-term liabilities \u00a01,856,708 \u00a0\u00a0\u00a0976,583 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0922,044 \u00a0\u00a0\u00a071,273 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\nAMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2023 \u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\n24", "original_text": "Total assets $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $43,752,080 \u00a0\u00a0$40,192,890 \u00a0\nAccrued expenses and other \u00a02,170,270 \u00a0\u00a0\u00a02,214,592 \u00a0\nShort-term debt \u00a0860,861 \u00a0\u00a0\u00a01,070,473 \u00a0\nTotal current liabilities \u00a046,783,211 \u00a0\u00a0\u00a043,477,955 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,159,853 \u00a0\u00a0\u00a04,632,360 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0284,020 \u00a0\u00a0\u00a0320,274 \u00a0\nDeferred income taxes \u00a01,716,360 \u00a0\u00a0\u00a01,620,413 \u00a0\nAccrued litigation liability \u00a05,455,000 \u00a0\u00a0\u00a05,461,758 \u00a0\nOther long-term liabilities \u00a01,856,708 \u00a0\u00a0\u00a0976,583 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0922,044 \u00a0\u00a0\u00a071,273 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\nAMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2023 \u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\n24", "page_label": "24", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "601ce026-0780-4d2a-9af2-83d717f863fe", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4ceda6f56610d7d4679f2c7b65bf541c9c2cfec0c69d11cba71212d644cfc93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bacaebc4-e64b-49b7-a5cf-e88274c91789", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED BAL ANCE SHEET S \n (in thousands) \n (unaudited)\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2023 \u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,389,345 \u00a0$3,388,189\nAccounts receivable, net \u00a020,796,648 \u00a0\u00a0\u00a018,452,675 \u00a0\nInventories \u00a016,852,340 \u00a0\u00a0\u00a015,556,394 \u00a0\nRight to recover assets \u00a01,417,551 \u00a0\u00a0\u00a01,532,061 \u00a0\nPrepaid expenses and other \u00a0530,700 \u00a0\u00a0\u00a0660,439 \u00a0\nTotal current assets \u00a040,986,584 \u00a0\u00a0\u00a039,589,758 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,147,881 \u00a0\u00a0\u00a02,135,003 \u00a0\nGoodwill and other intangible assets \u00a014,425,265 \u00a0\u00a0\u00a012,836,623 \u00a0\nDeferred income taxes \u00a0221,235 \u00a0\u00a0\u00a0237,571 \u00a0\nOther long-term assets \u00a03,396,231 \u00a0\u00a0\u00a01,761,661 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "original_text": "AMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED BAL ANCE SHEET S \n (in thousands) \n (unaudited)\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2023 \u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,389,345 \u00a0$3,388,189\nAccounts receivable, net \u00a020,796,648 \u00a0\u00a0\u00a018,452,675 \u00a0\nInventories \u00a016,852,340 \u00a0\u00a0\u00a015,556,394 \u00a0\nRight to recover assets \u00a01,417,551 \u00a0\u00a0\u00a01,532,061 \u00a0\nPrepaid expenses and other \u00a0530,700 \u00a0\u00a0\u00a0660,439 \u00a0\nTotal current assets \u00a040,986,584 \u00a0\u00a0\u00a039,589,758 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,147,881 \u00a0\u00a0\u00a02,135,003 \u00a0\nGoodwill and other intangible assets \u00a014,425,265 \u00a0\u00a0\u00a012,836,623 \u00a0\nDeferred income taxes \u00a0221,235 \u00a0\u00a0\u00a0237,571 \u00a0\nOther long-term assets \u00a03,396,231 \u00a0\u00a0\u00a01,761,661 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "page_label": "23", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c0e53166d9858d37757c8d9a4f34c88ae3875f3af0a19cb8e1066a146359f9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16dba72d-ebeb-4a32-b225-ce5df907947e", "node_type": "1", "metadata": {"window": "Net income $1,383,596 \u00a0\u00a0$1,367,864 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0899,803 \u00a0\u00a0\u00a0704,628 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,249,881 )\u00a0\u00a0(1,550,962 )\nInventories \u00a0(1,369,977 )\u00a0\u00a0(712,849 )\nAccounts payable \u00a03,513,686 \u00a0\u00a0\u00a02,074,612 \u00a0\nOther, net \u00a0(92,704 )\u00a0\u00a0(344,675 )\nNet cash provided by operating activities \u00a02,084,523 \u00a0\u00a0\u00a01,538,618 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(282,862 )\u00a0\u00a0(322,732 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,681 )\u00a0\u00a0(124,158 )\nCost of equity investments  2 \u00a0(737,025 )\u00a0\u00a0\u2014 \u00a0\nProceeds from the sale of businesses \u00a0\u2014 \u00a0\u00a0\u00a0258,082 \u00a0\nOther, net \u00a010,544 \u00a0\u00a0\u00a0(4,899 )\nNet cash used in investing activities \u00a0(2,419,024 )\u00a0\u00a0(193,707 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(581,557 )\u00a0\u00a0(576,303 )\nPurchases of common stock 3 \u00a0(907,214 )\u00a0\u00a0(248,422 )\nExercises of stock options \u00a050,078 \u00a0\u00a0\u00a083,954 \u00a0\nCash dividends on common stock \u00a0(300,413 )\u00a0\u00a0(295,239 )\nEmployee tax withholdings related to restricted share vesting \u00a0(71,059 )\u00a0\u00a0(35,273 )\nOther, net \u00a0(5,099 )\u00a0\u00a0(8,036 )\nNet cash used in financing activities \u00a0(1,815,264 )\u00a0\u00a0(1,079,319 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0104,479 \u00a0\u00a0\u00a0(33,056 )\n25", "original_text": "Net income $1,383,596 \u00a0\u00a0$1,367,864 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0899,803 \u00a0\u00a0\u00a0704,628 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,249,881 )\u00a0\u00a0(1,550,962 )\nInventories \u00a0(1,369,977 )\u00a0\u00a0(712,849 )\nAccounts payable \u00a03,513,686 \u00a0\u00a0\u00a02,074,612 \u00a0\nOther, net \u00a0(92,704 )\u00a0\u00a0(344,675 )\nNet cash provided by operating activities \u00a02,084,523 \u00a0\u00a0\u00a01,538,618 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(282,862 )\u00a0\u00a0(322,732 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,681 )\u00a0\u00a0(124,158 )\nCost of equity investments  2 \u00a0(737,025 )\u00a0\u00a0\u2014 \u00a0\nProceeds from the sale of businesses \u00a0\u2014 \u00a0\u00a0\u00a0258,082 \u00a0\nOther, net \u00a010,544 \u00a0\u00a0\u00a0(4,899 )\nNet cash used in investing activities \u00a0(2,419,024 )\u00a0\u00a0(193,707 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(581,557 )\u00a0\u00a0(576,303 )\nPurchases of common stock 3 \u00a0(907,214 )\u00a0\u00a0(248,422 )\nExercises of stock options \u00a050,078 \u00a0\u00a0\u00a083,954 \u00a0\nCash dividends on common stock \u00a0(300,413 )\u00a0\u00a0(295,239 )\nEmployee tax withholdings related to restricted share vesting \u00a0(71,059 )\u00a0\u00a0(35,273 )\nOther, net \u00a0(5,099 )\u00a0\u00a0(8,036 )\nNet cash used in financing activities \u00a0(1,815,264 )\u00a0\u00a0(1,079,319 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0104,479 \u00a0\u00a0\u00a0(33,056 )\n25"}, "hash": "b81d882950597af163c3735251d18c9372535bced32fed50001eab83c833a212", "class_name": "RelatedNodeInfo"}}, "text": "Total assets $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $43,752,080 \u00a0\u00a0$40,192,890 \u00a0\nAccrued expenses and other \u00a02,170,270 \u00a0\u00a0\u00a02,214,592 \u00a0\nShort-term debt \u00a0860,861 \u00a0\u00a0\u00a01,070,473 \u00a0\nTotal current liabilities \u00a046,783,211 \u00a0\u00a0\u00a043,477,955 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,159,853 \u00a0\u00a0\u00a04,632,360 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0284,020 \u00a0\u00a0\u00a0320,274 \u00a0\nDeferred income taxes \u00a01,716,360 \u00a0\u00a0\u00a01,620,413 \u00a0\nAccrued litigation liability \u00a05,455,000 \u00a0\u00a0\u00a05,461,758 \u00a0\nOther long-term liabilities \u00a01,856,708 \u00a0\u00a0\u00a0976,583 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0922,044 \u00a0\u00a0\u00a071,273 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\nAMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2023 \u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\n24", "start_char_idx": 0, "end_char_idx": 880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16dba72d-ebeb-4a32-b225-ce5df907947e": {"__data__": {"id_": "16dba72d-ebeb-4a32-b225-ce5df907947e", "embedding": null, "metadata": {"window": "Net income $1,383,596 \u00a0\u00a0$1,367,864 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0899,803 \u00a0\u00a0\u00a0704,628 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,249,881 )\u00a0\u00a0(1,550,962 )\nInventories \u00a0(1,369,977 )\u00a0\u00a0(712,849 )\nAccounts payable \u00a03,513,686 \u00a0\u00a0\u00a02,074,612 \u00a0\nOther, net \u00a0(92,704 )\u00a0\u00a0(344,675 )\nNet cash provided by operating activities \u00a02,084,523 \u00a0\u00a0\u00a01,538,618 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(282,862 )\u00a0\u00a0(322,732 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,681 )\u00a0\u00a0(124,158 )\nCost of equity investments  2 \u00a0(737,025 )\u00a0\u00a0\u2014 \u00a0\nProceeds from the sale of businesses \u00a0\u2014 \u00a0\u00a0\u00a0258,082 \u00a0\nOther, net \u00a010,544 \u00a0\u00a0\u00a0(4,899 )\nNet cash used in investing activities \u00a0(2,419,024 )\u00a0\u00a0(193,707 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(581,557 )\u00a0\u00a0(576,303 )\nPurchases of common stock 3 \u00a0(907,214 )\u00a0\u00a0(248,422 )\nExercises of stock options \u00a050,078 \u00a0\u00a0\u00a083,954 \u00a0\nCash dividends on common stock \u00a0(300,413 )\u00a0\u00a0(295,239 )\nEmployee tax withholdings related to restricted share vesting \u00a0(71,059 )\u00a0\u00a0(35,273 )\nOther, net \u00a0(5,099 )\u00a0\u00a0(8,036 )\nNet cash used in financing activities \u00a0(1,815,264 )\u00a0\u00a0(1,079,319 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0104,479 \u00a0\u00a0\u00a0(33,056 )\n25", "original_text": "Net income $1,383,596 \u00a0\u00a0$1,367,864 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0899,803 \u00a0\u00a0\u00a0704,628 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,249,881 )\u00a0\u00a0(1,550,962 )\nInventories \u00a0(1,369,977 )\u00a0\u00a0(712,849 )\nAccounts payable \u00a03,513,686 \u00a0\u00a0\u00a02,074,612 \u00a0\nOther, net \u00a0(92,704 )\u00a0\u00a0(344,675 )\nNet cash provided by operating activities \u00a02,084,523 \u00a0\u00a0\u00a01,538,618 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(282,862 )\u00a0\u00a0(322,732 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,681 )\u00a0\u00a0(124,158 )\nCost of equity investments  2 \u00a0(737,025 )\u00a0\u00a0\u2014 \u00a0\nProceeds from the sale of businesses \u00a0\u2014 \u00a0\u00a0\u00a0258,082 \u00a0\nOther, net \u00a010,544 \u00a0\u00a0\u00a0(4,899 )\nNet cash used in investing activities \u00a0(2,419,024 )\u00a0\u00a0(193,707 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(581,557 )\u00a0\u00a0(576,303 )\nPurchases of common stock 3 \u00a0(907,214 )\u00a0\u00a0(248,422 )\nExercises of stock options \u00a050,078 \u00a0\u00a0\u00a083,954 \u00a0\nCash dividends on common stock \u00a0(300,413 )\u00a0\u00a0(295,239 )\nEmployee tax withholdings related to restricted share vesting \u00a0(71,059 )\u00a0\u00a0(35,273 )\nOther, net \u00a0(5,099 )\u00a0\u00a0(8,036 )\nNet cash used in financing activities \u00a0(1,815,264 )\u00a0\u00a0(1,079,319 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0104,479 \u00a0\u00a0\u00a0(33,056 )\n25", "page_label": "25", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7b12765-a55d-4b0d-b110-b14ea4f47293", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fdbcf486a4304888df4ee37f49017ada6ba90893dd203025c19f700b8f43263", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ec6254b-9e65-46d7-ba61-834801256547", "node_type": "1", "metadata": {"window": "Total assets $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $43,752,080 \u00a0\u00a0$40,192,890 \u00a0\nAccrued expenses and other \u00a02,170,270 \u00a0\u00a0\u00a02,214,592 \u00a0\nShort-term debt \u00a0860,861 \u00a0\u00a0\u00a01,070,473 \u00a0\nTotal current liabilities \u00a046,783,211 \u00a0\u00a0\u00a043,477,955 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,159,853 \u00a0\u00a0\u00a04,632,360 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0284,020 \u00a0\u00a0\u00a0320,274 \u00a0\nDeferred income taxes \u00a01,716,360 \u00a0\u00a0\u00a01,620,413 \u00a0\nAccrued litigation liability \u00a05,455,000 \u00a0\u00a0\u00a05,461,758 \u00a0\nOther long-term liabilities \u00a01,856,708 \u00a0\u00a0\u00a0976,583 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0922,044 \u00a0\u00a0\u00a071,273 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\nAMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2023 \u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\n24", "original_text": "Total assets $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $43,752,080 \u00a0\u00a0$40,192,890 \u00a0\nAccrued expenses and other \u00a02,170,270 \u00a0\u00a0\u00a02,214,592 \u00a0\nShort-term debt \u00a0860,861 \u00a0\u00a0\u00a01,070,473 \u00a0\nTotal current liabilities \u00a046,783,211 \u00a0\u00a0\u00a043,477,955 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,159,853 \u00a0\u00a0\u00a04,632,360 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0284,020 \u00a0\u00a0\u00a0320,274 \u00a0\nDeferred income taxes \u00a01,716,360 \u00a0\u00a0\u00a01,620,413 \u00a0\nAccrued litigation liability \u00a05,455,000 \u00a0\u00a0\u00a05,461,758 \u00a0\nOther long-term liabilities \u00a01,856,708 \u00a0\u00a0\u00a0976,583 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0922,044 \u00a0\u00a0\u00a071,273 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\nAMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2023 \u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\n24", "page_label": "24", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "786b6c7a719e8c2471602ec2a6c64a1b4cab36a3dfa9f1f87299721f0ed4870e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d4f796f-d180-49dd-a35d-2d5d71effcef", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n"}, "hash": "872d22643fbb2fa693c966bee18a8d13ef57a046a830d1400dd644a82e1d1f5a", "class_name": "RelatedNodeInfo"}}, "text": "Net income $1,383,596 \u00a0\u00a0$1,367,864 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0899,803 \u00a0\u00a0\u00a0704,628 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,249,881 )\u00a0\u00a0(1,550,962 )\nInventories \u00a0(1,369,977 )\u00a0\u00a0(712,849 )\nAccounts payable \u00a03,513,686 \u00a0\u00a0\u00a02,074,612 \u00a0\nOther, net \u00a0(92,704 )\u00a0\u00a0(344,675 )\nNet cash provided by operating activities \u00a02,084,523 \u00a0\u00a0\u00a01,538,618 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(282,862 )\u00a0\u00a0(322,732 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,681 )\u00a0\u00a0(124,158 )\nCost of equity investments  2 \u00a0(737,025 )\u00a0\u00a0\u2014 \u00a0\nProceeds from the sale of businesses \u00a0\u2014 \u00a0\u00a0\u00a0258,082 \u00a0\nOther, net \u00a010,544 \u00a0\u00a0\u00a0(4,899 )\nNet cash used in investing activities \u00a0(2,419,024 )\u00a0\u00a0(193,707 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(581,557 )\u00a0\u00a0(576,303 )\nPurchases of common stock 3 \u00a0(907,214 )\u00a0\u00a0(248,422 )\nExercises of stock options \u00a050,078 \u00a0\u00a0\u00a083,954 \u00a0\nCash dividends on common stock \u00a0(300,413 )\u00a0\u00a0(295,239 )\nEmployee tax withholdings related to restricted share vesting \u00a0(71,059 )\u00a0\u00a0(35,273 )\nOther, net \u00a0(5,099 )\u00a0\u00a0(8,036 )\nNet cash used in financing activities \u00a0(1,815,264 )\u00a0\u00a0(1,079,319 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0104,479 \u00a0\u00a0\u00a0(33,056 )\n25", "start_char_idx": 0, "end_char_idx": 1351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d4f796f-d180-49dd-a35d-2d5d71effcef": {"__data__": {"id_": "0d4f796f-d180-49dd-a35d-2d5d71effcef", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c5a2ebc114d7a546feb982d4a1b56fc7321cdb73f142aeb6eb7389b95342ba7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16dba72d-ebeb-4a32-b225-ce5df907947e", "node_type": "1", "metadata": {"window": "Net income $1,383,596 \u00a0\u00a0$1,367,864 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0899,803 \u00a0\u00a0\u00a0704,628 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,249,881 )\u00a0\u00a0(1,550,962 )\nInventories \u00a0(1,369,977 )\u00a0\u00a0(712,849 )\nAccounts payable \u00a03,513,686 \u00a0\u00a0\u00a02,074,612 \u00a0\nOther, net \u00a0(92,704 )\u00a0\u00a0(344,675 )\nNet cash provided by operating activities \u00a02,084,523 \u00a0\u00a0\u00a01,538,618 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(282,862 )\u00a0\u00a0(322,732 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,681 )\u00a0\u00a0(124,158 )\nCost of equity investments  2 \u00a0(737,025 )\u00a0\u00a0\u2014 \u00a0\nProceeds from the sale of businesses \u00a0\u2014 \u00a0\u00a0\u00a0258,082 \u00a0\nOther, net \u00a010,544 \u00a0\u00a0\u00a0(4,899 )\nNet cash used in investing activities \u00a0(2,419,024 )\u00a0\u00a0(193,707 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(581,557 )\u00a0\u00a0(576,303 )\nPurchases of common stock 3 \u00a0(907,214 )\u00a0\u00a0(248,422 )\nExercises of stock options \u00a050,078 \u00a0\u00a0\u00a083,954 \u00a0\nCash dividends on common stock \u00a0(300,413 )\u00a0\u00a0(295,239 )\nEmployee tax withholdings related to restricted share vesting \u00a0(71,059 )\u00a0\u00a0(35,273 )\nOther, net \u00a0(5,099 )\u00a0\u00a0(8,036 )\nNet cash used in financing activities \u00a0(1,815,264 )\u00a0\u00a0(1,079,319 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0104,479 \u00a0\u00a0\u00a0(33,056 )\n25", "original_text": "Net income $1,383,596 \u00a0\u00a0$1,367,864 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0899,803 \u00a0\u00a0\u00a0704,628 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,249,881 )\u00a0\u00a0(1,550,962 )\nInventories \u00a0(1,369,977 )\u00a0\u00a0(712,849 )\nAccounts payable \u00a03,513,686 \u00a0\u00a0\u00a02,074,612 \u00a0\nOther, net \u00a0(92,704 )\u00a0\u00a0(344,675 )\nNet cash provided by operating activities \u00a02,084,523 \u00a0\u00a0\u00a01,538,618 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(282,862 )\u00a0\u00a0(322,732 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,681 )\u00a0\u00a0(124,158 )\nCost of equity investments  2 \u00a0(737,025 )\u00a0\u00a0\u2014 \u00a0\nProceeds from the sale of businesses \u00a0\u2014 \u00a0\u00a0\u00a0258,082 \u00a0\nOther, net \u00a010,544 \u00a0\u00a0\u00a0(4,899 )\nNet cash used in investing activities \u00a0(2,419,024 )\u00a0\u00a0(193,707 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(581,557 )\u00a0\u00a0(576,303 )\nPurchases of common stock 3 \u00a0(907,214 )\u00a0\u00a0(248,422 )\nExercises of stock options \u00a050,078 \u00a0\u00a0\u00a083,954 \u00a0\nCash dividends on common stock \u00a0(300,413 )\u00a0\u00a0(295,239 )\nEmployee tax withholdings related to restricted share vesting \u00a0(71,059 )\u00a0\u00a0(35,273 )\nOther, net \u00a0(5,099 )\u00a0\u00a0(8,036 )\nNet cash used in financing activities \u00a0(1,815,264 )\u00a0\u00a0(1,079,319 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0104,479 \u00a0\u00a0\u00a0(33,056 )\n25", "page_label": "25", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6ad42c9e64b63d51979418a103f78afa492e2079106d117d1f2868e48e072bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "980c971e-9534-4eaa-8f48-3f5cb0436ffe", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "2Includes a $718.4 million investment in OneOncology.\n"}, "hash": "7968e06847c2df60f86d47c0b9b5763d14c3fdd25ae00f1891f3efe49ed54e2d", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n", "start_char_idx": 0, "end_char_idx": 621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "980c971e-9534-4eaa-8f48-3f5cb0436ffe": {"__data__": {"id_": "980c971e-9534-4eaa-8f48-3f5cb0436ffe", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "2Includes a $718.4 million investment in OneOncology.\n", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c5a2ebc114d7a546feb982d4a1b56fc7321cdb73f142aeb6eb7389b95342ba7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d4f796f-d180-49dd-a35d-2d5d71effcef", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8db2d8d76ab5eb4dc2a39946489f12896224c9e004f5c1343430f2672c1b65b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47bc1676-528e-4460-b7c4-32a1ab530aea", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n"}, "hash": "41262c74d1b62f00848fa6fe5b075aa4b298dd7d40547aa0837bc7308113edc7", "class_name": "RelatedNodeInfo"}}, "text": "2Includes a $718.4 million investment in OneOncology.\n", "start_char_idx": 621, "end_char_idx": 675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47bc1676-528e-4460-b7c4-32a1ab530aea": {"__data__": {"id_": "47bc1676-528e-4460-b7c4-32a1ab530aea", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c5a2ebc114d7a546feb982d4a1b56fc7321cdb73f142aeb6eb7389b95342ba7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "980c971e-9534-4eaa-8f48-3f5cb0436ffe", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "2Includes a $718.4 million investment in OneOncology.\n", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90db86d81683fd2dea754d206fdc5f0d10f3d0fd9d517693c2d7294038e582f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f789eda8-411b-47be-8d4d-2e01b2009310", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "12e546d2dea2075ca8e29421c8cd8a960e40e8a6dd937991f6a7aadaf0a0597b", "class_name": "RelatedNodeInfo"}}, "text": "3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n", "start_char_idx": 675, "end_char_idx": 765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f789eda8-411b-47be-8d4d-2e01b2009310": {"__data__": {"id_": "f789eda8-411b-47be-8d4d-2e01b2009310", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c5a2ebc114d7a546feb982d4a1b56fc7321cdb73f142aeb6eb7389b95342ba7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47bc1676-528e-4460-b7c4-32a1ab530aea", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e91c4bde7e457a22b1e785e94e1ccae3d17214eb63e4cb0169bee5b4778713ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38c85abb-f9c3-498a-b40b-d1ba0a2c82a8", "node_type": "1", "metadata": {"window": "2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "64009d79b32706eb61a8818837d210cb6a072a11a459f87bf634973b8ed279b8", "class_name": "RelatedNodeInfo"}}, "text": "4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 765, "end_char_idx": 1568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38c85abb-f9c3-498a-b40b-d1ba0a2c82a8": {"__data__": {"id_": "38c85abb-f9c3-498a-b40b-d1ba0a2c82a8", "embedding": null, "metadata": {"window": "2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c5a2ebc114d7a546feb982d4a1b56fc7321cdb73f142aeb6eb7389b95342ba7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f789eda8-411b-47be-8d4d-2e01b2009310", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98aa23aadaaef004e703dbfab192e3305b117c0bb59b2e97f7494bf5e32c0ad1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9b76c13-05dd-42b4-ba8c-874ed8f3f86a", "node_type": "1", "metadata": {"window": "3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "667916062576b92d51cee8cd6a2fddf8a34b991ad25a290ade87346080bea10e", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 1568, "end_char_idx": 1683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9b76c13-05dd-42b4-ba8c-874ed8f3f86a": {"__data__": {"id_": "a9b76c13-05dd-42b4-ba8c-874ed8f3f86a", "embedding": null, "metadata": {"window": "3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c5a2ebc114d7a546feb982d4a1b56fc7321cdb73f142aeb6eb7389b95342ba7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38c85abb-f9c3-498a-b40b-d1ba0a2c82a8", "node_type": "1", "metadata": {"window": "2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21b61617f0913421ce15e35a13c9b76029c2a6633db627fa69d42019072b17e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05db4f1f-3088-4582-856a-2961cf429d29", "node_type": "1", "metadata": {"window": "4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "4b96da4359b5fac67fd7cdf7fd1cc8f00da2122c28910a56187677b6a77b2abf", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 1683, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05db4f1f-3088-4582-856a-2961cf429d29": {"__data__": {"id_": "05db4f1f-3088-4582-856a-2961cf429d29", "embedding": null, "metadata": {"window": "4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c5a2ebc114d7a546feb982d4a1b56fc7321cdb73f142aeb6eb7389b95342ba7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9b76c13-05dd-42b4-ba8c-874ed8f3f86a", "node_type": "1", "metadata": {"window": "3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10f285b69eff7d5eaf68e9552795fe5bc472ecb1116c892ec1a0efebfc6e7465", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "169747b7-7eb0-4798-8e0a-ed67fbc7f9da", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "26"}, "hash": "c267a38389f382431cdb2e4806a53bbd48cad9ea3389fd39231d2df651edf7db", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 1823, "end_char_idx": 1942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "169747b7-7eb0-4798-8e0a-ed67fbc7f9da": {"__data__": {"id_": "169747b7-7eb0-4798-8e0a-ed67fbc7f9da", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "26", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c5a2ebc114d7a546feb982d4a1b56fc7321cdb73f142aeb6eb7389b95342ba7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05db4f1f-3088-4582-856a-2961cf429d29", "node_type": "1", "metadata": {"window": "4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f214adeff4d92953afc7ce82ac562c822ad97d97982deb937acd151e5a3a7fa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90cd4eb7-1512-44ad-afd2-4f8b37fb97b2", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "91cb805397d94befe8f83fdd2f4f4d17d04b20aead0623c17372606843abd4ae", "class_name": "RelatedNodeInfo"}}, "text": "26", "start_char_idx": 316, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90cd4eb7-1512-44ad-afd2-4f8b37fb97b2": {"__data__": {"id_": "90cd4eb7-1512-44ad-afd2-4f8b37fb97b2", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "169747b7-7eb0-4798-8e0a-ed67fbc7f9da", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n 26", "original_text": "26", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fee2177ad433dbc3f259716e1698aa5f034ad9166be5d15f82201f1f6955187", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae44f02d-2263-4629-b613-7df0810fd7d4", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "bb90096abab670b9365c3b6994d9564eb74fc062984791d8de0d6c1404082f5b", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 0, "end_char_idx": 219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae44f02d-2263-4629-b613-7df0810fd7d4": {"__data__": {"id_": "ae44f02d-2263-4629-b613-7df0810fd7d4", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90cd4eb7-1512-44ad-afd2-4f8b37fb97b2", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bb88a101a7c7062d1aee6a444a84be159b58638a8257c253e18c91d5957d07e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cd68c38-8012-41ca-aa61-cdfbcb8bfd62", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "18da15b62219527c90ce5dba60322526e51f7b35153a3843dcb5612bfe655a75", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 219, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cd68c38-8012-41ca-aa61-cdfbcb8bfd62": {"__data__": {"id_": "6cd68c38-8012-41ca-aa61-cdfbcb8bfd62", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae44f02d-2263-4629-b613-7df0810fd7d4", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dab3a665a9b8ecccfef816017eb6547cb731175b406dd6bbda0d720aaee9369", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1e06e29-2b44-4367-ad0d-07dcc290c641", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). "}, "hash": "91ba66d4329fe3cfb14f62818df76583142da89649cc811b9a6aaab0efe63c10", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 401, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1e06e29-2b44-4367-ad0d-07dcc290c641": {"__data__": {"id_": "e1e06e29-2b44-4367-ad0d-07dcc290c641", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cd68c38-8012-41ca-aa61-cdfbcb8bfd62", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b401584ca24c0c93989c1518387f65a037b592d5f5761dee1ecb69834ce39c78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "137d1968-0b8d-4da1-b0c2-17bca472c931", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. "}, "hash": "3b79adebfeddf8f2f603c98147755a5a7a301cb8fbe60020867afaeafb9f5056", "class_name": "RelatedNodeInfo"}}, "text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "start_char_idx": 682, "end_char_idx": 1008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "137d1968-0b8d-4da1-b0c2-17bca472c931": {"__data__": {"id_": "137d1968-0b8d-4da1-b0c2-17bca472c931", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1e06e29-2b44-4367-ad0d-07dcc290c641", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1be7984a3cd7c1c9280781e59f897c96def16266ec8a5f12df1c920d71f73d1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d583ed4-ae53-4ea0-a1fb-269ba85efed8", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "0c6ccc3367f80edd5dc719c7c963ac0000119f31e107684d39dd9c2568e06d6b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "start_char_idx": 1008, "end_char_idx": 1093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d583ed4-ae53-4ea0-a1fb-269ba85efed8": {"__data__": {"id_": "9d583ed4-ae53-4ea0-a1fb-269ba85efed8", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "137d1968-0b8d-4da1-b0c2-17bca472c931", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91c0bd6c09ff0991444680a131480dc260ae3c4f09b452cc5a94670cc000643a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58572829-e6fa-478f-a5cd-e4d8762b0ebf", "node_type": "1", "metadata": {"window": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. "}, "hash": "84619f0ab542733acf873b0b5ef8b548b3e49034ddc21734d875628b89af7204", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 1093, "end_char_idx": 1250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58572829-e6fa-478f-a5cd-e4d8762b0ebf": {"__data__": {"id_": "58572829-e6fa-478f-a5cd-e4d8762b0ebf", "embedding": null, "metadata": {"window": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d583ed4-ae53-4ea0-a1fb-269ba85efed8", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ae483fcd7c7ea40458f79461e4b7196a80cc269fa7f40716aeac445662adc12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bae5bd7-c100-4a79-b839-ae57846dfa4d", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. "}, "hash": "2825c662353cdafe48ae4ed519cb1529eb5072e62b358be7818224cbc50999c9", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "start_char_idx": 1250, "end_char_idx": 1453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bae5bd7-c100-4a79-b839-ae57846dfa4d": {"__data__": {"id_": "0bae5bd7-c100-4a79-b839-ae57846dfa4d", "embedding": null, "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58572829-e6fa-478f-a5cd-e4d8762b0ebf", "node_type": "1", "metadata": {"window": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94aa958d8fdadf0dbf4eec0bf15a975735c57f8241d86bd05f96cd2da63a3e80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "478ab060-7f45-43ba-94e7-50d777bc0a15", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n"}, "hash": "8b2d912b18de7ae7f29a659b460a454c938184c12380873a36f91191c8695486", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "start_char_idx": 1453, "end_char_idx": 1749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "478ab060-7f45-43ba-94e7-50d777bc0a15": {"__data__": {"id_": "478ab060-7f45-43ba-94e7-50d777bc0a15", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bae5bd7-c100-4a79-b839-ae57846dfa4d", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cad5169b107d2403328c6face4fc51c1d618ac9108e677d0570fe41653e06418", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae5674db-23c9-43cb-9185-bfef75f392af", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. "}, "hash": "91b4564e6af02716694e039c3cadf067fe66ad2b2b07c6da0a5d9d6842cf8769", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "start_char_idx": 1749, "end_char_idx": 1931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae5674db-23c9-43cb-9185-bfef75f392af": {"__data__": {"id_": "ae5674db-23c9-43cb-9185-bfef75f392af", "embedding": null, "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "478ab060-7f45-43ba-94e7-50d777bc0a15", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "947d372e05bfd53702abb43189567e76cdf7f5a4cfab2c202efbea5f61cc1cc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38b611d9-3f08-42c0-a0d7-707b2ffc3bd0", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. "}, "hash": "f46d69060bf6829220dc686d014baa23a9ab58f57dfee5af4019e079c789ac77", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "start_char_idx": 1931, "end_char_idx": 2299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38b611d9-3f08-42c0-a0d7-707b2ffc3bd0": {"__data__": {"id_": "38b611d9-3f08-42c0-a0d7-707b2ffc3bd0", "embedding": null, "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae5674db-23c9-43cb-9185-bfef75f392af", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08ca3b03456d0890e9a5beac745946c6021d5521d0dd67398c5c2c81187d09e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76186493-f2be-443e-8567-7f3dc8c64c71", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. "}, "hash": "5aeadb939b344b939b7b71ab95150f68456f02ca53cd176397924f55fe611ad2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "start_char_idx": 2299, "end_char_idx": 2395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76186493-f2be-443e-8567-7f3dc8c64c71": {"__data__": {"id_": "76186493-f2be-443e-8567-7f3dc8c64c71", "embedding": null, "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38b611d9-3f08-42c0-a0d7-707b2ffc3bd0", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1889a5c67668056631fe43c6f723ca5b1a9f940a5dfe0441015bab5a4c9f1184", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2565b72e-3b81-40f2-a3b2-efdcad440555", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. "}, "hash": "21ec04265c0dcaa3e281b726cb2337db1f721368fb0fa12e8ceb29d6f952a4bc", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "start_char_idx": 2395, "end_char_idx": 2557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2565b72e-3b81-40f2-a3b2-efdcad440555": {"__data__": {"id_": "2565b72e-3b81-40f2-a3b2-efdcad440555", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76186493-f2be-443e-8567-7f3dc8c64c71", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70908e72891e7897a3e381be38583e94a666430e471ea6a5724b44d1488ec56d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f4f8272-7aa4-4f45-a399-2d113d4fa4f1", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n"}, "hash": "7f1398ddf5ffb4d3ce77d2552adc65a663add53eba32745f8a9fa9fd0c08fde1", "class_name": "RelatedNodeInfo"}}, "text": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "start_char_idx": 2557, "end_char_idx": 2727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f4f8272-7aa4-4f45-a399-2d113d4fa4f1": {"__data__": {"id_": "0f4f8272-7aa4-4f45-a399-2d113d4fa4f1", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2565b72e-3b81-40f2-a3b2-efdcad440555", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25ab0ea7004116692ae2c1e09be9af6b3d97c359dd1a24ea00f5935d98032317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab172ee0-362e-4c75-b8ab-518cbec2ff6a", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "cb7aa5eacc2e2410923250960f46fbfb21b21e9634f60b475038e3f438faf3db", "class_name": "RelatedNodeInfo"}}, "text": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "start_char_idx": 2727, "end_char_idx": 3037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab172ee0-362e-4c75-b8ab-518cbec2ff6a": {"__data__": {"id_": "ab172ee0-362e-4c75-b8ab-518cbec2ff6a", "embedding": null, "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f4f8272-7aa4-4f45-a399-2d113d4fa4f1", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6faf4cee00b4d2933981f8dcf607caac3933c5de70e40880521360de92b2b2f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23d32f99-b8df-4983-a098-ff5948cdae41", "node_type": "1", "metadata": {"window": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "de3449d9af9be4abb022de732b1410524f1ea0967ab3986f7275991f50b8246c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 3037, "end_char_idx": 3286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23d32f99-b8df-4983-a098-ff5948cdae41": {"__data__": {"id_": "23d32f99-b8df-4983-a098-ff5948cdae41", "embedding": null, "metadata": {"window": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab172ee0-362e-4c75-b8ab-518cbec2ff6a", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08cd42f928bf2bba37640b3eea5c7a0dfbba8f60455309410b2c27f90197a6ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b2083ab-9a9b-49df-b5cf-fa428fcbe9dd", "node_type": "1", "metadata": {"window": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "703789fd992220dbb4a12ab5b33e807a6cf9630dadd05b23b48c547bec71302f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 3286, "end_char_idx": 3379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b2083ab-9a9b-49df-b5cf-fa428fcbe9dd": {"__data__": {"id_": "5b2083ab-9a9b-49df-b5cf-fa428fcbe9dd", "embedding": null, "metadata": {"window": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23d32f99-b8df-4983-a098-ff5948cdae41", "node_type": "1", "metadata": {"window": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d41dc09a0035ea09f763fe6d368eee24c314cc37f0e00176f348754473d3f0bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dc2d178-b2c0-4e70-afe5-3da521db5fdd", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "29c08ec7e608e9a96cd9cf5823c84ecb394abb6f909fc6d1ef8486bab826995a", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 3379, "end_char_idx": 3626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dc2d178-b2c0-4e70-afe5-3da521db5fdd": {"__data__": {"id_": "5dc2d178-b2c0-4e70-afe5-3da521db5fdd", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b2083ab-9a9b-49df-b5cf-fa428fcbe9dd", "node_type": "1", "metadata": {"window": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b41a040bd6e4ecfbedd1334a61ca78fa1d5c659da4b56a3cbd67f3b938064708", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1fd3c22-cf45-4a7c-9e93-c9950927017f", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring. "}, "hash": "ebdc9ccdbcbd9c2976399936af66c64c5089825f324abdf3cce27bb0f59859fb", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 3626, "end_char_idx": 3831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1fd3c22-cf45-4a7c-9e93-c9950927017f": {"__data__": {"id_": "a1fd3c22-cf45-4a7c-9e93-c9950927017f", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dc2d178-b2c0-4e70-afe5-3da521db5fdd", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d44743f28722ca097f44d6f942d23bd30e36a151f05a1f8b7ed85674bd9b54b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "271bf4e5-91e5-4f98-978d-26513b5a6b9f", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n"}, "hash": "e5890e2daf21f7b9704ad901c9286a779c08ee178f8cd6ae56d8f975586b2a37", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring. ", "start_char_idx": 3831, "end_char_idx": 4188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "271bf4e5-91e5-4f98-978d-26513b5a6b9f": {"__data__": {"id_": "271bf4e5-91e5-4f98-978d-26513b5a6b9f", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1fd3c22-cf45-4a7c-9e93-c9950927017f", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "714b0834e0e201a2ed1a29e4ff6d6dbd461a42252eb987bead640c1bc652df19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82eebee9-9900-487e-b06c-f78e151420a1", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. "}, "hash": "d897bd0a73a9f1fc86a7455bf23219fec85226bbf9ad7b0d3a6139fbe705cebd", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "start_char_idx": 4188, "end_char_idx": 4353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82eebee9-9900-487e-b06c-f78e151420a1": {"__data__": {"id_": "82eebee9-9900-487e-b06c-f78e151420a1", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "271bf4e5-91e5-4f98-978d-26513b5a6b9f", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "daf86075ce97864301d5e3cbee58acdb5bc37b09c6b0b64ee9ffdd0c6ae821f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37a8a253-7ed1-4263-803f-35326a7660dd", "node_type": "1", "metadata": {"window": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "5460d002fa31afea1f940cfbf1662d3aeac0e392d84814f7df61bd09d120f0a7", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "start_char_idx": 4353, "end_char_idx": 4542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37a8a253-7ed1-4263-803f-35326a7660dd": {"__data__": {"id_": "37a8a253-7ed1-4263-803f-35326a7660dd", "embedding": null, "metadata": {"window": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82eebee9-9900-487e-b06c-f78e151420a1", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d8b06fff4a49298d19f5aed57f625607e92041bfdc2864eccc597ac875b069e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b874523-2c69-47ad-9411-23739d14e1a9", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "670a59014a02f1aa5ec34c60175ca85ce8bac0571351f1fcde4241e0243e1f65", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 4542, "end_char_idx": 4815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b874523-2c69-47ad-9411-23739d14e1a9": {"__data__": {"id_": "6b874523-2c69-47ad-9411-23739d14e1a9", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37a8a253-7ed1-4263-803f-35326a7660dd", "node_type": "1", "metadata": {"window": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, the gain (loss) on the currency remeasurement of the deferred tax asset\nrelating to 2020 S wiss tax reform, and the gain on the sale of businesses are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44939deb323ca88198712ad811f8526610243c02c1a68b8137341acb996e1a2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d16c2902-2482-408b-abf1-06a856e3c6f0", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense. "}, "hash": "5055a7f1d4188d1b515c4c8461b166c05d362ff1110df6095950e20ea7412d99", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 4815, "end_char_idx": 5053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d16c2902-2482-408b-abf1-06a856e3c6f0": {"__data__": {"id_": "d16c2902-2482-408b-abf1-06a856e3c6f0", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b874523-2c69-47ad-9411-23739d14e1a9", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ec85a05791a92163ab9144df2c85bb96325c113814539b70774f28b8936e765", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dc2344c-df30-4297-9f0d-c492b1e91ef2", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022. "}, "hash": "82348fd9f1805c14042c0fb8276a396317f1c664f9b2a301401b714f5ce86e97", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense. ", "start_char_idx": 5053, "end_char_idx": 5251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dc2344c-df30-4297-9f0d-c492b1e91ef2": {"__data__": {"id_": "8dc2344c-df30-4297-9f0d-c492b1e91ef2", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d16c2902-2482-408b-abf1-06a856e3c6f0", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd97db58b4db6dc723274b1f5c1a9f27c708017b46c6b7e4d2efd604de0ba7e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65fa66b3-4019-4ab1-8197-736592921cde", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "c99b198218f6965ffda5cd9c6b4e76b37015b045479b4e437d2897a1748deaa3", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022. ", "start_char_idx": 5251, "end_char_idx": 5408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65fa66b3-4019-4ab1-8197-736592921cde": {"__data__": {"id_": "65fa66b3-4019-4ab1-8197-736592921cde", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dc2344c-df30-4297-9f0d-c492b1e91ef2", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f08ee3a10b6173ecceb2768756ebcbde92228133bd8e507fce7ac4f8827ea408", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f21128f0-6ce9-4bcc-85a9-8b661c3119ee", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. "}, "hash": "fa0bc3673482e564f4e37cad27a405fa6198c10445687a670f69f6d2519a449f", "class_name": "RelatedNodeInfo"}}, "text": "Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 5408, "end_char_idx": 5652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f21128f0-6ce9-4bcc-85a9-8b661c3119ee": {"__data__": {"id_": "f21128f0-6ce9-4bcc-85a9-8b661c3119ee", "embedding": null, "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65fa66b3-4019-4ab1-8197-736592921cde", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a309caa35a7bda6b4bec7bcbede5cdab46747f7e8ff41666ff0ff993c0daa76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a64be202-c9f7-4c82-a9af-16e96c5afd2e", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Management believes that this\n27"}, "hash": "3fae626e14884402a5c87f22aad7f9561c98fa3578b71efcc13269bcc9b5e35c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "start_char_idx": 5652, "end_char_idx": 5866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a64be202-c9f7-4c82-a9af-16e96c5afd2e": {"__data__": {"id_": "a64be202-c9f7-4c82-a9af-16e96c5afd2e", "embedding": null, "metadata": {"window": "Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Management believes that this\n27", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e15a6216d217e6f6a14dc4cb464ce8224d8fe8b04a4b559642a431871dec67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f21128f0-6ce9-4bcc-85a9-8b661c3119ee", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b340e7af4bb72bfde365473e7d06fda57eaf9adc2d40ff7f050fee2cf30243d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec6f9965-37f2-43c8-92b0-5a7ca9aee972", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n"}, "hash": "d770f61193ee94129f3a6126ad7efc059277cd4fd501acaeb0a1998d5b1d41ed", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this\n27", "start_char_idx": 5866, "end_char_idx": 5898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec6f9965-37f2-43c8-92b0-5a7ca9aee972": {"__data__": {"id_": "ec6f9965-37f2-43c8-92b0-5a7ca9aee972", "embedding": null, "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a64be202-c9f7-4c82-a9af-16e96c5afd2e", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to 2020 S wiss tax\nreform are excluded from adjusted income tax expense for the nine months ended June 30, 2023 and 2022.  Management\nbelieves that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s\nperformance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\n27", "original_text": "Management believes that this\n27", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25c63cea12e214d8aa74ddbc975b46c818657d9ebf4b60a37cc34383f90023f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edaafec9-edeb-4c5c-9bf1-aa46d5089923", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. "}, "hash": "19b4bed14c5144371eaee2b0e3f181eba11ad7850b1e43fbcc628baff4c58f9f", "class_name": "RelatedNodeInfo"}}, "text": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "start_char_idx": 0, "end_char_idx": 141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edaafec9-edeb-4c5c-9bf1-aa46d5089923": {"__data__": {"id_": "edaafec9-edeb-4c5c-9bf1-aa46d5089923", "embedding": null, "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec6f9965-37f2-43c8-92b0-5a7ca9aee972", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e35bf39e0a6171e8fcac6cdcff0d319d42fbb6f03c1a5800b530a944d460b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f859c03-0652-4e65-ac7a-d2cda4d232b1", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "a221f3146dcebd57ddb45f99bd15ab6dcbf0b0048ca63199cb9f815239049609", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "start_char_idx": 141, "end_char_idx": 326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f859c03-0652-4e65-ac7a-d2cda4d232b1": {"__data__": {"id_": "6f859c03-0652-4e65-ac7a-d2cda4d232b1", "embedding": null, "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edaafec9-edeb-4c5c-9bf1-aa46d5089923", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1345f12979dd70b6a23448ffbc3a2cff76c3ef0e38d4e508e784a8e07494b6be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4c64bc7-eebc-474f-bd73-c4c4c34abad9", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. "}, "hash": "d02d38f4009efeedcdac0f9afce5ec00bfea286d6cefc8064e5827bce60d4054", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 326, "end_char_idx": 570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4c64bc7-eebc-474f-bd73-c4c4c34abad9": {"__data__": {"id_": "b4c64bc7-eebc-474f-bd73-c4c4c34abad9", "embedding": null, "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f859c03-0652-4e65-ac7a-d2cda4d232b1", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7834b6a68868fd1cbb4d5a8da2a80ae8d8937ed2a20d86c8495066997299d09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82d91389-6a90-494d-9a64-bd405d340334", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n"}, "hash": "a34b9a90c0499f1b10263a0b582ff2c5f5e250099025fcae927d9229b9d48ed5", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "start_char_idx": 570, "end_char_idx": 1317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82d91389-6a90-494d-9a64-bd405d340334": {"__data__": {"id_": "82d91389-6a90-494d-9a64-bd405d340334", "embedding": null, "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4c64bc7-eebc-474f-bd73-c4c4c34abad9", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6c672759d13c9053cf39f9b27df262cce6423684ad281860504dad857f5f4ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f7fd039-4c60-47df-bf2a-bb4611760c7f", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n"}, "hash": "a83c591522ca4e5f9da51fe2023303a5a2214482d476baebc2ab5361ced4772c", "class_name": "RelatedNodeInfo"}}, "text": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n", "start_char_idx": 1317, "end_char_idx": 1679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f7fd039-4c60-47df-bf2a-bb4611760c7f": {"__data__": {"id_": "2f7fd039-4c60-47df-bf2a-bb4611760c7f", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82d91389-6a90-494d-9a64-bd405d340334", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3d5324ee211a94066023047f3c2bda534d95504946e0b270b4e763df6e4ee63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de6298f0-3630-4b11-9950-171de2048d05", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. "}, "hash": "60cdb62e7f9a60160e725fac888091cf12da29690b910352cd7fae2e1e0d876f", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "start_char_idx": 1679, "end_char_idx": 2033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de6298f0-3630-4b11-9950-171de2048d05": {"__data__": {"id_": "de6298f0-3630-4b11-9950-171de2048d05", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f7fd039-4c60-47df-bf2a-bb4611760c7f", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56259e5a31535d7eefff19bf2a9dc65333cdfb4ead210d3ce94d1da9dd2649e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01d270eb-858a-4dd8-b8de-01f61c5f45fa", "node_type": "1", "metadata": {"window": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. "}, "hash": "474855f68cebf5fb3ceaa2ec6131c4ca1ba6faf827d08989a0295f931979b1ef", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "start_char_idx": 2033, "end_char_idx": 2306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01d270eb-858a-4dd8-b8de-01f61c5f45fa": {"__data__": {"id_": "01d270eb-858a-4dd8-b8de-01f61c5f45fa", "embedding": null, "metadata": {"window": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de6298f0-3630-4b11-9950-171de2048d05", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc69ccc128e46cc13c4a56d3a1aeb127d7c2be2a9c85b035c4adf242b9fcdb60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc3c3e16-e6e2-4d25-bbed-9cf5de03876c", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n"}, "hash": "8ffa1caece354059bf7ea2cab3d2be73f4600186947219c74dfcc066559bbc11", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "start_char_idx": 2306, "end_char_idx": 2544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc3c3e16-e6e2-4d25-bbed-9cf5de03876c": {"__data__": {"id_": "cc3c3e16-e6e2-4d25-bbed-9cf5de03876c", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01d270eb-858a-4dd8-b8de-01f61c5f45fa", "node_type": "1", "metadata": {"window": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the nine months ended June 30, 2022, and the per share impact of certain expenses relating to 2020 S wiss\ntax reform for the nine months ended June 30, 2023 and 2022 are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de99b62d7ce85018d137e1007a38a24a1c61e6730a39dafcb12b5cae4a2289d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0476d296-8060-4c87-8fb7-1abab245d6c3", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. "}, "hash": "425808da7b138c1bbac00ab8141880c3a2392106f50ae229c2e2ecff34436872", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "start_char_idx": 2544, "end_char_idx": 2840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0476d296-8060-4c87-8fb7-1abab245d6c3": {"__data__": {"id_": "0476d296-8060-4c87-8fb7-1abab245d6c3", "embedding": null, "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc3c3e16-e6e2-4d25-bbed-9cf5de03876c", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9559419381d8d21c7831c80fe609c1c7dc1cc899aaf6292752ff11a98e60152f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e7c8f64-a310-41c4-b78c-96ea40b9357e", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. "}, "hash": "bef6334f4a411360b4f47cf72149a7ba50a408aea9e8afb728221f4aa04ebf43", "class_name": "RelatedNodeInfo"}}, "text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "start_char_idx": 2840, "end_char_idx": 2994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e7c8f64-a310-41c4-b78c-96ea40b9357e": {"__data__": {"id_": "6e7c8f64-a310-41c4-b78c-96ea40b9357e", "embedding": null, "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0476d296-8060-4c87-8fb7-1abab245d6c3", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a04b22397a0e56f8916819397ba810d179a9382860b6bde1262b8837ee9a30a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9f53df2-15c1-41e5-b32a-ca155af02cc9", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. "}, "hash": "2af8b184c19c0579f4af7064d46f16423e1524ea60f63b3051569bbe46c25c87", "class_name": "RelatedNodeInfo"}}, "text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "start_char_idx": 2994, "end_char_idx": 3149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9f53df2-15c1-41e5-b32a-ca155af02cc9": {"__data__": {"id_": "b9f53df2-15c1-41e5-b32a-ca155af02cc9", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e7c8f64-a310-41c4-b78c-96ea40b9357e", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0c3c96e38a4758a58d637303b5b952a238eb1af9c9238c5077ec3e703535787", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f0a0841-2ff5-4bbd-8b2a-6e078ef07eca", "node_type": "1", "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. "}, "hash": "6cc3e33a9044e4cd54427e40f88948ec28d964ab2ba8aefd48a8f1a58760788a", "class_name": "RelatedNodeInfo"}}, "text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "start_char_idx": 3149, "end_char_idx": 3327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f0a0841-2ff5-4bbd-8b2a-6e078ef07eca": {"__data__": {"id_": "2f0a0841-2ff5-4bbd-8b2a-6e078ef07eca", "embedding": null, "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9f53df2-15c1-41e5-b32a-ca155af02cc9", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad0ffab5c3c2587dc813d963d3ade35940221c4a8ae64a86ecb2dd68e22f6251", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3bc5703-937d-4989-bc68-e7274b9e6c0e", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million. "}, "hash": "bfdf371200ed330e7c08a43becaee37176be8277914f1fe5e5edc7ab45d7d408", "class_name": "RelatedNodeInfo"}}, "text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "start_char_idx": 3327, "end_char_idx": 3483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3bc5703-937d-4989-bc68-e7274b9e6c0e": {"__data__": {"id_": "f3bc5703-937d-4989-bc68-e7274b9e6c0e", "embedding": null, "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f0a0841-2ff5-4bbd-8b2a-6e078ef07eca", "node_type": "1", "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "709fbabec49b901ba4ff21ea4ed1814882a1a9b4f2f876908719c96a2603d488", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77889e4a-43e9-4226-8040-d5700de3b59d", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n"}, "hash": "6195df89bfc917a47edbf1b4090d9ccf46a8b84e7d4abae723de3d6026f92490", "class_name": "RelatedNodeInfo"}}, "text": "For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million. ", "start_char_idx": 3483, "end_char_idx": 3880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77889e4a-43e9-4226-8040-d5700de3b59d": {"__data__": {"id_": "77889e4a-43e9-4226-8040-d5700de3b59d", "embedding": null, "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3bc5703-937d-4989-bc68-e7274b9e6c0e", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dde98a7cb6058058acd4935870f0d0d941ff8e19faf96ec5c4d96a02219aa1fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5890a73-0453-44c5-aa10-e23857df66f7", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "264cead691ff6e8cd4da94f228660d7eed804ffb1e8fb36ea16241b2f68337e4", "class_name": "RelatedNodeInfo"}}, "text": "For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n", "start_char_idx": 3880, "end_char_idx": 4325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5890a73-0453-44c5-aa10-e23857df66f7": {"__data__": {"id_": "a5890a73-0453-44c5-aa10-e23857df66f7", "embedding": null, "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77889e4a-43e9-4226-8040-d5700de3b59d", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4a510d8703c59eb162d1a4bcfab5334fb57b2241a916654becf758bc10ccb29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c6d49f3-ecd3-4260-89c0-653b6487640b", "node_type": "1", "metadata": {"window": "For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. "}, "hash": "cf723d1036952aa94f17a555bd9166f13f2c36c203cdb22867bcaea8f4627917", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 4325, "end_char_idx": 4775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c6d49f3-ecd3-4260-89c0-653b6487640b": {"__data__": {"id_": "2c6d49f3-ecd3-4260-89c0-653b6487640b", "embedding": null, "metadata": {"window": "For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5890a73-0453-44c5-aa10-e23857df66f7", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a999060b697704a21b81cf957e680a58e53fce52f790ffe8c377ddc6c5f586fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c0abc69-7c74-487b-aee2-a2b7be8ff361", "node_type": "1", "metadata": {"window": "For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "d5985a6a7c5536772fd0c2759fb72f81eac5f68d5eb8012f2955f98bcf7d6e07", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "start_char_idx": 4775, "end_char_idx": 5011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c0abc69-7c74-487b-aee2-a2b7be8ff361": {"__data__": {"id_": "3c0abc69-7c74-487b-aee2-a2b7be8ff361", "embedding": null, "metadata": {"window": "For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c6d49f3-ecd3-4260-89c0-653b6487640b", "node_type": "1", "metadata": {"window": "For the third\nquarter of fiscal 2023, (i) revenue of $66.9 billion was negatively impacted by foreign currency translation of $457 million, resulting\nin revenue on a constant currency basis of $67.4 billion, and (ii) operating income of $822 million was negatively impacted by\nforeign currency translation of $2 million, resulting in operating income on a constant currency basis of $824 million.  For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ec8d287949705fbb3709d386580ba38c238e5a1927b2c3c12ca8f5bc8ea5b64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66fe8f96-dbd5-4079-a53f-28c7b111ca8e", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n"}, "hash": "891f25c030872649a51e3c355d496ca9f33c75366ed807e3e29cc5ba284e1ee3", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 5011, "end_char_idx": 5327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66fe8f96-dbd5-4079-a53f-28c7b111ca8e": {"__data__": {"id_": "66fe8f96-dbd5-4079-a53f-28c7b111ca8e", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c0abc69-7c74-487b-aee2-a2b7be8ff361", "node_type": "1", "metadata": {"window": "For the third\nquarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $7.0 billion was negatively impacted by\nforeign currency translation of $457 million, resulting in revenue on a constant currency basis of $7.5 billion, and (ii) operating\nincome of $187 million was negatively impacted by foreign currency translation of $2 million, resulting in operating income on a\nconstant currency basis of $189 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c5fbec4e443eeef63b2bce8478684cb79cd47584feb3e849713bdffe70e03c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b242c87a-eaea-402c-bbd5-72f025ebc3b0", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28"}, "hash": "c96619f5e7aa6c0b38fd3bee5134583fbfa48a6339951cc0889c129d6287adb7", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "start_char_idx": 5327, "end_char_idx": 5511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b242c87a-eaea-402c-bbd5-72f025ebc3b0": {"__data__": {"id_": "b242c87a-eaea-402c-bbd5-72f025ebc3b0", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297c67e2e0257f6505b658ed5e10078fe8ffb4807ef109f9cfcb5a6158c0a516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66fe8f96-dbd5-4079-a53f-28c7b111ca8e", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d80ccfedcd874c538bb398e0c02be0123718d652cefcced7963352bc1b38ec2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d815a528-c936-4e6d-a70a-dea8db84b43b", "node_type": "1", "metadata": {"window": "bmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "bmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29"}, "hash": "d534cd21b3c61d237bc69444a69185b64afd6b11084283bf4466f35b1c19c646", "class_name": "RelatedNodeInfo"}}, "text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "start_char_idx": 5511, "end_char_idx": 5614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d815a528-c936-4e6d-a70a-dea8db84b43b": {"__data__": {"id_": "d815a528-c936-4e6d-a70a-dea8db84b43b", "embedding": null, "metadata": {"window": "bmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "bmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "page_label": "29", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12fc9d9e-7168-4713-a333-b8202f0baa25", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0a6ab024c0354b60fd260fa3f25baa45bf994206d371b1d2ace7bbbd6602d84", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b242c87a-eaea-402c-bbd5-72f025ebc3b0", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \n28", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcc861a47d48078af6759a2769ebe70348e9ff028616f0b46399f2df4affbd90", "class_name": "RelatedNodeInfo"}}, "text": "bmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "start_char_idx": 0, "end_char_idx": 72, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"218954c7-0dce-4db5-ac27-8da9fc654579": {"doc_hash": "6846ca60fa88c40583ab8be327a62f80268efc77d92a3a0a58f8d2520f81ba92", "ref_doc_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d"}, "fb1862ed-92be-4312-9d52-e2efb929686b": {"doc_hash": "217179bff10a39fd7d91fb31aa2ed8a9bc210ab8bba81708a43cfafd16c3ba18", "ref_doc_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d"}, "f1f21def-9e9b-4048-bd59-e229d377ca87": {"doc_hash": "c4733b967e4d936b946a83a322994423ad7aabd141b57ceaa2f0175f4678e8d0", "ref_doc_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d"}, "16875da3-25cc-4c16-9e42-1f6ff92231ef": {"doc_hash": "0967e62f15fdd3c9465ef89469de942a2a386bf5a34171560e49e7f5b2089175", "ref_doc_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d"}, "41e9a57b-7e46-420e-b7e2-b2b2e4cd74d0": {"doc_hash": "fb06823ac7405fc8cf38857099b36e244668d7cd63a3122a752420e0887dd77a", "ref_doc_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d"}, "19dc3735-8f0f-4908-91f7-1a97fe698bc3": {"doc_hash": "d9e4f405e2b3397f76a7045b961b5eb862b81dd303e8bdcf62ac586b3d5439ae", "ref_doc_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d"}, "0f7bfc3f-0f94-4f0c-a83a-931da51b446b": {"doc_hash": "b911fe05243dd0b6c8d3779cb2f30fb4603532b6bad1f3542294923eb2c3807d", "ref_doc_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d"}, "68922f8d-4872-4888-9e66-5de436a51877": {"doc_hash": "51b200ccd701914a4e0f2bd76a1624e95b23f86c5699ae381340ddc945afc50a", "ref_doc_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d"}, "757350f1-73cc-407f-a8eb-daf9d50b1cd5": {"doc_hash": "a129fba489bd871e69f98f2207cee706c4fee8ca806aebd8c58de77be9cb16d3", "ref_doc_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d"}, "c4f1a19d-574a-4d27-ae12-f00d6485f925": {"doc_hash": "7a946d758f21d8b62fd7d394f3040062335bd443b8c7db1ccb1872106654388a", "ref_doc_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d"}, "38dd3c78-e443-44b3-b969-04fbb5635547": {"doc_hash": "93d7ea96e0337c63632d42aa780ab964e0089369219e813336265ef01bb3eb08", "ref_doc_id": "3e7be363-cb7b-43d8-87df-35ba4c6cb72d"}, "fe017de2-ae3c-4eda-8d92-304ff7759914": {"doc_hash": "c1fd7f4e300b39b43cca966459b8781217b7928d5de59706fd51f1bfb2e74319", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "ebaf6125-b89c-4e9e-98f9-f57f3643e50f": {"doc_hash": "63cf672d0eaa1d523c86002b33246dfc368c6115f62bc8e72939523c344f5969", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "32969913-ef71-4bea-8597-eae5cf4a9a27": {"doc_hash": "c35093b641f7fcf09a8e4228c0382c9f1b6964be0df9073f8b37456da7023623", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "bd0cc6b1-d421-4360-b7eb-cbc27a6b1370": {"doc_hash": "a850ac3aa3a75225c9fda2fa83096fe0510a56dcf81ed7f4b4c88504028261b5", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "50e0e097-f287-4db3-b94d-92e557f24cda": {"doc_hash": "91f50903f62ab13157f1e5c167c152bf95919edf01b17e7915b8ae59a892ae3b", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "9e776022-e7fd-4452-bd93-504aa81728ed": {"doc_hash": "6c15eea395fcb8a153b545c5a46dfe49c06e3db841454cef54fe2f990e1b64da", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "d787bb72-7bcf-49e4-b37c-55b0bf911fa6": {"doc_hash": "8e3ab21679fefde6ff2fad0039bf4a35d1ca7d8c65ae687122d511056f8b5255", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "28017df6-416b-4a40-a916-a46f8ecc42c6": {"doc_hash": "459daaf76dbd843782d5f02f9d524fa0931413aee504ba25a7df1b11dd6ec5bb", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "00ac0c9f-6f20-404f-b965-dd5925ed64b1": {"doc_hash": "aed49c4eac5945ef08013f1e2059410fe9aded25cef3d6f8d937b63f1ac5a71c", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "7efede3d-b73c-45a3-8161-8970608fbbec": {"doc_hash": "9a7277a878d3634fe27c8a62232e72812a00cc2e2001660316e3255b325f9381", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "e791b09f-a485-43a3-a4a4-52fe9e562aeb": {"doc_hash": "fbe39d69b5d33f5e89d274261eb981b1f3ad1ebb3ffd76584a585d1cc555c5a6", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "5f08d6ea-d97f-432c-8b78-f9660ebc7d43": {"doc_hash": "6a3e39d2d494998ab9d1bb7e342028dc4bf13c25cea28e5baaa100969ef24684", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "65d22dec-46ba-4536-940a-3ecea7dc47a6": {"doc_hash": "512766b5f0d104e716659842249645fef0b194b2ad55401b2c816222f00d82f3", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "b05b5a4d-c0be-4c49-b5e3-b36a0fc247f7": {"doc_hash": "ecd1ee608d040a12d5c133f7a8ca8c870f4dae6a6cadbcb5e8771b216b7f2a35", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "33e76841-d178-4f06-8ab1-27ebb97c8fee": {"doc_hash": "3b9d04d66952ed010d60ea0c961e6c336f52503420bb9a747c10be49e6b9303f", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "c0076b34-8b7b-4fd8-9f06-8ddfd242dfc6": {"doc_hash": "9579797d26f3e8782dd72fc9b4674cb1dd8757d522fe8311a691a2b4e26c530f", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "48a45fa0-c01d-4e6b-a48f-84585365e67f": {"doc_hash": "2f524c518f831540ac173c7f5c8ab72cd52b395c9e7b7b401283aefc0a7b9bc2", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "51a22219-3d7b-4e2c-ae5a-02e90f0dff48": {"doc_hash": "7a1d3fc4b21d0c2fe38cef7ab484f5ba0108ead780f9b2d07f2f6a24e7a7ea83", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "6c288fa8-5116-4f96-adeb-3498b1fb2540": {"doc_hash": "15b4da51a9cc87ecac0f84d98eb65620b2c78ffde8c4e549a57c683edad20a17", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "9dba5edf-ca57-48fa-ae63-2bee61b9742a": {"doc_hash": "83f614e4c240b70fd7d4641f78440f1cd4b09a10b3b2e657c19260a27c9dbb9e", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "2d8d196e-91ac-4f54-8b13-d307e10f57a5": {"doc_hash": "cfcf5b37892161eda0c47d798471fd0111299bb07e786e4add71707efce00d91", "ref_doc_id": "cdfda1e0-68c5-4379-b156-215264f23181"}, "b839a19b-8689-40e4-aeb7-1efdb9eeb356": {"doc_hash": "2f8892e83ebef078f7ca5d9a0684f0f2bce3ba41fd8f7a3d1b744b4a45c6f715", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "fe234d44-e5ad-49ea-b13d-941ca4a26a07": {"doc_hash": "128e208df6c4733829fb5805e4e3c1afa7b1b5683a8a9995efe192f48f283df0", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "b802d3e3-1e20-48e1-902b-f5341afe1297": {"doc_hash": "2a2ddec138e9434ed37ba2a3914bf8a82bbc6931db59502d81946fb5a25ad1e5", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "39dc12cb-f59a-4446-8de8-01c972c5aa43": {"doc_hash": "099670c65c8db49c4cd83373a7b06bfb2082dd2fc4c80fae0d580076f747062f", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "7988bc19-9ebe-4cd9-a4c1-840f7e14d590": {"doc_hash": "7beee6a2051afb021a65d8f9ae17bc9b0d15d44fe2c780982a833daed2907a7c", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "cffa49e1-33cf-4269-8514-ca6f7bfec6b5": {"doc_hash": "14056136f075dea93b2bda66ddff99edbc3fda7560ae4622106bc201a7d106d4", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "b7304bee-cc7e-4eeb-b8a0-db7496516f65": {"doc_hash": "5b9ee70e7842f81e6e3d070bb15ee5d60638344a7c9fabf97bf133f028a6dfa2", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "0230bf29-9f49-43db-88a6-e90c1b9d5849": {"doc_hash": "6477188363703c226971c97cb2d0aef06e4db55fc9839dd945562e56234e06bf", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "f19364b7-4c45-46cd-8167-9abc12972c35": {"doc_hash": "e33e3a74e78b802234b7638637d00d569cec51937ec6dc2e3b6158c2a78f279d", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "c9c7a853-eff7-4b78-a1c3-4d7346a052a4": {"doc_hash": "e0be3e59277f2d9ce1bce040d3142a84eb08e091fdc10e38adb49e3f5804568f", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "1f8ac82f-d4cd-460a-afa3-7671abe92102": {"doc_hash": "3112afb062a1ee53900d9a74bafc62e28720a19917b91b754be7c4d58339ee9a", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "775e0f0c-1f59-4828-ac90-846e1e632721": {"doc_hash": "5fe2fb0f1cdf08f1abb9d72772e0b6202ac111f5d1dd6f297f4c9e67ed20a315", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "90ddc6f7-3628-4434-bdcb-dfd0343377a0": {"doc_hash": "199f9cfe43d801f64a04e11d806675febb357f986d778b90eb89ca5f59ba7be5", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "f66875f6-0dde-4d8c-b346-58b2cbe3ca5e": {"doc_hash": "8fa65e98fc766b0e1c6777e5fa85875652f947e3dab9249fb3ae3ec7eda81266", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "72f31ac3-5a70-49d8-9414-f7c53834d68b": {"doc_hash": "a6dd7f56254fb4c930188ea4cfcbd2aaed2813f9548ab052bde7f7d2fe567944", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "b531fbc8-1acd-45c2-96d9-00bfd156a431": {"doc_hash": "082a5f371d299bc1a636bacffc2f5f200fa27c2f9e8cfe1578c76a3add8259f6", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "5e3b7e8b-1216-41aa-8b08-845a58d41f4e": {"doc_hash": "91a37d9c295a1ab5c4e805d3a70355a66a2e1c0d3908f585af5c848aa0f29bc7", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "15a7ea17-7fbb-4388-a932-596bb02c7b6d": {"doc_hash": "9b2614fcea548416c9f4c47d581a634392f8cf9a700f44297fbb7aa26380b61a", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "f626c2d8-6ada-49a4-9f80-de222d475cca": {"doc_hash": "daa1f2425ca187f3607b26b11e8c327d1c0a6855672cb2a6f2f4ddcc91b338b2", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "34dbfc48-3e12-45c0-9ec0-5cf582af42b1": {"doc_hash": "0ba81a2de213eb66bd620c2f87adcf5fde29ce498a9bea5298fe9c01bde96de8", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "5636d6f8-89b9-4f9a-8296-43703bd671eb": {"doc_hash": "f7abdeec370336a84d067a46da9d72ab1d1c991dbe56bd15431795fef8a990a8", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "de259583-47c7-470d-8798-6fb176cc7946": {"doc_hash": "701ad318631ccc298ff9e5a105aec7c9305eabb341f8c92d15b96d7263b29fff", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "8ba428b5-f5f5-4d0e-adb3-c2ed59ca5262": {"doc_hash": "66bd28096906e62b51a8957d413a44ee670a69952b68f307215cb5ca1221ee41", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "b0802277-8e58-4628-99d4-849feadc23c8": {"doc_hash": "14e7a24a7e86bdf26a1e9f975d5e6cc250b883d8943cee9746d80e7a5ecda2f0", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "6fac31b2-457d-4be7-a98b-a918378289b3": {"doc_hash": "4a4c30f79e06ff8acbbc19757bb0025567239d9a92b81c681944de7146db5716", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "99df4e16-1a76-475b-945d-ee4c44a48900": {"doc_hash": "87f3bf26f6ebcb46afcbbd62a51b730838ea33bde2296b67278cac6463a7f1fa", "ref_doc_id": "43ff6916-3e41-4916-8c1d-0cef95d80dc2"}, "9cac3f12-2169-49e1-9f11-c4f3469de7b5": {"doc_hash": "38ac09511a094d9d339f1b413dcdf2ee362915b839a10337e9f4b30420ec9fc3", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "8b398d05-1468-44dd-b7d1-9dce166835fa": {"doc_hash": "c4e8c75da9ef7d424b4993df63156ee5e189cc90944538dcde5bbadfff83e13d", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "4f9ebd28-6c08-4db7-9abb-ee00fad49d15": {"doc_hash": "24d5737fc7724931ac9fe8e4fc9f4b60a4acab4c12ca3f3cdf00015dfb04b543", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "e9c4c81e-13d8-44ba-81c9-e47e637fd61c": {"doc_hash": "73b41004a1e288b7abcbd9c2577b098003238568294da050ccfea694a5c89466", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "3a535900-ea2a-4f9b-ab56-28008f655a46": {"doc_hash": "2a2dcffa559ff71019c567674ca1bdf83a74d90f9f6b3169cd606e5f86267795", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "2dfd6b94-7133-44f1-acec-9bab3e3c8ee1": {"doc_hash": "e9df8e14435cc80f051b93a19e5909f8c4e16e27843ea22c7b91a023124f818a", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "98ed7889-84fa-4275-aa2d-d6ae3eaf9e4a": {"doc_hash": "5e6383a5a8ef8051f48408c314990c94c557b90f2d754c4a3d0cf7d5db4f5e3b", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "d6dad90c-7024-4b57-9102-adf8eda60271": {"doc_hash": "5aaeb63a11ef32988415acc828e16f2cf5f29d3d3aaf37316e8aab3cf4971ffb", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "8a2ef243-27c3-4f30-92ee-32642bc122bf": {"doc_hash": "bbd1c8b708b465c59ff4165a965a6b2064667ff56ee4525dab159c9b6c6bf3c5", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "8bdecd8f-3bd6-4de2-bdb2-a898d558c2f7": {"doc_hash": "279945d1ed340b4e3d612199692cd0a6c58cf202436f11f532c88f11a72fb5cf", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "870c82c5-e47e-47e7-bfcf-227517d1c5b3": {"doc_hash": "b7dd7966829bf12a988cba20fa54a673e3fecd5f531c90d8b9506a5dac25fd00", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "ab7818fd-d02f-46e4-965d-64c9e2a58fd2": {"doc_hash": "8cdc9aef98e292e33c1f50864b34929291c57804a62e56debbecc17115864101", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "db9eef21-8226-44f8-af34-78f5aac9e3a3": {"doc_hash": "f761db078ff56858ec05943cc4cd017d08a37c061aedd78aee40eb951e80b069", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "ba0c139b-fb7d-426a-a92e-8b5f6fe6940f": {"doc_hash": "696001ac57937f9bcd844d848224db132758074ffcc703a4fadb0855f210a4dd", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "763b78f1-478d-4b40-b3f4-942191b26f3b": {"doc_hash": "c0be71ed46e6a727fa53fd79e767e26275b9f791657017de467c7ceb5666af0f", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "d1290457-5743-4cae-a317-a0a98dd50fb5": {"doc_hash": "eed4ebb767e7b44b7448df5d4c56a166d80c0fab38f8899354513f416603f0af", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "f5599d1a-f3a8-4bc9-853e-d984a0256967": {"doc_hash": "b1a4322295193887dcfe49a9cf487aaf031d1743abc01bc032d05e1e7440b7cd", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "a5a21cb1-df10-4f16-9cfa-86d862c74ba3": {"doc_hash": "a341972159e91a4533054777c13795df21a416c65cf21fbd8e5542f09184a4d1", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "f26689a4-3d85-48fa-8527-86dc6cb0900b": {"doc_hash": "fe5e3bbe7f25fdc55f2b6a47720653cb768c0ccbc66e4a8e811d3c621d0bb769", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "d1ffa613-b8c9-4237-b7d4-0593162e4139": {"doc_hash": "273f060c1b3e33381da56ee8fe11e8291d5d927c72ce2852d9f792c09ab43d41", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "36974146-18f2-482f-b545-b4511b67fe79": {"doc_hash": "4715363ee36d804863dd80ae597e87f60b9eed371c18170df141c3917eade54c", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "d2f55778-1555-4b01-a3ae-ccc2a5fa73e0": {"doc_hash": "95f1fe712dc73851dde9d26d32c4e4a5e44890f476f4946342173fd88a58b848", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "3664dbf6-98fd-48f9-b30a-39f618be35f0": {"doc_hash": "2431e94d71cc43c767f6a4bda041bd06c193a3460bfd99754d44b9035a12667c", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "05d24ea2-cbec-4a45-95cc-7800b7285c7b": {"doc_hash": "645619888b7846371824ca041b26efe4d4022ab6f420d32d77e6e75f2f30bb2f", "ref_doc_id": "0cd995c7-4c02-4521-8b96-219d3ddb6ea7"}, "42c78839-07a1-4a18-ba29-c5351faf793c": {"doc_hash": "296773d37bda0f1bb6aa9e7d1ad3ceadb7ee18d9ffe6eb457b325b5a242bb6e8", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "861191f4-8e2b-4be0-aad7-dc0c9041201e": {"doc_hash": "cf3eeee22295caf590279443032644562fafcc6a2f9a35df9d6a4477aba8d57d", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "a786d4e3-2c8c-486b-97a8-714a9f783f98": {"doc_hash": "df0b332d9ff1c050bf2a1b1a251a5d6324d74085639416aa85cc68e815f19f77", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "4baa3b76-3509-4e1a-951b-0cf7d64b5ef2": {"doc_hash": "ea99bc3f197984fb7c3e4329fa13fe520ecc64c04952813651b86cc7bf24da65", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "2cf9a015-110c-419c-a7fa-6787551430ff": {"doc_hash": "22d944a651979fb8055f3bf101f0db5e2d091b6ddd750889a8a12920ee36a0e0", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "d0c9f898-b4c6-4b06-998f-3bf91be0a098": {"doc_hash": "010a6681f619cba98e11125a7c73c5fa17757a831ecf3378e91f9d16cca0071f", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "5273373a-add9-4c38-812f-843d6da3eecf": {"doc_hash": "010b4512877d7ad34d53def24fb48bcc496532c0e4904b5c7c195b70f05404d6", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "983f1bc7-107f-4b9d-ba86-17a79dfc8195": {"doc_hash": "1d952235106c30842375c8eca2536720c95ac72f42455134aa103cde137c7530", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "cfa7d28a-5162-4b04-9e31-77085cd22c9c": {"doc_hash": "5382b88e1d1ee0c0fcbe19f8fadaf8c321fb561a10019a2a7c7c43bd43b4a3e0", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "15fc4415-2561-468c-972b-db601454e046": {"doc_hash": "afd1c395b34b7267cd4d68ad4e533855cc2dff0eb70dc83eae0cfa3d82eb1736", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "a8c49f3b-fcc0-4e81-82a9-8c1688c79b82": {"doc_hash": "dfe4698f64359cb248b08e0f838a26a2bf5235b6bab4c8bd553a912d454d1ce6", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "1ee92c0a-ced4-481a-948d-f81f4596bf12": {"doc_hash": "da24555cd06a37c59e2fc4fbdc56f9297b344bea01f66d3ddf4b9280d3a83381", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "870bfd00-a7fa-438f-b90f-2dfd19a8db9c": {"doc_hash": "68dbb5da58f88b5d5258dae03adb51b4e803f5bb12e2df6b183ef7593dbcb18e", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "70b8e530-6251-4226-a548-296abdbf6c7d": {"doc_hash": "4ac7cc47ebe03b1e23b89da22d386d6e83d41c2c747bfd4711f7a580049b2da0", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "573759bf-1adf-4214-a4c2-e0d515864f13": {"doc_hash": "061a4cfb855ac6d09efd51ce477872e004cc6387dc9960ec1962c29522849557", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "b989948f-bf78-41f9-b215-6d87ccb0cb9c": {"doc_hash": "8913c1cc77ac52ba46ebb3724de648f920d4e6a2910b553b603405113662c567", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "92fa3eca-130c-4f49-8478-c33c91330f99": {"doc_hash": "230e386c0731de33db70062becdd68004e98f68de066b85ec07cc68c63757eb7", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "b2874f08-6c3b-4cfd-830a-10cb75d17c55": {"doc_hash": "f717fa7936377d3a33135023b50df85b52ad807e758611c6f2569d1492e4aec1", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "75232879-0654-4bf4-a216-c04e248d7785": {"doc_hash": "7cbd4cb1412bf5be016ff0f8012e94486d3e625ba0ad3af91f07d7ce86de88ab", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "538c378f-5e0a-4e9d-a63e-5e15b017f5bf": {"doc_hash": "f41078e9d0d971497825b5c9e881b67a839324a91601ddc2a71c3a730d7e52a7", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "dd3722bf-08e4-459b-a40b-73baa74e9051": {"doc_hash": "d7134b0a5177866d82d27894d07e60a6f07ba38db72a76f2e2df8e16bbd4ec14", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "dd9c7210-a30d-4923-bbe9-c84c3a848e59": {"doc_hash": "a8710be50f2dc00d879c4840103c29e751cd73bbc1c03d535ff882322ee40491", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "5024e4c6-9387-458e-86c0-06677adb9353": {"doc_hash": "f2a7c1a81db46eb5e7f70cf9401370b01c409f2d46a0e3abf8d7239b9261adf8", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "191dca9b-02d4-413b-aa5f-c29142c88116": {"doc_hash": "a79eee64122cebcb3a2f9158f9a64226ece07751e996367cdcd89a2319ed37b4", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "5d3622f7-f749-4c1d-b616-f1aa865382db": {"doc_hash": "81f702a97c4baad6764382fcdc8ebffe10c308c3d18b262e91835ca4f4c35e64", "ref_doc_id": "1566f4d6-9561-4343-b260-d4f89df55e7c"}, "ee2298b0-2aaa-4521-bef6-48c570eed225": {"doc_hash": "f734d53172ab9037cf1c5f82a580c227d6f92b6e4fc9abafda15db7a5c9777b5", "ref_doc_id": "61039336-e01b-441b-852e-b8eb51b938aa"}, "cf08eda2-7279-463b-8849-1b71cff9e8ba": {"doc_hash": "353336c0da7bd2306cd9796e6cec1c66f3dee3b6871f399fe826f44e2bdfbb67", "ref_doc_id": "61039336-e01b-441b-852e-b8eb51b938aa"}, "05be8aae-ad7b-444c-adea-24dcd4b34841": {"doc_hash": "d95c1c0ef7ef9cf1a0f3d2da07a94d3f9d0024766ba1aa3106b49fa3f79c257c", "ref_doc_id": "61039336-e01b-441b-852e-b8eb51b938aa"}, "bdb0924a-8bdc-4ffb-a15f-39f3c689c3ca": {"doc_hash": "36b69ab1818bb8a95a0346bb8d0b8cee7ea3100ee2c0ab45c89d618225cba80f", "ref_doc_id": "61039336-e01b-441b-852e-b8eb51b938aa"}, "08e13b09-58ab-48c9-bf05-56b8e2a594d4": {"doc_hash": "45563c4187299c5e9557cd5a076c866e50b4047d7d3b29cd582bd9a1ff0473f4", "ref_doc_id": "61039336-e01b-441b-852e-b8eb51b938aa"}, "15976b30-2677-4a89-8dfa-3079d63a755e": {"doc_hash": "606e8b88351180dc5483d8e8811abba8328e35437e46d35f834adbc79f412158", "ref_doc_id": "61039336-e01b-441b-852e-b8eb51b938aa"}, "7d37018e-8d50-4bea-98e1-e18f94b010ef": {"doc_hash": "8182d9b2f44444f76a0859ca9f397f759f7e9daa3c5cdff817af185805b8e872", "ref_doc_id": "61039336-e01b-441b-852e-b8eb51b938aa"}, "386f6d8c-7761-4976-b69e-e130fffe3fbd": {"doc_hash": "2f01e896bdfd06ce341b5ce3b8d35f80d85eb25fa5e35a7ea92a584b2494246e", "ref_doc_id": "61039336-e01b-441b-852e-b8eb51b938aa"}, "6e7cf294-7f70-4679-96c9-ac420d7ead8c": {"doc_hash": "351dfe5e124f5e8dcd041507ba4fa71b963605557702b60970a924c5ab979b56", "ref_doc_id": "61039336-e01b-441b-852e-b8eb51b938aa"}, "c1958f19-4af6-4e0a-8269-1565cf73fb81": {"doc_hash": "4c24d09f6b9933a93700c035fa0e34366dfaf2b1ef8abf02f91ee6d4a9dbfef0", "ref_doc_id": "61039336-e01b-441b-852e-b8eb51b938aa"}, "31ee3eac-5d0a-4a82-a301-19fd12ac43c5": {"doc_hash": "c0b6ac8cdcd8687a27cb116d80d03e8ea76e2ef8bd79650c06002869a17804a8", "ref_doc_id": "61039336-e01b-441b-852e-b8eb51b938aa"}, "2ace612a-cae5-4d4d-a191-497cc4c1b34d": {"doc_hash": "d96233c0ece357e974087019d98a920910fdf15bf3d1f4976f27b9aedc1dd3f1", "ref_doc_id": "e563a3a8-f110-411d-abfe-c4214270a573"}, "941c0354-68d8-4850-a789-2342a161a352": {"doc_hash": "91d9350c2c7c79cd547dd0d40fefab39059dbf3c8c3a29cf420614fad29ff619", "ref_doc_id": "e563a3a8-f110-411d-abfe-c4214270a573"}, "1180eec6-7def-435c-8423-da2417e42805": {"doc_hash": "572f93f341ea814763ae6d38c4a8fecbd18b0122b4d1c30ecd9141f9291bf0cc", "ref_doc_id": "e563a3a8-f110-411d-abfe-c4214270a573"}, "bfeff777-71b1-44b9-aa1d-4566903b97ff": {"doc_hash": "562f115419b002112dc1ae4fb87802be8d295f58bae9343ae780ec6cf503cdea", "ref_doc_id": "e563a3a8-f110-411d-abfe-c4214270a573"}, "0cfcc48d-ab68-4c93-8c96-f02d3a3357b6": {"doc_hash": "f8ccae415b9dcd6555cadb517035b764b46760c198d157ad505a2b9114917a0d", "ref_doc_id": "e563a3a8-f110-411d-abfe-c4214270a573"}, "d0f60f4f-c0ae-4437-b177-42312f8c8101": {"doc_hash": "0143b154595c73f8fe20cd816d08ad1738b0d39ebf2a2ab586799006b3795eb1", "ref_doc_id": "e563a3a8-f110-411d-abfe-c4214270a573"}, "4245eda2-2418-466a-8f1f-e93fe705b3f1": {"doc_hash": "f7c197bc81325321b1ebf8c5ef7f56d6abb1184f4d84f0f123705da219eff05b", "ref_doc_id": "403889d1-3893-486c-84c5-06b58967796a"}, "2c4e1cea-9ad6-420d-805c-344e344929fc": {"doc_hash": "0df05c3245d70941caedd14144c5acc545ae361dc81b1466ee1e162cc9b0121d", "ref_doc_id": "12210a45-b151-4a5a-87fd-8b2953a99b23"}, "9f27e92a-b775-413b-b3af-632e69622206": {"doc_hash": "dee18fff0026d68c7c63691b9c317964c24276cccc1f297734331c4e796b7823", "ref_doc_id": "12210a45-b151-4a5a-87fd-8b2953a99b23"}, "b56e9a60-0ef3-4751-9a6a-0fa025608dce": {"doc_hash": "a90963986a0f2219fa2eca22d3fda5d5301416b3bc529e0b382675e01c03a687", "ref_doc_id": "12210a45-b151-4a5a-87fd-8b2953a99b23"}, "c68613e9-66fa-4305-bcc5-c0bcd84efe1a": {"doc_hash": "f3aca577b3506894c7b38670d6c717795d71440cfee8fc9d231b88adacf07a1b", "ref_doc_id": "12210a45-b151-4a5a-87fd-8b2953a99b23"}, "ca003966-1fb8-46ed-bb43-7372bdd42fcb": {"doc_hash": "2d7e555e14e247e72386297466c2e749a0e48556d08ebb6cfe9b927b50fc5132", "ref_doc_id": "12210a45-b151-4a5a-87fd-8b2953a99b23"}, "9472cfe2-f123-45a1-a749-8685fece04d3": {"doc_hash": "3e3a1e223649dc120e2ed5602e8c8ef902c30d47306663120a463acf5a648708", "ref_doc_id": "12210a45-b151-4a5a-87fd-8b2953a99b23"}, "276088be-7225-40e8-bfbb-366a0951ce3a": {"doc_hash": "c844b29344e9840b550ada177d7a59b86bfe8a9c6010b2b7379defef234545b7", "ref_doc_id": "12210a45-b151-4a5a-87fd-8b2953a99b23"}, "008e31ea-1071-43bd-8bee-78533f283e17": {"doc_hash": "01f0579ae9d3a235b5a30f331b91dd978d3404fe6fb1c5d5b455d50c099b778f", "ref_doc_id": "87f9a5b7-61fa-4b1c-8884-fa660fbf7a35"}, "863ef71d-6a51-4e7f-8dfc-36b9c473c51c": {"doc_hash": "7bea35aba84fa4d93ecbd6e13cdb289f07fe35531503208ef8363c8ff709188f", "ref_doc_id": "c920c468-d834-4ab3-b790-75fe74ceb760"}, "f447299d-e824-4301-9f12-fa8d809f3626": {"doc_hash": "e3f6b98744d1799a3c857138e71dc4fecd337c80979cb068322e30d039cc8d21", "ref_doc_id": "c920c468-d834-4ab3-b790-75fe74ceb760"}, "36900705-60cd-43b5-9329-602427ba09e4": {"doc_hash": "e09a8e4e7d03f68dfb0c4f99d02be8e4b885ed8e3c0f74bf0a71adf3884d39ad", "ref_doc_id": "c920c468-d834-4ab3-b790-75fe74ceb760"}, "667ff934-d571-4291-a0b7-22fbe279a436": {"doc_hash": "67599310e09800c92471cba9d7004793da263c338a1c2cfbc3ef6b9fc71c3688", "ref_doc_id": "c920c468-d834-4ab3-b790-75fe74ceb760"}, "7f739847-cdcd-4c17-817a-f70841f5c4f2": {"doc_hash": "0f3597518974acfa2455e98631a1def6706c485de3e71097fed6a0d1f3c5aa7a", "ref_doc_id": "c920c468-d834-4ab3-b790-75fe74ceb760"}, "a1f977a1-97c8-4c68-89a9-3e07f8e626a0": {"doc_hash": "151607d4124e5db3fbbc085c3e520c11f1b3d46c3fcbb73ace31d2f549621400", "ref_doc_id": "c920c468-d834-4ab3-b790-75fe74ceb760"}, "4908475e-a3a3-4d27-a534-ee43500bd6a8": {"doc_hash": "92466814bbc720be6b2c40cb92b203fd2d532d9d7c49338fe68e2f1622b9bf30", "ref_doc_id": "c920c468-d834-4ab3-b790-75fe74ceb760"}, "9f5b0d1e-9971-477b-bccb-112f3d2f69ad": {"doc_hash": "64c0c5937e69c9f933330df97dcfc7f308ac3bc4eced8682aac4bd1eb6a6e1a8", "ref_doc_id": "ec519faf-8c72-4d79-b13f-c0eaa494d3f3"}, "41d1c070-d7d9-439e-b173-420bb0e0009e": {"doc_hash": "ebc910db094bfbd7d27e8754c7eefbffab407723e3afd3c3e04366d853876a3e", "ref_doc_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7"}, "dbb1eb20-1656-4a47-b1fc-0becd813ecfe": {"doc_hash": "74e5de775aab879a2d22735e2772c353b5b722f978171e85c0cde036ca956b40", "ref_doc_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7"}, "f2866fe5-35b3-42f7-935c-86a634492dc8": {"doc_hash": "044bd7d171de30ab210649c3958de3f662bd11e79f1391c462837a5cc056c6b0", "ref_doc_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7"}, "f3ab3498-b782-4985-8075-bc5a4a4b383f": {"doc_hash": "801620ec567bcbacb98bc45ba04709470d808f5d73628cef29ef066e24cdc9a9", "ref_doc_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7"}, "19e618b5-bca3-47ba-aa2d-fb63f1249bca": {"doc_hash": "4be90b01bfd88a33e20883cddf103ba310b59c9f73c26299d06660e98b949c2a", "ref_doc_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7"}, "83b6918a-594a-415c-b0b7-1a913603c26d": {"doc_hash": "cf1b220586cd5061275775a6b39ba0278e9ce65cae2ae8ea1af016301ac0c927", "ref_doc_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7"}, "f62e4aa3-5764-4ed0-ac38-61a4bb16f6e7": {"doc_hash": "200b800d7443eaa190c53f5c5b996012b7afdee661452515a262782e29526ae1", "ref_doc_id": "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7"}, "7df7fe71-963a-4170-866f-d8c7d424700c": {"doc_hash": "a0629a2f69c24a1f40cf62436c00571052c44e3d7eb445dc7eafb953fba0878f", "ref_doc_id": "0dc22fe7-c04e-4cdd-bbee-1e2ccf44bc91"}, "61b0e9d4-1e2d-4adf-a26c-1a01406bfe38": {"doc_hash": "6806a5fbe81e10687bb0afffd70cbed196784d34a7faaaced783bab126b32f04", "ref_doc_id": "80410240-586e-4299-b19b-f4fe6745802a"}, "c5eb7efc-c326-484b-8717-e1c0fc054b16": {"doc_hash": "23c7bdf8fded697fa06a4cafe8b669b3b84409989932f6e38091e488944cba5c", "ref_doc_id": "80410240-586e-4299-b19b-f4fe6745802a"}, "cb756de1-b21b-4b97-a7dd-f51220b982a4": {"doc_hash": "71c3a31e3ebfd2e18a21a4593b1e151b9fa50b927d2dbb1d082627f6901c2b61", "ref_doc_id": "80410240-586e-4299-b19b-f4fe6745802a"}, "13eee86b-affe-4c50-b47a-ff89d12e9038": {"doc_hash": "304fba902fb2f4f7839f12d7963b752b4eb5570a412a46a8800966da08166710", "ref_doc_id": "80410240-586e-4299-b19b-f4fe6745802a"}, "2f1da757-962c-42e8-ae64-6391b5a2b8ad": {"doc_hash": "9997c6a0eb432183bb77b9bbe5ae168a8401ec47ee4a815b042074938f7749d3", "ref_doc_id": "155679d0-1d96-433e-b071-6e1b37c5a889"}, "be295d28-8448-4238-a077-722f46e925a3": {"doc_hash": "bb9bfe17841b9437854526e922e5f3012fceed8f0ba20ab0422acf11d2589063", "ref_doc_id": "155679d0-1d96-433e-b071-6e1b37c5a889"}, "e7f3381b-f42b-4799-ae6c-9a02fdb84a7f": {"doc_hash": "6f6014a417db3281a0e39e7580c9f58169f8ea730ea7a01214f0430474168660", "ref_doc_id": "63207d80-146d-4b31-9d2d-6493950bdc19"}, "9884b84a-2dd4-4910-8bb5-f8562286679c": {"doc_hash": "b490df4d32e1ebb7861198716390db79c1676f823aee5d4c0aeda2047732a957", "ref_doc_id": "63207d80-146d-4b31-9d2d-6493950bdc19"}, "04cb0bd1-badc-4668-9e9b-b357539b102c": {"doc_hash": "9885fddffdf38da9461de7817446ca3d088a63444dac08288487a650b2f4ad21", "ref_doc_id": "63207d80-146d-4b31-9d2d-6493950bdc19"}, "7b585166-d964-460e-a969-0c00ce2c0eae": {"doc_hash": "1f8efed16498bbeaf379df88a31ce718d666f5cd81a321e7b431609ecae346a5", "ref_doc_id": "63207d80-146d-4b31-9d2d-6493950bdc19"}, "98b37981-f4d9-41d8-8417-58c0780e19cc": {"doc_hash": "49fe12dbb1e6eca9966614b155e8f05eeb3a6603c178a222491ff34c8cdbaaca", "ref_doc_id": "63207d80-146d-4b31-9d2d-6493950bdc19"}, "90c55f0e-58c1-423d-8a38-ad094edae6f1": {"doc_hash": "85b0d55c612475fa3e943c7b0375f3cea4fbce4d912254c07e9f00caa6725009", "ref_doc_id": "63207d80-146d-4b31-9d2d-6493950bdc19"}, "6d34738d-0a16-435b-98e4-7c88a4cf79fe": {"doc_hash": "6d07fcf63a25ae680372ed2d3b9cef6e6717c86a932e4c1a83d663dff0e1bcc9", "ref_doc_id": "a5f3bf78-ae07-48d9-8e79-6d5cb2146ad0"}, "14a0d4f0-9820-4a46-9b78-a52317210776": {"doc_hash": "af809cf1c10eecb76bfbbab55792a6db703ef8318b0a659308d3315fcd75494b", "ref_doc_id": "17c0f4bc-1904-4832-874f-f5afe7384803"}, "11eeb226-e95e-4bce-82a1-017f3e5a7b68": {"doc_hash": "958d70d26e87b2e61c28955edaccba0c9e01f8f5752d1b68bbc7a3edf0b2bc22", "ref_doc_id": "17c0f4bc-1904-4832-874f-f5afe7384803"}, "617a56b6-0403-4f01-a95b-fcd54c92872c": {"doc_hash": "e25e7f68a0dce3d7d3bd6372a9be5d86290287d096cfd3beeae4e2f34d5b8344", "ref_doc_id": "17c0f4bc-1904-4832-874f-f5afe7384803"}, "57e8bd2f-7514-4c89-b407-bf0eeffac7fe": {"doc_hash": "cc31c92661007ac410fbb7ad3c1a71b87cb2c4c37f895af687d0d58ba33221c8", "ref_doc_id": "17c0f4bc-1904-4832-874f-f5afe7384803"}, "2bb09df0-e152-4f59-8a54-374ed01c78cc": {"doc_hash": "1f7f26f0560c458a42fdc104f191d7b0f30ab96a224b964829e9d3033b67b246", "ref_doc_id": "17c0f4bc-1904-4832-874f-f5afe7384803"}, "4e8b87d8-9a4a-4a50-9669-9d38af526af2": {"doc_hash": "2b2357b143fab2f4dc0b3ba2ed627148ba5e02ee8168a0b1a29be84b95231265", "ref_doc_id": "17c0f4bc-1904-4832-874f-f5afe7384803"}, "71cee173-dc46-4d1b-bad9-ee405d93e205": {"doc_hash": "9e09029c494b20d5965ac2f1d2d665d60f9cb88922d20ddabf27bcafa5d8fc8e", "ref_doc_id": "ec0ed34a-d2bd-4a70-b995-4894391fab16"}, "9b3d13ec-30f9-4ee2-903b-527519bf006b": {"doc_hash": "fe1af6bca301779f0c56f99ea18d181a8bde1745d9dbe42b314fe1b671cfaabd", "ref_doc_id": "ec0ed34a-d2bd-4a70-b995-4894391fab16"}, "66eae9ec-7c9d-452d-a1e1-7fea129e59f8": {"doc_hash": "583a8781f741d4ad029e5f860b231282f86b67fae8c3f0e54f53d6ec64aa7e89", "ref_doc_id": "f8bf94e8-aea2-49f0-b52d-1a5443cd3e34"}, "9a31a7ca-8e7c-4bbc-aab4-2e3065e3441f": {"doc_hash": "e8b8adadab4a38b97c3935eb6b0ba675b98aad158decb1e0791f38d221600cda", "ref_doc_id": "f8bf94e8-aea2-49f0-b52d-1a5443cd3e34"}, "256878f0-fe0d-4628-ba9f-d3158285a91e": {"doc_hash": "57568ffac6d6f8cee4445786b35a9d5b6a6744200d90093f965251631b1c2f6f", "ref_doc_id": "f8bf94e8-aea2-49f0-b52d-1a5443cd3e34"}, "8bbbf0a4-5916-4b8e-937c-cdeefd29ee98": {"doc_hash": "68cb86f1b742b47651f16b8d434e117485550ec638b45d03dc6739d5650e62f8", "ref_doc_id": "f8bf94e8-aea2-49f0-b52d-1a5443cd3e34"}, "63e839c1-039b-4ffe-bcde-a9540e7e437d": {"doc_hash": "dcf7843e0d1e54e4e118eaa4d45cc2ab630a3861b8271680363580d56f980069", "ref_doc_id": "16315473-540d-424a-9e4f-772f79cceea8"}, "6da1a4c3-15d7-4444-aa0d-930b2b4a05fb": {"doc_hash": "ecaa8268770e259ed202fb041d0c518860f1ba1fe27076ade1150fd63b7f28ae", "ref_doc_id": "16315473-540d-424a-9e4f-772f79cceea8"}, "ff16f042-2195-47a8-ace6-2d704b64cefd": {"doc_hash": "b448a1c51b935d67dfecf4bef7e83717217979947e6100448114eb0a04e2c03c", "ref_doc_id": "f4fbb8b3-21bb-4377-9587-a63e396b892e"}, "bacaebc4-e64b-49b7-a5cf-e88274c91789": {"doc_hash": "8c0e53166d9858d37757c8d9a4f34c88ae3875f3af0a19cb8e1066a146359f9a", "ref_doc_id": "f4fbb8b3-21bb-4377-9587-a63e396b892e"}, "5ec6254b-9e65-46d7-ba61-834801256547": {"doc_hash": "786b6c7a719e8c2471602ec2a6c64a1b4cab36a3dfa9f1f87299721f0ed4870e", "ref_doc_id": "601ce026-0780-4d2a-9af2-83d717f863fe"}, "16dba72d-ebeb-4a32-b225-ce5df907947e": {"doc_hash": "d6ad42c9e64b63d51979418a103f78afa492e2079106d117d1f2868e48e072bb", "ref_doc_id": "f7b12765-a55d-4b0d-b110-b14ea4f47293"}, "0d4f796f-d180-49dd-a35d-2d5d71effcef": {"doc_hash": "c8db2d8d76ab5eb4dc2a39946489f12896224c9e004f5c1343430f2672c1b65b", "ref_doc_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33"}, "980c971e-9534-4eaa-8f48-3f5cb0436ffe": {"doc_hash": "90db86d81683fd2dea754d206fdc5f0d10f3d0fd9d517693c2d7294038e582f9", "ref_doc_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33"}, "47bc1676-528e-4460-b7c4-32a1ab530aea": {"doc_hash": "e91c4bde7e457a22b1e785e94e1ccae3d17214eb63e4cb0169bee5b4778713ad", "ref_doc_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33"}, "f789eda8-411b-47be-8d4d-2e01b2009310": {"doc_hash": "98aa23aadaaef004e703dbfab192e3305b117c0bb59b2e97f7494bf5e32c0ad1", "ref_doc_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33"}, "38c85abb-f9c3-498a-b40b-d1ba0a2c82a8": {"doc_hash": "21b61617f0913421ce15e35a13c9b76029c2a6633db627fa69d42019072b17e0", "ref_doc_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33"}, "a9b76c13-05dd-42b4-ba8c-874ed8f3f86a": {"doc_hash": "10f285b69eff7d5eaf68e9552795fe5bc472ecb1116c892ec1a0efebfc6e7465", "ref_doc_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33"}, "05db4f1f-3088-4582-856a-2961cf429d29": {"doc_hash": "f214adeff4d92953afc7ce82ac562c822ad97d97982deb937acd151e5a3a7fa9", "ref_doc_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33"}, "169747b7-7eb0-4798-8e0a-ed67fbc7f9da": {"doc_hash": "4fee2177ad433dbc3f259716e1698aa5f034ad9166be5d15f82201f1f6955187", "ref_doc_id": "c7593f26-abfc-4168-b0e9-63460fc1ae33"}, "90cd4eb7-1512-44ad-afd2-4f8b37fb97b2": {"doc_hash": "3bb88a101a7c7062d1aee6a444a84be159b58638a8257c253e18c91d5957d07e", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "ae44f02d-2263-4629-b613-7df0810fd7d4": {"doc_hash": "8dab3a665a9b8ecccfef816017eb6547cb731175b406dd6bbda0d720aaee9369", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "6cd68c38-8012-41ca-aa61-cdfbcb8bfd62": {"doc_hash": "b401584ca24c0c93989c1518387f65a037b592d5f5761dee1ecb69834ce39c78", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "e1e06e29-2b44-4367-ad0d-07dcc290c641": {"doc_hash": "1be7984a3cd7c1c9280781e59f897c96def16266ec8a5f12df1c920d71f73d1f", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "137d1968-0b8d-4da1-b0c2-17bca472c931": {"doc_hash": "91c0bd6c09ff0991444680a131480dc260ae3c4f09b452cc5a94670cc000643a", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "9d583ed4-ae53-4ea0-a1fb-269ba85efed8": {"doc_hash": "8ae483fcd7c7ea40458f79461e4b7196a80cc269fa7f40716aeac445662adc12", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "58572829-e6fa-478f-a5cd-e4d8762b0ebf": {"doc_hash": "94aa958d8fdadf0dbf4eec0bf15a975735c57f8241d86bd05f96cd2da63a3e80", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "0bae5bd7-c100-4a79-b839-ae57846dfa4d": {"doc_hash": "cad5169b107d2403328c6face4fc51c1d618ac9108e677d0570fe41653e06418", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "478ab060-7f45-43ba-94e7-50d777bc0a15": {"doc_hash": "947d372e05bfd53702abb43189567e76cdf7f5a4cfab2c202efbea5f61cc1cc2", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "ae5674db-23c9-43cb-9185-bfef75f392af": {"doc_hash": "08ca3b03456d0890e9a5beac745946c6021d5521d0dd67398c5c2c81187d09e0", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "38b611d9-3f08-42c0-a0d7-707b2ffc3bd0": {"doc_hash": "1889a5c67668056631fe43c6f723ca5b1a9f940a5dfe0441015bab5a4c9f1184", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "76186493-f2be-443e-8567-7f3dc8c64c71": {"doc_hash": "70908e72891e7897a3e381be38583e94a666430e471ea6a5724b44d1488ec56d", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "2565b72e-3b81-40f2-a3b2-efdcad440555": {"doc_hash": "25ab0ea7004116692ae2c1e09be9af6b3d97c359dd1a24ea00f5935d98032317", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "0f4f8272-7aa4-4f45-a399-2d113d4fa4f1": {"doc_hash": "6faf4cee00b4d2933981f8dcf607caac3933c5de70e40880521360de92b2b2f4", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "ab172ee0-362e-4c75-b8ab-518cbec2ff6a": {"doc_hash": "08cd42f928bf2bba37640b3eea5c7a0dfbba8f60455309410b2c27f90197a6ef", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "23d32f99-b8df-4983-a098-ff5948cdae41": {"doc_hash": "d41dc09a0035ea09f763fe6d368eee24c314cc37f0e00176f348754473d3f0bb", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "5b2083ab-9a9b-49df-b5cf-fa428fcbe9dd": {"doc_hash": "b41a040bd6e4ecfbedd1334a61ca78fa1d5c659da4b56a3cbd67f3b938064708", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "5dc2d178-b2c0-4e70-afe5-3da521db5fdd": {"doc_hash": "d44743f28722ca097f44d6f942d23bd30e36a151f05a1f8b7ed85674bd9b54b8", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "a1fd3c22-cf45-4a7c-9e93-c9950927017f": {"doc_hash": "714b0834e0e201a2ed1a29e4ff6d6dbd461a42252eb987bead640c1bc652df19", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "271bf4e5-91e5-4f98-978d-26513b5a6b9f": {"doc_hash": "daf86075ce97864301d5e3cbee58acdb5bc37b09c6b0b64ee9ffdd0c6ae821f4", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "82eebee9-9900-487e-b06c-f78e151420a1": {"doc_hash": "0d8b06fff4a49298d19f5aed57f625607e92041bfdc2864eccc597ac875b069e", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "37a8a253-7ed1-4263-803f-35326a7660dd": {"doc_hash": "44939deb323ca88198712ad811f8526610243c02c1a68b8137341acb996e1a2b", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "6b874523-2c69-47ad-9411-23739d14e1a9": {"doc_hash": "8ec85a05791a92163ab9144df2c85bb96325c113814539b70774f28b8936e765", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "d16c2902-2482-408b-abf1-06a856e3c6f0": {"doc_hash": "fd97db58b4db6dc723274b1f5c1a9f27c708017b46c6b7e4d2efd604de0ba7e2", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "8dc2344c-df30-4297-9f0d-c492b1e91ef2": {"doc_hash": "f08ee3a10b6173ecceb2768756ebcbde92228133bd8e507fce7ac4f8827ea408", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "65fa66b3-4019-4ab1-8197-736592921cde": {"doc_hash": "2a309caa35a7bda6b4bec7bcbede5cdab46747f7e8ff41666ff0ff993c0daa76", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "f21128f0-6ce9-4bcc-85a9-8b661c3119ee": {"doc_hash": "b340e7af4bb72bfde365473e7d06fda57eaf9adc2d40ff7f050fee2cf30243d6", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "a64be202-c9f7-4c82-a9af-16e96c5afd2e": {"doc_hash": "25c63cea12e214d8aa74ddbc975b46c818657d9ebf4b60a37cc34383f90023f2", "ref_doc_id": "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2"}, "ec6f9965-37f2-43c8-92b0-5a7ca9aee972": {"doc_hash": "12e35bf39e0a6171e8fcac6cdcff0d319d42fbb6f03c1a5800b530a944d460b0", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "edaafec9-edeb-4c5c-9bf1-aa46d5089923": {"doc_hash": "1345f12979dd70b6a23448ffbc3a2cff76c3ef0e38d4e508e784a8e07494b6be", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "6f859c03-0652-4e65-ac7a-d2cda4d232b1": {"doc_hash": "c7834b6a68868fd1cbb4d5a8da2a80ae8d8937ed2a20d86c8495066997299d09", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "b4c64bc7-eebc-474f-bd73-c4c4c34abad9": {"doc_hash": "e6c672759d13c9053cf39f9b27df262cce6423684ad281860504dad857f5f4ea", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "82d91389-6a90-494d-9a64-bd405d340334": {"doc_hash": "f3d5324ee211a94066023047f3c2bda534d95504946e0b270b4e763df6e4ee63", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "2f7fd039-4c60-47df-bf2a-bb4611760c7f": {"doc_hash": "56259e5a31535d7eefff19bf2a9dc65333cdfb4ead210d3ce94d1da9dd2649e1", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "de6298f0-3630-4b11-9950-171de2048d05": {"doc_hash": "bc69ccc128e46cc13c4a56d3a1aeb127d7c2be2a9c85b035c4adf242b9fcdb60", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "01d270eb-858a-4dd8-b8de-01f61c5f45fa": {"doc_hash": "de99b62d7ce85018d137e1007a38a24a1c61e6730a39dafcb12b5cae4a2289d8", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "cc3c3e16-e6e2-4d25-bbed-9cf5de03876c": {"doc_hash": "9559419381d8d21c7831c80fe609c1c7dc1cc899aaf6292752ff11a98e60152f", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "0476d296-8060-4c87-8fb7-1abab245d6c3": {"doc_hash": "a04b22397a0e56f8916819397ba810d179a9382860b6bde1262b8837ee9a30a9", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "6e7c8f64-a310-41c4-b78c-96ea40b9357e": {"doc_hash": "a0c3c96e38a4758a58d637303b5b952a238eb1af9c9238c5077ec3e703535787", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "b9f53df2-15c1-41e5-b32a-ca155af02cc9": {"doc_hash": "ad0ffab5c3c2587dc813d963d3ade35940221c4a8ae64a86ecb2dd68e22f6251", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "2f0a0841-2ff5-4bbd-8b2a-6e078ef07eca": {"doc_hash": "709fbabec49b901ba4ff21ea4ed1814882a1a9b4f2f876908719c96a2603d488", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "f3bc5703-937d-4989-bc68-e7274b9e6c0e": {"doc_hash": "dde98a7cb6058058acd4935870f0d0d941ff8e19faf96ec5c4d96a02219aa1fe", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "77889e4a-43e9-4226-8040-d5700de3b59d": {"doc_hash": "e4a510d8703c59eb162d1a4bcfab5334fb57b2241a916654becf758bc10ccb29", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "a5890a73-0453-44c5-aa10-e23857df66f7": {"doc_hash": "a999060b697704a21b81cf957e680a58e53fce52f790ffe8c377ddc6c5f586fb", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "2c6d49f3-ecd3-4260-89c0-653b6487640b": {"doc_hash": "9ec8d287949705fbb3709d386580ba38c238e5a1927b2c3c12ca8f5bc8ea5b64", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "3c0abc69-7c74-487b-aee2-a2b7be8ff361": {"doc_hash": "3c5fbec4e443eeef63b2bce8478684cb79cd47584feb3e849713bdffe70e03c8", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "66fe8f96-dbd5-4079-a53f-28c7b111ca8e": {"doc_hash": "1d80ccfedcd874c538bb398e0c02be0123718d652cefcced7963352bc1b38ec2", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "b242c87a-eaea-402c-bbd5-72f025ebc3b0": {"doc_hash": "dcc861a47d48078af6759a2769ebe70348e9ff028616f0b46399f2df4affbd90", "ref_doc_id": "e6211d0d-2c42-4257-9a1f-4e9a76d59a96"}, "d815a528-c936-4e6d-a70a-dea8db84b43b": {"doc_hash": "4c4f444903fb85b448600da006aba31d8b0001d7bdf1a82f32010f5594ecfdec", "ref_doc_id": "12fc9d9e-7168-4713-a333-b8202f0baa25"}}, "docstore/ref_doc_info": {"3e7be363-cb7b-43d8-87df-35ba4c6cb72d": {"node_ids": ["218954c7-0dce-4db5-ac27-8da9fc654579", "fb1862ed-92be-4312-9d52-e2efb929686b", "f1f21def-9e9b-4048-bd59-e229d377ca87", "16875da3-25cc-4c16-9e42-1f6ff92231ef", "41e9a57b-7e46-420e-b7e2-b2b2e4cd74d0", "19dc3735-8f0f-4908-91f7-1a97fe698bc3", "0f7bfc3f-0f94-4f0c-a83a-931da51b446b", "68922f8d-4872-4888-9e66-5de436a51877", "757350f1-73cc-407f-a8eb-daf9d50b1cd5", "c4f1a19d-574a-4d27-ae12-f00d6485f925", "38dd3c78-e443-44b3-b969-04fbb5635547"], "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to\n$1.92 in the prior year third quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 11.5 percent to $2.92 in the fiscal third quarter from $2.62 in the prior year third quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2023 Thir d Quar ter Results\n8/2/2023\nRevenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92\nAdjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023\nCompany will begin operating as Cencora and trading under the ticker symbol \u201cCOR,\u201d effective August 30, 2023\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nthird quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cdfda1e0-68c5-4379-b156-215264f23181": {"node_ids": ["fe017de2-ae3c-4eda-8d92-304ff7759914", "ebaf6125-b89c-4e9e-98f9-f57f3643e50f", "32969913-ef71-4bea-8597-eae5cf4a9a27", "bd0cc6b1-d421-4360-b7eb-cbc27a6b1370", "50e0e097-f287-4db3-b94d-92e557f24cda", "9e776022-e7fd-4452-bd93-504aa81728ed", "d787bb72-7bcf-49e4-b37c-55b0bf911fa6", "28017df6-416b-4a40-a916-a46f8ecc42c6", "00ac0c9f-6f20-404f-b965-dd5925ed64b1", "7efede3d-b73c-45a3-8161-8970608fbbec", "e791b09f-a485-43a3-a4a4-52fe9e562aeb", "5f08d6ea-d97f-432c-8b78-f9660ebc7d43", "65d22dec-46ba-4536-940a-3ecea7dc47a6", "b05b5a4d-c0be-4c49-b5e3-b36a0fc247f7", "33e76841-d178-4f06-8ab1-27ebb97c8fee", "c0076b34-8b7b-4fd8-9f06-8ddfd242dfc6", "48a45fa0-c01d-4e6b-a48f-84585365e67f", "51a22219-3d7b-4e2c-ae5a-02e90f0dff48", "6c288fa8-5116-4f96-adeb-3498b1fb2540", "9dba5edf-ca57-48fa-ae63-2bee61b9742a", "2d8d196e-91ac-4f54-8b13-d307e10f57a5"], "metadata": {"window": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2023, revenue was $66.9 billion, up 11.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 12.2 percent increase in revenue within U.S. ", "original_text": "Interest Expense, Net $58M $58M\nEffectiv e Tax Rat e 21.3% 21.5%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $596M\nDilut ed Earnings P er Shar e $2.35 $2.92\nDilut ed Shar es Outstanding 204.4M 204.4M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "43ff6916-3e41-4916-8c1d-0cef95d80dc2": {"node_ids": ["b839a19b-8689-40e4-aeb7-1efdb9eeb356", "fe234d44-e5ad-49ea-b13d-941ca4a26a07", "b802d3e3-1e20-48e1-902b-f5341afe1297", "39dc12cb-f59a-4446-8de8-01c972c5aa43", "7988bc19-9ebe-4cd9-a4c1-840f7e14d590", "cffa49e1-33cf-4269-8514-ca6f7bfec6b5", "b7304bee-cc7e-4eeb-b8a0-db7496516f65", "0230bf29-9f49-43db-88a6-e90c1b9d5849", "f19364b7-4c45-46cd-8167-9abc12972c35", "c9c7a853-eff7-4b78-a1c3-4d7346a052a4", "1f8ac82f-d4cd-460a-afa3-7671abe92102", "775e0f0c-1f59-4828-ac90-846e1e632721", "90ddc6f7-3628-4434-bdcb-dfd0343377a0", "f66875f6-0dde-4d8c-b346-58b2cbe3ca5e", "72f31ac3-5a70-49d8-9414-f7c53834d68b", "b531fbc8-1acd-45c2-96d9-00bfd156a431", "5e3b7e8b-1216-41aa-8b08-845a58d41f4e", "15a7ea17-7fbb-4388-a932-596bb02c7b6d", "f626c2d8-6ada-49a4-9f80-de222d475cca", "34dbfc48-3e12-45c0-9ec0-5cf582af42b1", "5636d6f8-89b9-4f9a-8296-43703bd671eb", "de259583-47c7-470d-8798-6fb176cc7946", "8ba428b5-f5f5-4d0e-adb3-c2ed59ca5262", "b0802277-8e58-4628-99d4-849feadc23c8", "6fac31b2-457d-4be7-a98b-a918378289b3", "99df4e16-1a76-475b-945d-ee4c44a48900"], "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.33 percent in the fiscal 2023 third quarter, a decrease of 11 basis\npoints from the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to lower\nsales of C OVID-19 treatments and increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower profit margins.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 7.6 percent\nincrease compared to the same period in the prior fiscal year, driven by an increase in distribution, selling, and administrative\nexpenses.\n", "original_text": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "page_label": "3", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0cd995c7-4c02-4521-8b96-219d3ddb6ea7": {"node_ids": ["9cac3f12-2169-49e1-9f11-c4f3469de7b5", "8b398d05-1468-44dd-b7d1-9dce166835fa", "4f9ebd28-6c08-4db7-9abb-ee00fad49d15", "e9c4c81e-13d8-44ba-81c9-e47e637fd61c", "3a535900-ea2a-4f9b-ab56-28008f655a46", "2dfd6b94-7133-44f1-acec-9bab3e3c8ee1", "98ed7889-84fa-4275-aa2d-d6ae3eaf9e4a", "d6dad90c-7024-4b57-9102-adf8eda60271", "8a2ef243-27c3-4f30-92ee-32642bc122bf", "8bdecd8f-3bd6-4de2-bdb2-a898d558c2f7", "870c82c5-e47e-47e7-bfcf-227517d1c5b3", "ab7818fd-d02f-46e4-965d-64c9e2a58fd2", "db9eef21-8226-44f8-af34-78f5aac9e3a3", "ba0c139b-fb7d-426a-a92e-8b5f6fe6940f", "763b78f1-478d-4b40-b3f4-942191b26f3b", "d1290457-5743-4cae-a317-a0a98dd50fb5", "f5599d1a-f3a8-4bc9-853e-d984a0256967", "a5a21cb1-df10-4f16-9cfa-86d862c74ba3", "f26689a4-3d85-48fa-8527-86dc6cb0900b", "d1ffa613-b8c9-4237-b7d4-0593162e4139", "36974146-18f2-482f-b545-b4511b67fe79", "d2f55778-1555-4b01-a3ae-ccc2a5fa73e0", "3664dbf6-98fd-48f9-b30a-39f618be35f0", "05d24ea2-cbec-4a45-95cc-7800b7285c7b"], "metadata": {"window": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen will change its name to Cencora, Inc.  and begin trading under the ticker symbol \u201cC OR\u201d on the New Y ork\nStock Exchange on August 30, 2023. ", "original_text": "AmerisourceBergen and TPG closed their acquisition of OneOncology, a network of leading oncology practices.\n", "page_label": "4", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1566f4d6-9561-4343-b260-d4f89df55e7c": {"node_ids": ["42c78839-07a1-4a18-ba29-c5351faf793c", "861191f4-8e2b-4be0-aad7-dc0c9041201e", "a786d4e3-2c8c-486b-97a8-714a9f783f98", "4baa3b76-3509-4e1a-951b-0cf7d64b5ef2", "2cf9a015-110c-419c-a7fa-6787551430ff", "d0c9f898-b4c6-4b06-998f-3bf91be0a098", "5273373a-add9-4c38-812f-843d6da3eecf", "983f1bc7-107f-4b9d-ba86-17a79dfc8195", "cfa7d28a-5162-4b04-9e31-77085cd22c9c", "15fc4415-2561-468c-972b-db601454e046", "a8c49f3b-fcc0-4e81-82a9-8c1688c79b82", "1ee92c0a-ced4-481a-948d-f81f4596bf12", "870bfd00-a7fa-438f-b90f-2dfd19a8db9c", "70b8e530-6251-4226-a548-296abdbf6c7d", "573759bf-1adf-4214-a4c2-e0d515864f13", "b989948f-bf78-41f9-b215-6d87ccb0cb9c", "92fa3eca-130c-4f49-8478-c33c91330f99", "b2874f08-6c3b-4cfd-830a-10cb75d17c55", "75232879-0654-4bf4-a216-c04e248d7785", "538c378f-5e0a-4e9d-a63e-5e15b017f5bf", "dd3722bf-08e4-459b-a40b-73baa74e9051", "dd9c7210-a30d-4923-bbe9-c84c3a848e59", "5024e4c6-9387-458e-86c0-06677adb9353", "191dca9b-02d4-413b-aa5f-c29142c88116", "5d3622f7-f749-4c1d-b616-f1aa865382db"], "metadata": {"window": "range of 3 to 5 percent.  Expectations for segment operating income growth excluding C OVID-19 contributions to be in\nthe range of 7 to 8 percent, from the previous range of 6 to 8 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 0 to 4 percent, up from the\nprevious range of a 3 percent decline to 1 percent growth;\nAdjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-C OVID-19 contribution and ex-\nM&A and divestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable August 28, 2023, to\nstockholders of record at the close of business on August 11, 2023.\n", "original_text": "range of 3 to 5 percent. ", "page_label": "5", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "61039336-e01b-441b-852e-b8eb51b938aa": {"node_ids": ["ee2298b0-2aaa-4521-bef6-48c570eed225", "cf08eda2-7279-463b-8849-1b71cff9e8ba", "05be8aae-ad7b-444c-adea-24dcd4b34841", "bdb0924a-8bdc-4ffb-a15f-39f3c689c3ca", "08e13b09-58ab-48c9-bf05-56b8e2a594d4", "15976b30-2677-4a89-8dfa-3079d63a755e", "7d37018e-8d50-4bea-98e1-e18f94b010ef", "386f6d8c-7761-4976-b69e-e130fffe3fbd", "6e7cf294-7f70-4679-96c9-ac420d7ead8c", "c1958f19-4af6-4e0a-8269-1565cf73fb81", "31ee3eac-5d0a-4a82-a301-19fd12ac43c5"], "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. ", "page_label": "6", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e563a3a8-f110-411d-abfe-c4214270a573": {"node_ids": ["2ace612a-cae5-4d4d-a191-497cc4c1b34d", "941c0354-68d8-4850-a789-2342a161a352", "1180eec6-7def-435c-8423-da2417e42805", "bfeff777-71b1-44b9-aa1d-4566903b97ff", "0cfcc48d-ab68-4c93-8c96-f02d3a3357b6", "d0f60f4f-c0ae-4437-b177-42312f8c8101"], "metadata": {"window": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of C OVID-19;\nfinancial and other impacts of C OVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the situation in Russia and\nUkraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United S tates and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk F actors), in the Company\u2019s Annual R eport on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the description of business risks\ndescribed in Item IA to our Form 10-Q for the fiscal quarter ended March 31, 2023, to which reference is made herein and (ii) in\nother reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "Alliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between W algreens Boots Alliance, Inc. ", "page_label": "7", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "403889d1-3893-486c-84c5-06b58967796a": {"node_ids": ["4245eda2-2418-466a-8f1f-e93fe705b3f1"], "metadata": {"window": "Revenue \u00a0$66,947,043 \u00a0\u00a0 \u00a0$60,064,601 \u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a064,682,397 \u00a0\u00a0\u00a0 \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a011.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,264,646 \u00a0\u00a03.38 %\u00a0\u00a02,015,369 \u00a0\u00a03.36 %\u00a012.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,304,141 \u00a0\u00a01.95 %\u00a0\u00a01,212,152 \u00a0\u00a02.02 %\u00a07.6 %\nDepreciation and amortization \u00a0\u00a0274,272 \u00a0\u00a00.41 %\u00a0\u00a0172,114 \u00a0\u00a00.29 %\u00a059.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(67,102 )\u00a0\u00a0 \u00a0\u00a023,442 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a019,283 \u00a0\u00a0\u00a0 \u00a0\u00a036,570 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a063,924 \u00a0\u00a0\u00a0 \u00a0\u00a07,858 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,594,518 \u00a0\u00a02.38 %\u00a0\u00a01,528,072 \u00a0\u00a02.54 %\u00a04.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0670,128 \u00a0\u00a01.00 %\u00a0\u00a0487,297 \u00a0\u00a00.81 %\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a0\u00a03,436 \u00a0\u00a0\u00a0 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a057,864 \u00a0\u00a0\u00a0 \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0608,828 \u00a0\u00a00.91 %\u00a0\u00a0476,323 \u00a0\u00a00.79 %\u00a027.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0129,615 \u00a0\u00a0\u00a0 \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0479,213 \u00a0\u00a00.72 %\u00a0\u00a0363,203 \u00a0\u00a00.60 %\u00a031.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a0368 \u00a0\u00a0\u00a0 \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "Revenue \u00a0$66,947,043 \u00a0\u00a0 \u00a0$60,064,601 \u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a064,682,397 \u00a0\u00a0\u00a0 \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a011.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,264,646 \u00a0\u00a03.38 %\u00a0\u00a02,015,369 \u00a0\u00a03.36 %\u00a012.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,304,141 \u00a0\u00a01.95 %\u00a0\u00a01,212,152 \u00a0\u00a02.02 %\u00a07.6 %\nDepreciation and amortization \u00a0\u00a0274,272 \u00a0\u00a00.41 %\u00a0\u00a0172,114 \u00a0\u00a00.29 %\u00a059.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(67,102 )\u00a0\u00a0 \u00a0\u00a023,442 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a019,283 \u00a0\u00a0\u00a0 \u00a0\u00a036,570 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a063,924 \u00a0\u00a0\u00a0 \u00a0\u00a07,858 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,594,518 \u00a0\u00a02.38 %\u00a0\u00a01,528,072 \u00a0\u00a02.54 %\u00a04.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0670,128 \u00a0\u00a01.00 %\u00a0\u00a0487,297 \u00a0\u00a00.81 %\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a0\u00a03,436 \u00a0\u00a0\u00a0 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a057,864 \u00a0\u00a0\u00a0 \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0608,828 \u00a0\u00a00.91 %\u00a0\u00a0476,323 \u00a0\u00a00.79 %\u00a027.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0129,615 \u00a0\u00a0\u00a0 \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0479,213 \u00a0\u00a00.72 %\u00a0\u00a0363,203 \u00a0\u00a00.60 %\u00a031.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a0368 \u00a0\u00a0\u00a0 \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "12210a45-b151-4a5a-87fd-8b2953a99b23": {"node_ids": ["2c4e1cea-9ad6-420d-805c-344e344929fc", "9f27e92a-b775-413b-b3af-632e69622206", "b56e9a60-0ef3-4751-9a6a-0fa025608dce", "c68613e9-66fa-4305-bcc5-c0bcd84efe1a", "ca003966-1fb8-46ed-bb43-7372bdd42fcb", "9472cfe2-f123-45a1-a749-8685fece04d3", "276088be-7225-40e8-bfbb-366a0951ce3a"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023.  Includes Turkey foreign currency\nremeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the three months ended June 30,\n2023.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$479,581 \u00a0\u00a00.72 %\u00a0$406,964 \u00a0\u00a00.68 %\u00a017.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.37 \u00a0\u00a0\u00a0 \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a021.5 %\nDiluted \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a022.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,349 \u00a0\u00a0\u00a0 \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\nDiluted \u00a0\u00a0204,375 \u00a0\u00a0\u00a0 \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0(3.5 )%\n________________________________________\n1Includes a $118.6 million gain from antitrust litigation settlements, Turkey foreign currency remeasurement expense of $50.6\nmillion, and a $35.0 million LIFO expense in the three months ended June 30, 2023. ", "page_label": "9", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "87f9a5b7-61fa-4b1c-8884-fa660fbf7a35": {"node_ids": ["008e31ea-1071-43bd-8bee-78533f283e17"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,706,041 \u00a0\u00a03.47 %\u00a0\u00a06,310,808 \u00a0\u00a03.56 %\u00a06.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,916,156 \u00a0\u00a02.03 %\u00a0\u00a03,585,500 \u00a0\u00a02.02 %\u00a09.2 %\nDepreciation and amortization \u00a0\u00a0687,678 \u00a0\u00a00.36 %\u00a0\u00a0523,333 \u00a0\u00a00.29 %\u00a031.4 %\nLitigation and opioid-related (credit)\nexpenses 2 \u00a0\u00a0(38,583 )\u00a0\u00a0 \u00a0\u00a0108,167 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a099,392 \u00a0\u00a0\u00a0 \u00a0\u00a069,710 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0177,608 \u00a0\u00a0\u00a0 \u00a0\u00a031,357 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,842,251 \u00a0\u00a02.51 %\u00a0\u00a04,398,949 \u00a0\u00a02.48 %\u00a010.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,863,790 \u00a0\u00a00.96 %\u00a0\u00a01,911,859 \u00a0\u00a01.08 %\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0\u00a0(18,612 )\u00a0\u00a0 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0167,989 \u00a0\u00a0\u00a0 \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a05.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,714,413 \u00a0\u00a00.89 %\u00a0\u00a01,800,717 \u00a0\u00a01.01 %\u00a0(4.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0330,817 \u00a0\u00a0\u00a0 \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,383,596 \u00a0\u00a00.72 %\u00a0\u00a01,367,864 \u00a0\u00a00.77 %\u00a01.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a011,132 \u00a0\u00a0\u00a0 \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,706,041 \u00a0\u00a03.47 %\u00a0\u00a06,310,808 \u00a0\u00a03.56 %\u00a06.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,916,156 \u00a0\u00a02.03 %\u00a0\u00a03,585,500 \u00a0\u00a02.02 %\u00a09.2 %\nDepreciation and amortization \u00a0\u00a0687,678 \u00a0\u00a00.36 %\u00a0\u00a0523,333 \u00a0\u00a00.29 %\u00a031.4 %\nLitigation and opioid-related (credit)\nexpenses 2 \u00a0\u00a0(38,583 )\u00a0\u00a0 \u00a0\u00a0108,167 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a099,392 \u00a0\u00a0\u00a0 \u00a0\u00a069,710 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0177,608 \u00a0\u00a0\u00a0 \u00a0\u00a031,357 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,842,251 \u00a0\u00a02.51 %\u00a0\u00a04,398,949 \u00a0\u00a02.48 %\u00a010.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,863,790 \u00a0\u00a00.96 %\u00a0\u00a01,911,859 \u00a0\u00a01.08 %\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0\u00a0(18,612 )\u00a0\u00a0 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0167,989 \u00a0\u00a0\u00a0 \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a05.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,714,413 \u00a0\u00a00.89 %\u00a0\u00a01,800,717 \u00a0\u00a01.01 %\u00a0(4.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0330,817 \u00a0\u00a0\u00a0 \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,383,596 \u00a0\u00a00.72 %\u00a0\u00a01,367,864 \u00a0\u00a00.77 %\u00a01.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a011,132 \u00a0\u00a0\u00a0 \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c920c468-d834-4ab3-b790-75fe74ceb760": {"node_ids": ["863ef71d-6a51-4e7f-8dfc-36b9c473c51c", "f447299d-e824-4301-9f12-fa8d809f3626", "36900705-60cd-43b5-9329-602427ba09e4", "667ff934-d571-4291-a0b7-22fbe279a436", "7f739847-cdcd-4c17-817a-f70841f5c4f2", "a1f977a1-97c8-4c68-89a9-3e07f8e626a0", "4908475e-a3a3-4d27-a534-ee43500bd6a8"], "metadata": {"window": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023.  Includes a $37.7 million LIFO credit and\nTurkey foreign currency remeasurement expense of $27.6 million in the nine months ended June 30, 2022.\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the nine months ended June 30,\n2023.\n", "original_text": "Net income attributable to AmerisourceBergen\nCorporation \u00a0$1,394,728 \u00a0\u00a00.72 %\u00a0$1,404,083 \u00a0\u00a00.79 %\u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.87 \u00a0\u00a0\u00a0 \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a02.2 %\nDiluted \u00a0$6.80 \u00a0\u00a0\u00a0 \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a02.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,908 \u00a0\u00a0\u00a0 \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,995 \u00a0\u00a0\u00a0 \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n________________________________________\n1Includes a $168.5 million gain from antitrust litigation settlements, a $114.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $59.0 million in the nine months ended June 30, 2023. ", "page_label": "11", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ec519faf-8c72-4d79-b13f-c0eaa494d3f3": {"node_ids": ["9f5b0d1e-9971-477b-bccb-112f3d2f69ad"], "metadata": {"window": "Gains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(118,611 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(118,611 )\u00a0\u00a0(118,611 )\u00a0\u00a0(27,518 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(91,093 )\u00a0\u00a0(0.45 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a034,952 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a08,037 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,915 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a050,580 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a050,580 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,154 )\u00a0\u00a0169,154 \u00a0\u00a0\u00a0169,154 \u00a0\u00a0\u00a039,087 \u00a0\u00a0\u00a0(969 )\u00a0\u00a0129,098 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,102 \u00a0\u00a0\u00a0(67,102 )\u00a0\u00a0(67,102 )\u00a0\u00a03,750 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,852 )\u00a0\u00a0(0.35 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(19,283 )\u00a0\u00a019,283 \u00a0\u00a0\u00a019,283 \u00a0\u00a0\u00a04,393 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,890 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,924 )\u00a0\u00a063,924 \u00a0\u00a0\u00a063,924 \u00a0\u00a0\u00a014,733 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a049,191 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,823 )\u00a0\u00a0(8,748 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,925 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,231,567 \u00a0\u00a0$1,409,259 \u00a0\u00a0$822,308 \u00a0\u00a0$760,186 \u00a0\u00a0$163,349 \u00a0\u00a0$(601 )\u00a0$596,236 \u00a0\u00a0$2.92 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "Gains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(118,611 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(118,611 )\u00a0\u00a0(118,611 )\u00a0\u00a0(27,518 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(91,093 )\u00a0\u00a0(0.45 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a034,952 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a034,952 \u00a0\u00a0\u00a08,037 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,915 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a050,580 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a050,580 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a057,581 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,154 )\u00a0\u00a0169,154 \u00a0\u00a0\u00a0169,154 \u00a0\u00a0\u00a039,087 \u00a0\u00a0\u00a0(969 )\u00a0\u00a0129,098 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,102 \u00a0\u00a0\u00a0(67,102 )\u00a0\u00a0(67,102 )\u00a0\u00a03,750 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,852 )\u00a0\u00a0(0.35 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(19,283 )\u00a0\u00a019,283 \u00a0\u00a0\u00a019,283 \u00a0\u00a0\u00a04,393 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,890 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,924 )\u00a0\u00a063,924 \u00a0\u00a0\u00a063,924 \u00a0\u00a0\u00a014,733 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a049,191 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,000 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,823 )\u00a0\u00a0(8,748 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,925 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,231,567 \u00a0\u00a0$1,409,259 \u00a0\u00a0$822,308 \u00a0\u00a0$760,186 \u00a0\u00a0$163,349 \u00a0\u00a0$(601 )\u00a0$596,236 \u00a0\u00a0$2.92 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "page_label": "12", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ab91ae9f-55ab-40e4-b0e1-bc215537f5b7": {"node_ids": ["41d1c070-d7d9-439e-b173-420bb0e0009e", "dbb1eb20-1656-4a47-b1fc-0becd813ecfe", "f2866fe5-35b3-42f7-935c-86a634492dc8", "f3ab3498-b782-4985-8075-bc5a4a4b383f", "19e618b5-bca3-47ba-aa2d-fb63f1249bca", "83b6918a-594a-415c-b0b7-1a913603c26d", "f62e4aa3-5764-4ed0-ac38-61a4bb16f6e7"], "metadata": {"window": "Adjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a08.0 %\u00a0\u00a07.6 %\u00a0\u00a08.7 %\u00a0\u00a08.6 %\u00a0\u00a015.5 %\u00a0\u00a0 \u00a0\u00a07.5 %\u00a0\u00a011.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.38% \u00a03.33%\nOperating expenses \u00a02.38% \u00a02.11%\nOperating income \u00a01.00% \u00a01.23%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other Loss (Income), Net.\n", "original_text": "Adjusted Non-\nGAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0dc22fe7-c04e-4cdd-bbee-1e2ccf44bc91": {"node_ids": ["7df7fe71-963a-4170-866f-d8c7d424700c"], "metadata": {"window": "LIFO expense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a023,442 \u00a0\u00a0\u00a023,442 \u00a0\u00a0\u00a07,795 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a015,647 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(36,570 )\u00a0\u00a036,570 \u00a0\u00a0\u00a036,570 \u00a0\u00a0\u00a010,791 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,779 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(7,858 )\u00a0\u00a07,858 \u00a0\u00a0\u00a07,858 \u00a0\u00a0\u00a02,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a05,005 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.36% \u00a03.44%\n14", "original_text": "LIFO expense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a023,442 \u00a0\u00a0\u00a023,442 \u00a0\u00a0\u00a07,795 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a015,647 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(36,570 )\u00a0\u00a036,570 \u00a0\u00a0\u00a036,570 \u00a0\u00a0\u00a010,791 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,779 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(7,858 )\u00a0\u00a07,858 \u00a0\u00a0\u00a07,858 \u00a0\u00a0\u00a02,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a05,005 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\nGross profit \u00a03.36% \u00a03.44%\n14", "page_label": "14", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "80410240-586e-4299-b19b-f4fe6745802a": {"node_ids": ["61b0e9d4-1e2d-4adf-a26c-1a01406bfe38", "c5eb7efc-c326-484b-8717-e1c0fc054b16", "cb756de1-b21b-4b97-a7dd-f51220b982a4", "13eee86b-affe-4c50-b47a-ff89d12e9038"], "metadata": {"window": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n GAAP T O NON-GAAP REC ONCILIA TIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$6,706,041 \u00a0\u00a0$4,842,251 \u00a0\u00a0$1,863,790 \u00a0\u00a0$1,714,413 \u00a0\u00a0$330,817 \u00a0\u00a0$11,132 \u00a0\u00a0$1,394,728 \u00a0\u00a0$6.80 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,510 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,510 )\u00a0\u00a0(168,510 )\u00a0\u00a0(39,175 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(129,335 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0114,272 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a0114,272 \u00a0\u00a0\u00a026,566 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a087,706 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a059,019 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,019 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a066,022 \u00a0\u00a0\u00a00.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\n15", "original_text": "Operating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Loss (Income), Net.\n", "page_label": "15", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "155679d0-1d96-433e-b071-6e1b37c5a889": {"node_ids": ["2f1da757-962c-42e8-ae64-6391b5a2b8ad", "be295d28-8448-4238-a077-722f46e925a3"], "metadata": {"window": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n prior year \u00a0\u00a06.5 %\u00a0\u00a08.9 %\u00a0\u00a02.7 %\u00a0\u00a02.7 %\u00a0\u00a0(2.2 )%\u00a0\u00a0 \u00a0\u00a04.9 %\u00a0\u00a08.3 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n16", "original_text": "amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(381,146 )\u00a0\u00a0381,146 \u00a0\u00a0\u00a0381,146 \u00a0\u00a0\u00a088,609 \u00a0\u00a0\u00a0(3,111 )\u00a0\u00a0289,426 \u00a0\u00a0\u00a01.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a038,583 \u00a0\u00a0\u00a0(38,583 )\u00a0\u00a0(38,583 )\u00a0\u00a010,412 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,995 )\u00a0\u00a0(0.24 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(99,392 )\u00a0\u00a099,392 \u00a0\u00a0\u00a099,392 \u00a0\u00a0\u00a023,107 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a076,285 \u00a0\u00a0\u00a00.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(177,608 )\u00a0\u00a0177,608 \u00a0\u00a0\u00a0177,608 \u00a0\u00a0\u00a041,290 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0136,318 \u00a0\u00a0\u00a00.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign\ncurrency\ngain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-\ncustomer\nnote\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,148 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,462 )\u00a0\u00a0(20,356 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,894 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,710,822 \u00a0\u00a0$4,222,688 \u00a0\u00a0$2,488,134 \u00a0\u00a0$2,324,487 \u00a0\u00a0$461,270 \u00a0\u00a0$8,021 \u00a0\u00a0$1,871,238 \u00a0\u00a0$9.13 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change vs.\n", "page_label": "16", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "63207d80-146d-4b31-9d2d-6493950bdc19": {"node_ids": ["e7f3381b-f42b-4799-ae6c-9a02fdb84a7f", "9884b84a-2dd4-4910-8bb5-f8562286679c", "04cb0bd1-badc-4668-9e9b-b357539b102c", "7b585166-d964-460e-a969-0c00ce2c0eae", "98b37981-f4d9-41d8-8417-58c0780e19cc", "90c55f0e-58c1-423d-8a38-ad094edae6f1"], "metadata": {"window": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0", "original_text": "Gross profit \u00a03.47% \u00a03.47%\nOperating expenses \u00a02.51% \u00a02.19%\nOperating income \u00a00.96% \u00a01.29%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. ", "page_label": "17", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a5f3bf78-ae07-48d9-8e79-6d5cb2146ad0": {"node_ids": ["6d34738d-0a16-435b-98e4-7c88a4cf79fe"], "metadata": {"window": "Acquisition-\nrelated intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0108,167 \u00a0\u00a0\u00a0108,167 \u00a0\u00a0\u00a019,005 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a089,162 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(69,710 )\u00a0\u00a069,710 \u00a0\u00a0\u00a069,710 \u00a0\u00a0\u00a018,507 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,203 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(31,357 )\u00a0\u00a031,357 \u00a0\u00a0\u00a031,357 \u00a0\u00a0\u00a08,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,033 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n18", "original_text": "Acquisition-\nrelated intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0108,167 \u00a0\u00a0\u00a0108,167 \u00a0\u00a0\u00a019,005 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a089,162 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(69,710 )\u00a0\u00a069,710 \u00a0\u00a0\u00a069,710 \u00a0\u00a0\u00a018,507 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,203 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(31,357 )\u00a0\u00a031,357 \u00a0\u00a0\u00a031,357 \u00a0\u00a0\u00a08,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,033 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-\nGAAP\n18", "page_label": "18", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "17c0f4bc-1904-4832-874f-f5afe7384803": {"node_ids": ["14a0d4f0-9820-4a46-9b78-a52317210776", "11eeb226-e95e-4bce-82a1-017f3e5a7b68", "617a56b6-0403-4f01-a95b-fcd54c92872c", "57e8bd2f-7514-4c89-b407-bf0eeffac7fe", "2bb09df0-e152-4f59-8a54-374ed01c78cc", "4e8b87d8-9a4a-4a50-9669-9d38af526af2"], "metadata": {"window": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n 2The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S. ", "original_text": "Gross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other Income, Net.\n", "page_label": "19", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ec0ed34a-d2bd-4a70-b995-4894391fab16": {"node_ids": ["71cee173-dc46-4d1b-bad9-ee405d93e205", "9b3d13ec-30f9-4ee2-903b-527519bf006b"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.36 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.29 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a01.09 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.65 %\u00a0\u00a011.05 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.99 %\u00a0\u00a08.41 %\u00a0\u00a0\nOperating income \u00a0\u00a02.66 %\u00a0\u00a02.64 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.38 %\u00a0\u00a03.36 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.38 %\u00a0\u00a02.54 %\u00a0\u00a0\nOperating income \u00a0\u00a01.00 %\u00a0\u00a00.81 %\u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0118,611 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(34,952 )\u00a0\u00a0(23,070 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(50,580 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(169,154 )\u00a0\u00a0(74,408 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a067,102 \u00a0\u00a0\u00a0(23,442 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(19,283 )\u00a0\u00a0(36,570 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(63,924 )\u00a0\u00a0(7,858 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nOperating income \u00a0$670,128 \u00a0\u00a0$487,297 \u00a0\u00a037.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "20", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f8bf94e8-aea2-49f0-b52d-1a5443cd3e34": {"node_ids": ["66eae9ec-7c9d-452d-a1e1-7fea129e59f8", "9a31a7ca-8e7c-4bbc-aab4-2e3065e3441f", "256878f0-fe0d-4628-ba9f-d3158285a91e", "8bbbf0a4-5916-4b8e-937c-cdeefd29ee98"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n SUMMAR Y SEGMENT INFORMA TION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$172,830,234 \u00a0\u00a0$157,311,755 \u00a0\u00a09.9 %\nInternational Healthcare Solutions \u00a0\u00a020,423,990 \u00a0\u00a0\u00a020,104,199 \u00a0\u00a01.6 %\nIntersegment eliminations \u00a0\u00a0(3,144 )\u00a0\u00a0(3,097 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$193,251,080 \u00a0\u00a0$177,412,857 \u00a0\u00a08.9 %\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02023 \u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,963,729 \u00a0\u00a0$1,878,556 \u00a0\u00a04.5 %\nInternational Healthcare Solutions \u00a0\u00a0524,405 \u00a0\u00a0\u00a0543,400 \u00a0\u00a0(3.5 )%\nTotal segment operating income \u00a0\u00a02,488,134 \u00a0\u00a0\u00a02,421,956 \u00a0\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0168,510 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.33 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.11 %\u00a0\u00a02.18 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.26 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "21", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "16315473-540d-424a-9e4f-772f79cceea8": {"node_ids": ["63e839c1-039b-4ffe-bcde-a9540e7e437d", "6da1a4c3-15d7-4444-aa0d-930b2b4a05fb"], "metadata": {"window": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.52 %\u00a0\u00a02.59 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.38 %\u00a0\u00a01.39 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.19 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.57 %\u00a0\u00a011.09 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.00 %\u00a0\u00a08.39 %\u00a0\u00a0\nOperating income \u00a0\u00a02.57 %\u00a0\u00a02.70 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.47 %\u00a0\u00a03.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.51 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating income \u00a0\u00a00.96 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n22", "original_text": "LIFO (expense) credit \u00a0\u00a0(114,272 )\u00a0\u00a037,668 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(59,019 )\u00a0\u00a0(27,618 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(381,146 )\u00a0\u00a0(231,866 )\u00a0\u00a0\nLitigation and opioid-related credit (expenses) \u00a0\u00a038,583 \u00a0\u00a0\u00a0(108,167 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(99,392 )\u00a0\u00a0(69,710 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(177,608 )\u00a0\u00a0(31,357 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$1,863,790 \u00a0\u00a0$1,911,859 \u00a0\u00a0(2.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "22", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f4fbb8b3-21bb-4377-9587-a63e396b892e": {"node_ids": ["ff16f042-2195-47a8-ace6-2d704b64cefd", "bacaebc4-e64b-49b7-a5cf-e88274c91789"], "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED BAL ANCE SHEET S \n (in thousands) \n (unaudited)\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2023 \u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,389,345 \u00a0$3,388,189\nAccounts receivable, net \u00a020,796,648 \u00a0\u00a0\u00a018,452,675 \u00a0\nInventories \u00a016,852,340 \u00a0\u00a0\u00a015,556,394 \u00a0\nRight to recover assets \u00a01,417,551 \u00a0\u00a0\u00a01,532,061 \u00a0\nPrepaid expenses and other \u00a0530,700 \u00a0\u00a0\u00a0660,439 \u00a0\nTotal current assets \u00a040,986,584 \u00a0\u00a0\u00a039,589,758 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,147,881 \u00a0\u00a0\u00a02,135,003 \u00a0\nGoodwill and other intangible assets \u00a014,425,265 \u00a0\u00a0\u00a012,836,623 \u00a0\nDeferred income taxes \u00a0221,235 \u00a0\u00a0\u00a0237,571 \u00a0\nOther long-term assets \u00a03,396,231 \u00a0\u00a0\u00a01,761,661 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.47 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.19 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.29 %\u00a0\u00a01.37 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "23", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "601ce026-0780-4d2a-9af2-83d717f863fe": {"node_ids": ["5ec6254b-9e65-46d7-ba61-834801256547"], "metadata": {"window": "Total assets $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $43,752,080 \u00a0\u00a0$40,192,890 \u00a0\nAccrued expenses and other \u00a02,170,270 \u00a0\u00a0\u00a02,214,592 \u00a0\nShort-term debt \u00a0860,861 \u00a0\u00a0\u00a01,070,473 \u00a0\nTotal current liabilities \u00a046,783,211 \u00a0\u00a0\u00a043,477,955 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,159,853 \u00a0\u00a0\u00a04,632,360 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0284,020 \u00a0\u00a0\u00a0320,274 \u00a0\nDeferred income taxes \u00a01,716,360 \u00a0\u00a0\u00a01,620,413 \u00a0\nAccrued litigation liability \u00a05,455,000 \u00a0\u00a0\u00a05,461,758 \u00a0\nOther long-term liabilities \u00a01,856,708 \u00a0\u00a0\u00a0976,583 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0922,044 \u00a0\u00a0\u00a071,273 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\nAMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2023 \u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\n24", "original_text": "Total assets $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $43,752,080 \u00a0\u00a0$40,192,890 \u00a0\nAccrued expenses and other \u00a02,170,270 \u00a0\u00a0\u00a02,214,592 \u00a0\nShort-term debt \u00a0860,861 \u00a0\u00a0\u00a01,070,473 \u00a0\nTotal current liabilities \u00a046,783,211 \u00a0\u00a0\u00a043,477,955 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,159,853 \u00a0\u00a0\u00a04,632,360 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0284,020 \u00a0\u00a0\u00a0320,274 \u00a0\nDeferred income taxes \u00a01,716,360 \u00a0\u00a0\u00a01,620,413 \u00a0\nAccrued litigation liability \u00a05,455,000 \u00a0\u00a0\u00a05,461,758 \u00a0\nOther long-term liabilities \u00a01,856,708 \u00a0\u00a0\u00a0976,583 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0922,044 \u00a0\u00a0\u00a071,273 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $61,177,196 \u00a0\u00a0$56,560,616 \u00a0\nAMERISOUR CEBER GEN C ORPORA TION \n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2023 \u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\n24", "page_label": "24", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f7b12765-a55d-4b0d-b110-b14ea4f47293": {"node_ids": ["16dba72d-ebeb-4a32-b225-ce5df907947e"], "metadata": {"window": "Net income $1,383,596 \u00a0\u00a0$1,367,864 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0899,803 \u00a0\u00a0\u00a0704,628 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,249,881 )\u00a0\u00a0(1,550,962 )\nInventories \u00a0(1,369,977 )\u00a0\u00a0(712,849 )\nAccounts payable \u00a03,513,686 \u00a0\u00a0\u00a02,074,612 \u00a0\nOther, net \u00a0(92,704 )\u00a0\u00a0(344,675 )\nNet cash provided by operating activities \u00a02,084,523 \u00a0\u00a0\u00a01,538,618 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(282,862 )\u00a0\u00a0(322,732 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,681 )\u00a0\u00a0(124,158 )\nCost of equity investments  2 \u00a0(737,025 )\u00a0\u00a0\u2014 \u00a0\nProceeds from the sale of businesses \u00a0\u2014 \u00a0\u00a0\u00a0258,082 \u00a0\nOther, net \u00a010,544 \u00a0\u00a0\u00a0(4,899 )\nNet cash used in investing activities \u00a0(2,419,024 )\u00a0\u00a0(193,707 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(581,557 )\u00a0\u00a0(576,303 )\nPurchases of common stock 3 \u00a0(907,214 )\u00a0\u00a0(248,422 )\nExercises of stock options \u00a050,078 \u00a0\u00a0\u00a083,954 \u00a0\nCash dividends on common stock \u00a0(300,413 )\u00a0\u00a0(295,239 )\nEmployee tax withholdings related to restricted share vesting \u00a0(71,059 )\u00a0\u00a0(35,273 )\nOther, net \u00a0(5,099 )\u00a0\u00a0(8,036 )\nNet cash used in financing activities \u00a0(1,815,264 )\u00a0\u00a0(1,079,319 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0104,479 \u00a0\u00a0\u00a0(33,056 )\n25", "original_text": "Net income $1,383,596 \u00a0\u00a0$1,367,864 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0899,803 \u00a0\u00a0\u00a0704,628 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,249,881 )\u00a0\u00a0(1,550,962 )\nInventories \u00a0(1,369,977 )\u00a0\u00a0(712,849 )\nAccounts payable \u00a03,513,686 \u00a0\u00a0\u00a02,074,612 \u00a0\nOther, net \u00a0(92,704 )\u00a0\u00a0(344,675 )\nNet cash provided by operating activities \u00a02,084,523 \u00a0\u00a0\u00a01,538,618 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(282,862 )\u00a0\u00a0(322,732 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,681 )\u00a0\u00a0(124,158 )\nCost of equity investments  2 \u00a0(737,025 )\u00a0\u00a0\u2014 \u00a0\nProceeds from the sale of businesses \u00a0\u2014 \u00a0\u00a0\u00a0258,082 \u00a0\nOther, net \u00a010,544 \u00a0\u00a0\u00a0(4,899 )\nNet cash used in investing activities \u00a0(2,419,024 )\u00a0\u00a0(193,707 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(581,557 )\u00a0\u00a0(576,303 )\nPurchases of common stock 3 \u00a0(907,214 )\u00a0\u00a0(248,422 )\nExercises of stock options \u00a050,078 \u00a0\u00a0\u00a083,954 \u00a0\nCash dividends on common stock \u00a0(300,413 )\u00a0\u00a0(295,239 )\nEmployee tax withholdings related to restricted share vesting \u00a0(71,059 )\u00a0\u00a0(35,273 )\nOther, net \u00a0(5,099 )\u00a0\u00a0(8,036 )\nNet cash used in financing activities \u00a0(1,815,264 )\u00a0\u00a0(1,079,319 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0104,479 \u00a0\u00a0\u00a0(33,056 )\n25", "page_label": "25", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c7593f26-abfc-4168-b0e9-63460fc1ae33": {"node_ids": ["0d4f796f-d180-49dd-a35d-2d5d71effcef", "980c971e-9534-4eaa-8f48-3f5cb0436ffe", "47bc1676-528e-4460-b7c4-32a1ab530aea", "f789eda8-411b-47be-8d4d-2e01b2009310", "38c85abb-f9c3-498a-b40b-d1ba0a2c82a8", "a9b76c13-05dd-42b4-ba8c-874ed8f3f86a", "05db4f1f-3088-4582-856a-2961cf429d29", "169747b7-7eb0-4798-8e0a-ed67fbc7f9da"], "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n 2Includes a $718.4 million investment in OneOncology.\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0June 30,\n2023 \u00a0September 30,\n2022 \u00a0June 30,\n2022 \u00a0September 30,\n2021\nCash and cash equivalents \u00a0$1,389,345 \u00a0$3,388,189 \u00a0$3,034,233 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a096,623 \u00a0\u00a0\u00a0144,980 \u00a0\u00a0\u00a0207,722 \u00a0\u00a0\u00a0462,986 \u00a0\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a062,285 \u00a0\u00a0\u00a060,370 \u00a0\u00a0\u00a060,099 \u00a0\u00a0\u00a060,000 \u00a0\nCash, cash equivalents, and restricted cash \u00a0$1,548,253 \u00a0\u00a0$3,593,539 \u00a0\u00a0$3,302,054 \u00a0\u00a0$3,070,128 \u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(2,045,286 )\u00a0\u00a0232,536 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(2,045,286 )\u00a0\u00a0231,926 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 4 $1,548,253 \u00a0\u00a0$3,302,054 \u00a0\n________________________________________\n1Includes $1,406.3 million for the acquisition of PharmaLex.\n", "page_label": "26", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c11dd2e4-e473-4b81-b78f-c307e8ce5fa2": {"node_ids": ["90cd4eb7-1512-44ad-afd2-4f8b37fb97b2", "ae44f02d-2263-4629-b613-7df0810fd7d4", "6cd68c38-8012-41ca-aa61-cdfbcb8bfd62", "e1e06e29-2b44-4367-ad0d-07dcc290c641", "137d1968-0b8d-4da1-b0c2-17bca472c931", "9d583ed4-ae53-4ea0-a1fb-269ba85efed8", "58572829-e6fa-478f-a5cd-e4d8762b0ebf", "0bae5bd7-c100-4a79-b839-ae57846dfa4d", "478ab060-7f45-43ba-94e7-50d777bc0a15", "ae5674db-23c9-43cb-9185-bfef75f392af", "38b611d9-3f08-42c0-a0d7-707b2ffc3bd0", "76186493-f2be-443e-8567-7f3dc8c64c71", "2565b72e-3b81-40f2-a3b2-efdcad440555", "0f4f8272-7aa4-4f45-a399-2d113d4fa4f1", "ab172ee0-362e-4c75-b8ab-518cbec2ff6a", "23d32f99-b8df-4983-a098-ff5948cdae41", "5b2083ab-9a9b-49df-b5cf-fa428fcbe9dd", "5dc2d178-b2c0-4e70-afe5-3da521db5fdd", "a1fd3c22-cf45-4a7c-9e93-c9950927017f", "271bf4e5-91e5-4f98-978d-26513b5a6b9f", "82eebee9-9900-487e-b06c-f78e151420a1", "37a8a253-7ed1-4263-803f-35326a7660dd", "6b874523-2c69-47ad-9411-23739d14e1a9", "d16c2902-2482-408b-abf1-06a856e3c6f0", "8dc2344c-df30-4297-9f0d-c492b1e91ef2", "65fa66b3-4019-4ab1-8197-736592921cde", "f21128f0-6ce9-4bcc-85a9-8b661c3119ee", "a64be202-c9f7-4c82-a9af-16e96c5afd2e"], "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "27", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e6211d0d-2c42-4257-9a1f-4e9a76d59a96": {"node_ids": ["ec6f9965-37f2-43c8-92b0-5a7ca9aee972", "edaafec9-edeb-4c5c-9bf1-aa46d5089923", "6f859c03-0652-4e65-ac7a-d2cda4d232b1", "b4c64bc7-eebc-474f-bd73-c4c4c34abad9", "82d91389-6a90-494d-9a64-bd405d340334", "2f7fd039-4c60-47df-bf2a-bb4611760c7f", "de6298f0-3630-4b11-9950-171de2048d05", "01d270eb-858a-4dd8-b8de-01f61c5f45fa", "cc3c3e16-e6e2-4d25-bbed-9cf5de03876c", "0476d296-8060-4c87-8fb7-1abab245d6c3", "6e7c8f64-a310-41c4-b78c-96ea40b9357e", "b9f53df2-15c1-41e5-b32a-ca155af02cc9", "2f0a0841-2ff5-4bbd-8b2a-6e078ef07eca", "f3bc5703-937d-4989-bc68-e7274b9e6c0e", "77889e4a-43e9-4226-8040-d5700de3b59d", "a5890a73-0453-44c5-aa10-e23857df66f7", "2c6d49f3-ecd3-4260-89c0-653b6487640b", "3c0abc69-7c74-487b-aee2-a2b7be8ff361", "66fe8f96-dbd5-4079-a53f-28c7b111ca8e", "b242c87a-eaea-402c-bbd5-72f025ebc3b0"], "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment\nof assets, including goodwill; the gain on the sale of businesses; and the gain (loss) on the currency remeasurement related to\n2020 S wiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "28", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "12fc9d9e-7168-4713-a333-b8202f0baa25": {"node_ids": ["d815a528-c936-4e6d-a70a-dea8db84b43b"], "metadata": {"window": "bmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "bmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n29", "page_label": "29", "file_name": "CEN-Q3-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 259484, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}